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The Comparative Pathogenesis of Influenza in Ferrets 
Abstract 
 
Influenza is an enveloped, segmented, single-stranded, negative sense RNA virus that causes annual 
seasonal epidemics and occasional pandemics.  Influenza causes roughly 200,000 to 500,000 deaths 
per year globally and affects up to 15% of the world’s population annually.  Influenza is a major public 
health concern. Influenza presents a spectrum of clinical signs including: fever, sneezing, lethargy and 
can range from a mild to a severe disease.  It also leads to death in high-risk individuals such as 
pregnant women, the elderly and very young, the immunocompromised and those with underlying 
medical conditions.  Seasonal influenza viruses continuously evolve antigenically meaning individuals  
can become infected on numerous occasions throughout their lives.   Due to the rapid evolution of these 
viruses, the influenza vaccine composition needs to be updated regularly to protect against current 
circulating strains.   
 
The ferret is the gold standard model for influenza infections in the laboratory.  The model produces 
similar clinical readouts to humans; sneezing, nasal discharge, fever and malaise.  Human isolates can 
be used to infect ferrets with no prior need for adaptation. This PhD investigates the pathogenesis of 
H3N2 A/Perth/16/2009 and its ability to cause disease in the ferret using three different models of 
infection; intranasal, nose-only aerosol and non-contact transmission.  Scrutiny of these models using 
a range of virological and immunological techniques showed while there are some small differences 
between routes of infection, using the same influenza virus strain results in similar disease in ferrets.  
Further analysis of the intranasal route of inoculation and comparison with H1N1 A/California/04/2009, 
showed distinctions in pathogenesis between viruses despite identical routes of infection, highlighting 
the differences in the viral kinetics and cellular immune response between H3N2 and H1N1 in the ferret 
model.  This work enhances and improves the versatility of the ferret model for studying the 
pathogenesis of influenza. 
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1 Introduction 
 
1.1 Influenza Overview 
 
Influenza is a multi-segmented, negative sense, single stranded (ss) RNA virus and a member 
of the Orthomyxoviridae virus family.   It presents two distinct challenges to public health. The 
first is from influenza viruses circulating endemically in the human population that seasonally 
cause a low severity respiratory illness with symptoms such as fever, headache, myalgia, 
malaise and cough.  It has a high attack rate and results in annual epidemics.  Although 
seasonal influenza is preventable, annual vaccinations are required due to the plasticity of the 
virus’ RNA genome and the high error rate of the viral polymerase.  This allows the virus to 
continually evolve, causing antigenic drift.  The second challenge is the emergence of a novel 
influenza A virus from a diverse animal reservoir (WHO, 2014) or genetic reassortment 
between several viruses in an animal host (CDC, 2009, Smith et al., 2009), known as antigenic 
shift creating novel viruses that the human population have not been exposed to.     These 
viruses cross the species barrier sporadically, going on to cause human illness and could 
potentially lead to global pandemics with high fatality rates.   Currently, there are four 
recognised types of influenza virus (summarised in Table 1.1.1).  
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1.1.1 Influenza A 
 
Influenza A virus (IAV) is endemic in the world’s wild bird population.  It has spilt over into the 
domestic bird population and subsequently been able to infect other domesticated mammals 
and humans (Fig. 1.1).  The introduction and adaptation of IAVs to the human population has 
been the cause of several global pandemics which has resulted in the IAVs continued 
circulation in the human population as endemic seasonal viruses (Petrova and Russell, 2017).   
IAV’s have been able to continually evolve due to their RNA genome, host immune pressures 
and their broad host range.  Influenza A subtypes are categorised by their two surface 
glycoproteins; haemagglutinin (HA) and neuraminidase (NA).  There are numerous subtypes 
(potentially 144) (Spackman, 2008) circulating within the wild bird population and there are 
two current IAV subtypes circulating in the human population; H1N1 and H3N2, causing 
seasonal epidemics. 
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Figure 1.1 Ecology of Influenza A Viruses (Long et al., 2019) Influenza A viruses (haemagglutinin 
(HA) subtypes 1-16) circulate in the wild bird reservoir.  The light blue arrows denote subtypes that 
cross into different species either through intermediate hosts or via adaptive mutations.  The dark blue 
circles denote subtypes that predominately circulate within species.   HA subtypes H17 and H18 
currently only circulate in bats (Tong et al., 2012). Many species have been experimentally infected with 
influenza viruses including ferrets, mice, guinea pig and NHPs (Bouvier, 2015, Bouvier and Lowen, 
2010, Maher and DeStefano, 2004, Lowen et al., 2006) .  
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1.1.2 Influenza B 
 
Influenza B virus (IBV) was first identified in 1940 (Francis, 1940) and has no known animal 
reservoir.   Two antigenically and genetically distinct lineages of influenza B, B/Victoria/2/87-
like (Victoria lineage) and B/Yamagata/16/88-like (Yamagata lineage), emerged in 1983 and 
sequence analysis of the hemagglutinin (HA) genes of several  isolates indicated that the HA1 
domains of the two  virus lineages isolated differed by 27 amino acids (Rota et al., 1990).  
Historically, new strains of IBV have emerged much less frequently compared to IAV due to 
its limited host range.  Between 1985 and 2000 one of the two lineages of IBV has dominated 
the other during the influenza season; however, since 2001 both lineages of IBV have been 
co-circulating globally.  IBV is less of a disease burden in humans than IAV and unlike IAV is 
not known to cause severe pandemics.   More research is focussed on IAV and limited global 
media coverage of IBV compared to that of IAV reinforces the perception that IBV does not 
pose a serious public health risk. 
 
1.1.3 Influenza C 
 
Influenza C virus (ICV) has a seven-segmented genome which codes for nine proteins and 
can infect humans and pigs.  In humans, influenza C has been associated with milder 
symptoms than types A and B and has been found to cause infections mostly during childhood.   
Unlike IAV, ICV has very little genetic diversity and therefore evolves at a comparatively slower 
pace.  In contrast to IAV, ICVs consist of a single subtype in humans with a novel strain 
identified in swine with no cross reaction observed between human and swine strains (Hause 
et al., 2013). 
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1.1.4 Influenza D 
 
 
Influenza D viruses (IDV) are known to infect cattle, sheep and goats (Quast et al., 2015) but 
do not infect humans.  IDV is a single-strand, negative-sense RNA virus with seven genomic 
segments encoding nine proteins.  IDV shares less than 50% of its protein sequence identity 
with ICV, its genetically closest member of the influenza virus family (Hause et al., 2013).  
Studies have shown that IDV has the ability to infect swine and ferrets (Hause et al., 2013) 
however, it’s been shown that transmission of IDV from infected cattle to ferrets via fomites 
does not occur (Ferguson et al., 2016).  Studies have shown that there are two lineages of 
IDV that share a common ancestor of approximately 44.6 years ago, suggesting that these 
lineages emerged recently (Su et al., 2017). 
 
The body of work described in this thesis will focus on the currently circulating 
seasonal influenza A virus subtype H3N2. 
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Table 1.1.1 Comparison of Current Influenza Types 
 IAV IBV ICV IDV 
Genome 
-ssRNA 
8 segments 
-ssRNA 
8 segments 
-ssRNA 
7 segments 
-ssRNA 
7 segments 
Subtypes Up to 144 
Two lineages; 
Yamagata & 
Victoria 
One Two 
Spread in 
humans 
Pandemic 
Epidemic 
Epidemic Sporadic None observed 
Antigenic 
changes 
Shift 
Drift 
Slow Drift V. Slow Drift V. Slow Drift 
Severity of 
illness in 
humans 
+++ ++ + N/A 
Vaccine 
Yes; seasonal & 
pandemic 
Yes; seasonal No No 
Animal reservoir Yes; wild birds No No 
Cattle, sheep, 
goats 
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1.1.5 History of Influenza  
 
Influenza pandemics have occurred at irregular intervals since at least the 9th century AD 
(Saunders-Hastings and Krewski, 2016). Influenza was first recognised as an infectious 
disease in the 17th Century, with recurrent epidemics of disease recorded as occurring every 
1 to 3 years over the past 400 years (Treanor, 2015). Influenza was first experimentally 
administered to ferrets in 1933 contributing significantly to the modern understanding of the 
virus (Smith et al., 1933). Major developments then followed with the discovery that the virus 
could be propagated in fertilised hens eggs (Burnet, 1936) and the ability of the virus to cause 
the haemagglutination of red blood cells (Hirst, 1942).  Both discoveries allowed for extensive 
studies of the properties of influenza. 
 
One of the worst recorded IAV pandemics in history was the 1918 Spanish Flu outbreak, which 
killed an estimated 50-100 million people worldwide. In March of 1918 severe cases of 
influenza were reported in the United States marking the first wave of Spanish Flu 
(Taubenberger J K, 2001, Watanabe and Kawaoka, 2011). Following the deployment of US 
military troops to Europe the virus began to spread throughout the US, Europe and Asia. As 
Spain was neutral during the First World War they did not have a censored media and were 
able to report on the spread of the disease, hence the name “Spanish Flu”.  The first wave of 
Spanish Flu killed relatively few people. However, by the second and third waves in the 
autumn and winter of 1918 the virus, having had several passages through humans, became 
lethal.   It is estimated that 30% of the world’s 1.7 billion individuals became clinically infected 
(Taubenberger J K, 2001, Watanabe and Kawaoka, 2011).  Due to the scarcity of antibiotics, 
secondary bacterial pneumonia is thought to have caused most of deaths.  However, the virus 
also killed quickly with either acute pulmonary haemorrhage or pulmonary oedema with the 
disease course often less than 5 days.       
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A further two milder pandemics occurred in 1957 and 1968, caused by IAV H2N2 and H3N2 
respectively. The 1957 pandemic, also known as the Asian Pandemic, first occurred in 
localised outbreaks in continental China during February and March of 1957 with the virus 
quickly reaching Hong Kong and other parts of Asia in the following weeks (Chowell, 2017, 
Influenza Other Respir Viruses).  The pandemic reached Europe in June 1957 and had spread 
to the rest of the world by August 1957.  Phylogenic studies show that the H2N2 strain that 
caused the 1957 pandemic was a genetic reassortant.  A genetic reassortant is a virus that 
has resulted from the mixing of the genetic material from two or more strains.  In 1957 this 
occurred between a previously circulating human H1N1 virus and an avian virus, with novel 
H2, N2 and PB1 (a subunit of the RNA polymerase) genes derived from an avian Eurasian 
virus (Kilbourne 2006). This highlights the key role antigenic shift plays in pandemic influenza 
outbreaks.  
 
In 1968 a novel strain of H3N2 IAV emerged in Hong Kong (Alymova et al., 2016) resulting 
from a reassortment of the HA and PB1 genes from an avian H3N2 with the NA from the 1957 
pandemic subtype. The new strain possessed the ability to infect and transmit between 
humans effectively (Westgeest et al., 2014) and the emergence of novel H3N2 led to a global 
pandemic associated with more than one million deaths worldwide.  Since 1968, H3N2 IAVs 
have circulated seasonally in the human population resulting in frequent, significant morbidity 
and mortality (Allen and Ross, 2018). The H3N2 IAV subtype has now been circulating in the 
human population for 51 years causing annual seasonal outbreaks (Fig. 1.1.5.1).  
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Figure 1.1.5.1 Introduction of Seasonal Subtypes (Hutchinson, 2018) Timeline briefly summarising 
the history of the introduction of seasonal influenza strains into global circulation. The 1918 H1N1, 1957 
H2N2, 1968 H3N2 and the 2009 H1N1 all began circulating seasonally following pandemics caused by 
these subtypes.   
 
The Global Influenza Surveillance and Response System (GISRS) was introduced by the 
WHO in 1952 to support the worldwide detection and characterisation of influenza viruses.  It 
was formerly known as the Global Influenza Surveillance Network (GISN) and the new name 
came into effect after adoption of the Pandemic Influenza Preparedness (PIP) framework in 
2011.  (The PIP framework brings together Member States, industry, stakeholders and the 
WHO to implement a global approach to pandemic influenza preparedness and response). 
GISRS performs two main functions: 
 
1) Monitoring the evolution of influenza viruses and providing recommendations in areas 
including laboratory diagnostics, vaccines, antiviral susceptibility and risk assessment 
(WHO, 2017a). 
 
2) Serving as a global alert mechanism for the emergence of influenza viruses with 
pandemic potential (WHO, 2017a). 
 
 
IAV 
pandemics 
introduce 
new 
seasonal 
strains 
H1N1 
1918 
H2N2 
1957 
H1N1 
1977 
H1N1 
2009 
H3N2 
1968 
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Globally, 143 influenza centres perform polymerase chain reaction (PCR) testing of clinical 
samples, characterising the influenza virus type and subtype, and isolate the viruses in culture.    
These centres submit samples to one of six international reference laboratories (located in 
Melbourne, Beijing, Tokyo, London, Atlanta, & Memphis) where samples undergo further 
characterisations as well a whole genome sequencing (Jernigan and Cox, 2013).  This 
increased surveillance coupled with greater movement of people and livestock has resulted in 
an increase in the recognition of novel IAVs with the ability to infect the human population.  
There are several key strains that have been identified in the past years that have remained 
under surveillance by GISRS due to their pandemic potential.   
 
In 1996 a high pathogenicity avian influenza (HPAI) A(H5N1) was first identified (WHO, 2014). 
It has now spread throughout South East Asia and beyond, with migratory birds being the 
main reservoir for the virus.  The first human cases were confirmed in Hong Kong in 1997 
(WHO, 2014). Ongoing surveillance has shown that globally from January 2003 to June 2019 
there were 861 cases of human infection with HPAI A(H5N1) reported across 17 countries.   
Of these 861 cases, 455 were fatal (WHO, 2019a). HPAI A(H5N1) causes severe disease 
characterised by a high viral load and intense inflammatory responses that progresses to 
severe pneumonia, acute respiratory distress syndrome and death; with a fatality rate of 53% 
(de Jong et al., 2006).  The majority of HPAI A(H5N1) cases have occurred following exposure 
to infected poultry, and the virus is yet to sustain successful transmission from human to 
human.  However, despite the relatively low number of human infections annually, compared 
to seasonal influenzas, the high case fatality associated with HPAI A(H5N1) infection and the 
potential for the virus to acquire a transmissible phenotype and cause a pandemic means that 
this virus is an ongoing public health threat.   
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Swine-origin influenza A(H1N1) emerged in the Americas in 2009 (Smith et al., 2009).  It was 
the first influenza pandemic of the 21st century and was the first to emerge following major 
global investment in pandemic preparedness (Leung and Nicoll, 2010).  The virus was 
identified in May 2009 (Team, 2009) as a reassortment  of a triple reassortant virus with a 
Eurasian avian-like swine virus (Fig. 1.1.5.2) containing three classical swine genes (H1, NP 
and NS), one human gene (H3N2 PB1), two North American avian genes (PB2 and PA), and 
two Eurasian avian-like swine genes (N1 and M).  While previous pandemics had been marked 
by an antigenic shift to a different subtype the 2009 pandemic involved an antigenic change 
from a human H1N1 to a swine H1N1 subtype.  
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Figure 1.1.5.2 Genesis of swine-origin H1N1 influenza viruses (Neumann et al., 2009) The diagram 
shows the origin of the 2009 pandemic H1N1.  In the late 1990s, reassortment between human H3N2, 
North American avian, and classical swine viruses resulted in triple reassortant H3N2 and H1N2 swine 
viruses that have since circulated in North American pig populations. A triple reassortant swine virus 
reassorted with a Eurasian avian-like swine virus, resulting in the swine-origin influenza virus that began 
circulating in humans in 2009.   
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Around 60% of the reported cases of swine-origin influenza A(H1N1) were reported to have 
occurred in individuals under 18 years of age (Team, 2009). The clinical characteristics of 
swine-origin influenza A(H1N1) was like those of seasonal influenza; fever, headache, 
myalgia, malaise and cough. Additionally, it was noted that patients infected with this strain 
were more likely to have gastrointestinal symptoms such as nausea, vomiting and diarrhoea.   
An estimated 1 in 10 infected patients were admitted to hospital.  In 2010 the WHO declared 
the pandemic over. The H1N1 strain in now a circulating seasonal strain (Fig. 1.5.1.1) and is 
included in the annual influenza vaccine.  
 
In March 2013 the first human infections with a low-pathogenicity avian influenza (LPAI) 
A(H7N9) virus were reported in China (Chowell et al., 2013).  Subsequently the virus spread 
rapidly throughout the country, with 1567 laboratory confirmed cases and 612 deaths recorded 
as of January 2019 (PHE, 2019).  In December 2016, the first human infection caused by a 
A(H7N9) virus strain with a poly-basic cleavage site at the HA cleavage site was recorded. 
This cleavage site is often associated with HPAI strains of avian influenza, this particular 
isolate did not appear to cause disease that differed from previous infections with LPAI 
A(H7N9) and clinical and virological evidence suggested that systemic dissemination did not 
occur (Ke et al., 2017).  However, the number of human infections with A(H7N9) and the 
geographical range of human cases in the previous wave of infection (fifth, originated 1st 
October 2016) were greater than any other previous and subsequent waves (WHO, 2017b) 
highlighting the need for continued surveillance.  
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1.1.6 Clinical Manifestation  
 
 
There are several characteristic symptoms of influenza infection, including; fever, headache, 
myalgia, malaise and anorexia, these are usually accompanied by respiratory symptoms such 
as non-productive coughing, nasal discharge, and sore throat. Cough and malaise can 
occasionally persist for up to two weeks after resolution of fever (Paules and Subbarao, 2017, 
WHO, 2018). These are known as influenza like-illness (ILI) and are often applied to a wide 
range of infectious diseases. Otitis media and vomiting is often reported in children infected 
with influenza.  Influenza can also cause primary viral pneumonia; exacerbate underlying 
conditions (such as cardiac or pulmonary disease); and lead to secondary bacterial 
pneumonia, sinusitis, or otitis media; or contribute to coinfections with other viral or bacterial 
infections (CDC, 2018).   
 
The typical incubation period for influenza is approximately 1-4 days.  Healthy adults usually 
begin to infect others 1 day before symptoms develop and can remain infectious up to 5 to 7 
days after symptoms manifest. Some groups of people, especially young children and 
immunocompromised may remain infectious for a longer period (CDC, 2018). Many 
individuals will recover from the fever and other symptoms within a week without requiring 
medical attention, however influenza infection can cause severe illness and even death, 
especially in people at high risk. Hospitalisation and deaths occur in mainly high-risk groups.   
Annual epidemics are estimated to result in approximately 3-5 million severe cases of illness 
and around 290,000 to 650,000 respiratory deaths (WHO, 2018).  Yearly epidemics can result 
in high levels of worker and school absenteeism as well as productivity loss.  In addition, clinics 
and hospitals can often be overwhelmed during peak illness periods.  
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Organisations, such as the WHO, release yearly campaigns (Fig. 1.1.6.1) to help the public 
recognise the signs of influenza infection and encourage those who are most vulnerable to 
infection to get vaccinated.    
 
 
Figure 1.1.6.1. World Health Organisation Infographic (WHO, 2019b). These infographics help 
present ideas on how influenza affects health to the public concisely. 
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1.2 Virology  
 
1.2.1 Genome  
 
Influenza A viruses have a single stranded, segmented, negative-sense RNA genome of 
approximately 13.5Kb (Fig. 1.2.1.1).  IAVs have eight gene segments, which code 17 proteins.  
To date there are 18 types of HA and 11 types of NA, with the combination of HA and NA 
subtypes providing the basis for IAV classification (Deng et al., 2015). 
 
 
Figure 1.2.1.1 Influenza Genome (ViralZone, 2014) Segmented ssRNA(-) linear genome.  Contains 
8 segments coding for 17 proteins depending on strains. Segments size range from 890 to 2,341nt. 
Genome total size is 13.5Kb. 
 
The majority of IAV subtypes are found in avian, and some in swine, human and other species 
such as bats.  For IAVs to be capable of infecting multiple host species they require 
adaptations to allow replication in different host cells, increasing their fitness and permitting 
sustainable replication and transmition of the virus.  For example, it is well recognised that 
avian IAV HAs have a binding preference for α-2,3  sialic acid residues, commonly found on 
the surface of avian cells.  To gain entry to human cells, with α-2,6 sialic acid residues, 
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modifications to the HA binding site may be required to allow this interaction (Horman et al., 
2018).   
 
Currently H1N1 and H3N2 are the subtypes of IAV circulating endemically in the human 
population; with sporadic cases of human infection with other IAV subtypes such as H5N1 and 
H7N9 in recent years. The influenza RNA genome has a high mutation rate because the viral 
RNA polymerase does not have the ability to proofread, unlike DNA polymerase, and therefore 
more errors are introduced into the genome.    
 
The plasticity of influenza’s RNA genome means that it can undergo two processes, antigenic 
drift and antigenic shift (Fig. 1.2.1.2).  Antigenic drift occurs due to gradual changes in the 
surface antigens of the virus, the HA and NA.  These two proteins continuously evolve due to 
host immune pressures from previous influenza infections. This causes seasonal epidemics.  
In contrast to this, the six internal genes of the virus are relatively conserved.  Antigenic shift 
occurs less frequently and is caused by the sporadic genetic reassortment between different 
IAV subtypes from avian and swine species, and less frequently from humans.   Such a 
reassortment took place to produce the 2009 swine flu pandemic virus (Smith et al., 2009), 
where genes from several influenza swine origins reasserted (Garten et al., 2009).  Antigenic 
shift can lead to pandemic influenza outbreaks. 
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Figure 1.2.1.2. Antigenic Drift and Antigenic Shift (Hutchinson, 2018) An illustration of the 
mechanisms of antigenic drift and antigenic shift.  
 
The IAV genome (Fig. 1.2.1.3) is made up of eight viral ribonucleoproteins. These encode the 
proteins described below.  The surface of the virion is coated in the haemagglutinin (HA) and 
neuraminidase (NA) glycoproteins.  The virus surface protein (M2) acts as an ion channel and 
the nuclear export protein (NEP) mediates the export of vRNP complexes from the nucleus.    
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Figure 1.2.1.3 Influenza A Virion (Tao and Zheng, 2012) The IAV genome is composed of eight viral 
ribonucleoproteins (vRNP) complexes.   
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Table 1.2.1.1 contains a summary of the eight segments of the influenza genome, the protein 
name and a brief function 
 
Table 1.2.1.1 Summary of Influenza A Virus Genome 
Segment Protein Function(s) 
1 PB2 Cap-binding subunit of the viral RdRp;cap-binding 
2 PB1 Central location of the polymerase domain of the viral RdRp 
3 PA Cap-snatching endonuclease subunit of the viral RdRp 
4 HA Surface glycoprotein; receptor binding, membrane fusion 
5 NP Nucleoprotein; encapsidation of viral genomic and anti-genomic RNA 
6 NA Surface glycoprotein; receptor destroying neuraminidase activity enabling 
virus release  
7 M1 Matrix protein 
  M2 Ion channel activity 
8 NS1 
Regulation of viral RdRp activity; Interferon antagonist; Enhancer of viral mRNA 
translation.  
  NEP Nuclear export factor 
 
 
 Haemagglutinin (HA)  
 
The haemagglutinin (HA) gene encodes the major viral surface antigen that is responsible for 
sialic acid binding and membrane fusion protein during virus entry into cells.  The HA consists 
of two domains; a globular head (HA1) and stalk domain (HA2), linked by a single disulphide 
bond following cleavage from a single polypeptide precursor (HA0) (Skehel and Wiley, 2000).   
Cleavage of precursor HA0 by host proteases is a prerequisite for virus infectivity (Hashem, 
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2015) as well as a determinant of virulence and tissue tropism (Bertram et al., 2010). The 
receptor binding and antigenic sites are located at the immune-dominant globular head which 
continuously undergoes antigenic drift. The HA is highly variable and is classified into 18 
subtypes, which cluster into two major phylogenetic groups (Medina and García-Sastre, 
2011).  Antibodies that are directed against the stalk tend to be less effective but are broadly 
neutralising against seasonal and pandemic strains.  
 
During viral replication the HA glycoprotein binds to specific sialic acid receptors on the surface 
of susceptible cells. Human IAVs target α 2, 6- linked sialic acid receptors which are found in 
abundance in the upper respiratory tract of humans while avian influenza viruses target α 2, 
3- linked sialic acid receptors distributed in the intestinal tract of birds and lower respiratory 
tract of humans.  Following binding of the HA to the sialic acid receptors the virus enters the 
cell via receptor mediated endocytosis. Following this a drop in the pH in the endosome leads 
to a conformational change of the HA which then mediates fusion of the viral membrane with 
the endosomal membrane and the viral ribonucleoproteins are released into the cell.  It is 
thought that the HA stalk could be a promising target for a future universal vaccine, however 
some have suggested this may not be the case as the stalk is also susceptible to immune 
pressures (Anderson et al., 2017).  
  
 Neuraminidase (NA) 
 
Neuraminidase (NA) enables the virus to be released from the host cell and is not required for 
viral entry. Neuraminidases are receptor destroying enzymes that function as sialidases by 
cleaving sialic acid groups from glycoproteins. They are required for influenza virus release 
preventing HA mediated aggregation of nascent virus particles at the surface of the viral cell 
and allowing for viral release (Krammer et al., 2014).   
22 
 
 
NA is a homotetrameric protein (made up of four identical subunits), with each subunit 
composed of a stalk domain which supports a head domain.  NA is classified into 11 subtypes, 
N1 to N11. Much like HA, NA sequences can be phylogenetically classified into two groups; 
Group 1 including N1, N4, N5 and N8 and Group 2 including N2, N3, N6, N7 and N9. The 
more recently discovered novel NA subtypes isolated in bats (N10 and N11) appear to be 
quite distantly related to existing subtypes and do not display any sialidase activity (Tong et 
al., 2013). In the absence of NA activity the virus is able to infect the cell and carry out one 
replication cycle, but virus particles are unable to be cleaved from the host cell surface and 
fail to spread to uninfected cells (Palese et al., 1974).    
 
 Matrix (M) 
 
The Matrix (M) gene encodes the matrix – 1(M1) and matrix – 2 (M2) proteins.  The M1 protein 
is a membrane/RNA-binding protein with two functions. It mediates the encapsidation of RNA-
nucleoprotein cores into the membrane envelope. It also mediates the transport of newly 
synthesised viral nucleoproteins from the nucleus to the cytoplasm.  The M2 protein is a 
proton-selective ion-channel protein, integral in the viral envelope. The ion channels are 
responsible for the acidification of the virion and neutralisation of pH in the endosomes and 
Golgi network, early and late in the virus replication. The M1 and M2 proteins have been found 
to be highly conserved among different sub-types of influenza (Kreijtz et al., 2011).   
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 Polymerase Basic Protein 1 (PB1), Polymerase Basic Protein 2 (PB2) and 
Polymerase Acidic Protein (PA) 
 
Polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2) and polymerase acidic 
protein (PA) working together make up the IAV viral polymerase.  Following release of viral 
ribonucleoproteins into the cell, viral proteins are trafficked to the cell’s nucleus where the viral 
RNA-dependent RNA polymerase complex transcribes and replicates the viral nucleoproteins.   
  
 Nucleocapsid Protein (NP) 
 
The Nucleocapsid Protein (NP) plays a central role in viral replication by encapsidating the 
virus genome for the purposes of RNA transcription, replication and packaging (Eisfeld et al., 
2015) . The NP is a structural protein with no intrinsic enzymatic activity (Compans et al., 
1972) and is an important target for protective T cells.  Following virus replication genetic 
material is packaged and released from infected cells.  Each of the eight genome segments 
are associated with multiple NP molecules and a single, trimeric polymerase comprising of the 
PB2, PB1 and PA proteins.  This complex of vRNA-NP-polymerase is referred to as the viral 
ribonucleoprotein (vRNP) (Eisfeld et al., 2015). 
 
 Non- Structural (NS) 
 
The non-structual (NS) gene encodes non-structual protein 1 (NS1) and the nuclear export 
protein (NEP).  NS1 is multifuctional with the ability to regulate viral RNA-dependent RNA 
polymerase activity, enhance viral mRNA translation and act to circumvent antiviral repsonses 
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of the host.   NEP acts to mediate the export of the virus ribonucleoprotein complexes from 
the nucleus alongside M1. 
 
 Accessory Proteins 
 
In addition to the eight major viral proteins encoded by the IAV segmented genome, various 
accessory proteins have been identified that have been shown to modulate influenza infection 
both in vitro and in vivo.  
 
PB1-F2  
The translation of PB1-F2 occurs in a second open reading frame of the PB1 gene segment 
via a leaky ribosomal scanning mechanism (Chen et al., 2001). PB1-F2 has been implicated 
in regulation of polymerase activity, immunopathology, susceptibility to secondary bacterial 
infection, and induction of apoptosis (Buehler et al., 2013). Leaky ribosomal scanning 
combined with re-initiation of PB1 mRNA is also responsible for the translation of a third 
protein known as N-40 (Wise et al., 2011). 
 
PB2-S1 
PB2-S1 is translated from spliced mRNA transcribed from the PB2 segment and appears to 
be conserved among pre-2009 human pandemic H1N1 viruses. This protein is able to bind to 
PB1, localise to mitochondria, and inhibit the RIG-I-dependent signalling pathway (Yamayoshi 
et al., 2016).  
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PA-X  
When IAV enters the cells it relies of the molecular machinery of the host to help it replicate, 
relying on the ribosomes of the host cell to translate viral messenger RNA (mRNA) into 
polypeptides.  “Host shut-off” occurs when IAV impairs the translation of cellular mRNA to 
prevent the production of anti-viral, host defence proteins.  PA-X is a novel protein expressed 
by ribosomal frameshifting has been found to play a major role in influenza virus-induced host 
shut-off (Hayashi et al., 2016).  
 
PA-N155 & PA-N182 
Expression of PA-N155 and PA-N182 is universal among most IAVs and also occurs due to 
leaky ribosomal scanning (Gong et al., 2014).     
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1.3 Transmission of Influenza 
 
Transmission of an infectious disease is the process by which an infectious organism moves 
from one host to another and causes disease. There are many factors that contribute to and 
influence this process and to appreciate them one must first understand the basic 
pathophysiology of the underlying disease process (Killingley and Nguyen-Van-Tam, 2013). 
 
The multiple mechanisms affecting influenza transmission are still not fully understood and 
this influences infection prevention and mitigation strategies during outbreaks. There are 
several key factors that can affect the effective transmission of IAV.  
 
1.3.1 Host Specificity of Influenza 
 
The human respiratory tract expresses α2-6-linked sialic acids more abundantly in the upper 
respiratory tract when compared to the lower respiratory tract (Fig. 1.3.1.1). In the 
nasopharynx of humans SA receptors are detected on both ciliated and mucus producing 
cells. In contrast, in the bronchus, these receptors are distributed in the epithelium with no 
obvious distinction between ciliated and non-ciliated cells (de Graaf and Fouchier, 2014).   
It has been noted that the bronchial epithelium of the human respiratory tract contains a 
higher percentage of α2-3-linked SAs compared to α2-6-linked SAs (Nicholls et al., 2007).  
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Figure 1.3.1.1 Distribution of sialyl (α2-3) and/or (α2-6) linkages containing oligosaccharides in 
human respiratory tracts (Yoo, 2014). The human lungs and lower respiratory tract have mainly sialyl 
(α2-3)-linked receptors for avian viruses, such as H5N1. The human bronchus and upper respiratory 
contain mixtures of (α2-3)- and (α2-6)-linked sialic acid, which are receptors for human-adapted viruses, 
such as H3N2 and H1N1. The bronchus contains more (α2-3)-linked sialic acid than does the upper 
respiratory tract. 
 
Birds have both α2-3-linked SAs and α2-6-linked SAs in their respiratory and intestinal tract, 
with the abundance of these receptors varying amongst species.  Pigs also express both 
α2-3-linked SAs and α2-6-linked SAs in their respiratory tract (de Graaf and Fouchier, 
2014).  Ferrets are used as the ‘gold standard’ experimental animal model because they 
have a similar α2-3-linked SA and α2-6-linked SA distribution throughout their respiratory 
tract as humans (Kirkeby et al., 2009). Much like humans, α2-6-linked SAs are found in 
abundance in the trachea and bronchus on ciliated cells and submucosal glands. With 
alveoli expressing both α2-6-linked SA and α2-3-linked SA, with the former being far more 
abundant (Jayaraman et al., 2012).   
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Sialic acid moiety is fundamental to species specificity of IAVs.  The majority of mammalian 
and avian species present two main types of sialic acid on the terminal positions of the glycan 
of their glycoproteins or glycolipids. The receptor binding site on the HAs of avian IAVs bind 
to the thin, straight trans confirmation α2-3-linked SAs (Fig. 1.3.1.2A), whereas human-
adapted IAVs HAs bind to a bulkier cis conformation α2-6-linked SA (Fig. 1.3.1.2B).  Human 
IAVs have adapted mutations in the receptor binding site of their HAs allowing them to bind 
to this bulkier cis conformation. Receptor specificity of IAV strains has consequences for 
HPAI such as H5N1 infecting humans.  H5N1 undergoes limited replication in the human 
respiratory tract due to the limited number of α2-3-linked SAs. However, efficient human to 
human transmission of these viruses requires that avian influenzas recognise α2-6-linked 
SAs. For example, isolates from the 1918, 1957 and 1968 pandemics suggest that these 
viruses preferentially recognise α2-6-linked SAs.   
 
 
Figure 1.3.1.2 (Yoo, 2014) IAV HAs bind to sialic acids (SAs) on the cell surface.  SAs are terminal 
sugars lined to larger glycans of glycoproteins and glycolipids on vertebrate cells.  Differences in the 
structure of the SAs can determine species specific susceptibility to IAV infection (A & B). 
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Human infection with avian or swine IAVs occur sporadically and do not usually result in the 
establishment of a new lineage. The viral HA protein and its ability to bind to specific SA 
receptors has been identified as a major host restriction factor that can limit interspecies 
transmission.   
 
1.3.2 Physical Transmission of Influenza  
 
There are three routes of human influenza infection transmission that are widely accepted: 
 
 Droplet (>5µm): Large droplets that deposit in the upper respiratory tract such as the 
mouth and the nose.   
 Droplet nuclei (<5µm): Small aerosol particles that can be deposited along the 
respiratory tract and can reach the lower respiratory tract. 
 Contact transmission: Particles are transferred to mucous membranes of the upper 
respiratory tract either directly or via contaminated object or person (Killingley and 
Nguyen-Van-Tam, 2013). 
 
Currently, evidence on influenza transmission supports a potential role for all the above routes.  
Transmission can likely occur through multiple routes during the same ‘event’ and therefore is 
a dynamic and opportunistic process.  
 
Respiratory droplets can be expelled by talking, coughing, sneezing and normal tidal 
breathing.  There is evidence that humans generate infectious particles in both respiratory 
droplets and aerosols (Lindsley et al., 2010) and this is enhanced during influenza infection 
(Lindsley et al., 2012). Data from ferret studies also shows that when the animals are infected 
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with highly transmissible human influenza viruses (H3N2 & H1N1) they exhale and sneeze 
out more respiratory particles overall than those infected with poorly transmissible avian 
influenzas (H5N1) (Gustin et al., 2013).  Experimental data has also confirmed the association 
between influenza transmissibility in ferrets and the amount of viral RNA found in exhaled 
aerosols (Lakdawala et al., 2011). However, the longer the time between the inoculation of 
the donor and the exposure of the naïve ferret, the less efficient the transmission despite viral 
RNA level remaining constant over the monitored timeframe (5 days) (Koster et al., 2012).    
 
Transmission via fomites (inanimate objects that can transfer disease when contaminated with 
an infectious agent) can occur when infectious particles are deposited onto hand-touch 
surfaces.  These surface act as a vector for the transfer of viral particles to mucus membranes 
of susceptible individuals.  The detection of infectious virus from surfaces is relatively limited 
and often constrained by low collection efficiencies associated with swab sampling and high 
detection limits of influenza enumeration assays (Killingley et al., 2010).  However, it has been 
shown that viability of influenza viruses can be maintained for a considerable period if the 
initial viral titres are high enough (Thompson and Bennett, 2017).  
 
1.3.3 Environmental factors affecting transmissibility 
 
Studies have reported that variations in humidity and temperature are important in IAV survival 
and therefore ability for the virus to be transmitted.  For example, at constant humidity avian 
IAVs have been shown to remain viable in aerosols for longer periods of time that human IAVs 
(Mitchell et al., 1968).  Influenza transmission has also been shown to have increased 
efficiency at lower relative and absolute humidities (Lowen et al., 2007) which correlates with 
findings that show the biological decay of IAVs increases as relative humidity is increased 
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(Richard and Fouchier, 2016).  Higher temperatures (of around 30ºC) have also been shown 
to be detrimental to transmission of IAVs (Lowen et al., 2008).    These findings suggest that 
cool dry conditions enhance influenza survival and transmissibility and could be one 
explanation for the seasonality of influenza.  
 
1.3.4 Zoonotic Transmission of Influenza 
 
Researchers are yet to have a complete picture of the factors and mechanisms that are 
required for influenza virus transmission within species and between species.  (Fig. 1.3.4.1) 
Zoonotic transmission of IAVs from wildfowl to humans is rarely reported, most likely due to 
the frequency of human exposure to large, wild bird populations.  Far more common is the 
zoonotic transmission of IAVs through an intermediate host such as poultry or swine to 
humans. This is thought to be due to more frequent exposure to these animals through 
agricultural practices.  Most of these transmission events do not include human to human 
transfer and result from close contact with animals either at markets or on farms.   
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Figure 1.3.4.1 Zoonotic transmission of Influenza  (Richard and Fouchier, 2016) Potential routes 
of transmission and adaptation of influenza viruses. Many scenarios could support the transmission of 
influenza viruses from their original reservoir to humans and subsequent adaption to transmit via the 
airborne route: (i) direct transmission from waterfowl to humans and subsequent adaptation in humans; 
(ii) transmission from waterfowl to intermediate hosts, adaptation in these hosts and subsequent 
transmission to humans; and (iii) reassortment in intermediate hosts of influenza viruses originating 
from diverse animals species and transmission to humans. 
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1.3.5 Cell Entry, Replication, Assembly and Movement 
 
 Attachment 
 
IAVs use the HA molecules on their envelope surface to initiate the infection process (Fig. 
1.3.5.1.1). The HA receptor-binding site attaches the virus surface to terminal sialic acid 
residues (Hamilton et al., 2012, Gamblin and Skehel, 2010) and the HA-mediated binding to 
the receptor triggers endocytosis of the virion. Endocytosis occurs either by 
macrophagocytosis (de Vries et al., 2011, De Conto et al., 2011), or in a clathrin-dependent 
manner (Lakadamyali et al., 2004).  Once the virus has successfully entered the cell it is 
trafficked to the endosome where the low pH activates the M2 ion channel on the viral 
envelope causing a conformational change in the HA exposing the fusion peptide.  The 
opening of the M2 ion channel allows the inside of the virus to become acidified causing the 
release of the packaged vRNPs to the host cell cytoplasm.    Fusion of the viral-endosomal 
membranes occurs through several steps and requires the cleavage of the HA into two 
subunits, HA1 and HA2, by host cell proteases. 
 
 
34 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.5.1.1 Influenza replication cycle (Hutchinson, 2018) A brief summary of the replication 
cycle of influenza virus. Influenza viruses infect the respiratory epithelium. The haemagglutinin (HA) 
proteins of IAV bind sialic acid, causing endocytosis. The viral genome replicates in the nucleus. New 
viruses assemble at the cell surface and are released by the receptor-cleaving neuraminidase (NA) 
proteins of IAV. 
 
 Replication & Transcription 
 
Once inside the nucleus the viral RNA-dependent RNA polymerase functions to carry out the 
transcription and replication of vRNA (Pflug et al., 2017).  Replication occurs in two steps: 
transcription of complimentary RNA (cRNA) and transcription of new vRNA using the cRNA 
as templates (Matsuoka et al., 2013).  
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 Translation 
 
IAV viral mRNAs are translated by the host cell translation machinery.  Following synthesis in 
the cytoplasm, the viral polymerase subunit proteins and NP are imported into the nucleus via 
their nuclear localisation signals to catalyse the replication and translation of vRNA (Matsuoka 
et al., 2013).  M1 and NEP/NS2 are imported into the nucleus as part of their role in vRNP 
nuclear export. Meanwhile NS1 is also imported into the nucleus for its role in the processing 
and export in cellular and viral mRNAs (Schneider and Wolff, 2009). 
 
 Assembly and Budding 
 
Viral NEP/NS2 and M1 help export newly synthesised vRNP from the nucleus. Following 
synthesis by cellular machinery HA, NA and M2 proteins enter the endoplasmic reticulum 
(Klenk et al., 2001).  These proteins are then transported to the plasma membrane of the cell 
where HA and NA associate with distinct membrane regions rich in sphingolipids and 
cholesterol (lipid rafts) (Gerl et al., 2012) (Lingwood and Simons, 2010, Dou et al., 2018).  
Virion assembly and incorporation of the eight vRNPs occurs following specific signals from 
the viral RNAs.  The M2 protein appears to mediate membrane scission and particle release 
(Rossman et al., 2010).   The virus is then released from the cellular membrane by the enzyme 
activity of viral NA protein.  
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1.4 The Immune Response to Influenza  
 
 
 
Figure 1.4.1 Innate and adaptive immune responses to influenza (Nüssing et al., 2018)  IAV 
infection leads to activation of innate cells, such as macrophages and neutrophils, to secrete pro-
inflammatory cytokines resulting in the recruitment of other leukocytes. Innate T cells play an important 
role in reducing the effects of influenza infection by the secretion of cytokines and cytotoxic molecules. 
Innate T cells provide important signal molecules to enhance antigen presenting cell activity, which 
present influenza antigens to CD8+ T cells and CD4+ T cells for effective viral clearance.  
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1.4.1 The Innate Immune Response  
 
The first line of defence against influenza is chiefly controlled by the innate immune response.      
The mucosal barrier produces a sialic acid rich layer of mucus which is able to bind viral HA 
protein and trap some of the influenza virus particles that have infected the host (Matrosovich 
and Klenk, 2003).  This mechanism effectively acts to reduce the infectious dose to the host 
(Cohen et al., 2013) by preventing the infection of epithelial cells. Following successful 
infection pattern recognition receptors (PRRs) can recognise viral RNA, the major pathogen-
associated marker pattern (PAMP) of IAV. The PRRs consist of host cell toll-like receptors 
(TLRs), retinoic acid inducible gene-I (RIG-I) and the NOD- like receptor family pyrin domain 
containing 3 (NLRP3) protein (Pang and Iwasaki, 2011). Following signalling via these 
receptors type I interferons and pro-inflammatory cytokines are produced.  The expression of 
interferon alpha (IFN-α) and interferon beta (IFN-β) is stimulated, both of which possess 
antiviral activity by inhibiting protein synthesis in host cells therefore limiting viral replication 
(Kreijtz et al., 2011). Interferon stimulated genes are also induced by type 1 interferons via the 
JAK/STAT signalling pathway.  One of these genes is the myxovirus gene that encodes the 
MxA protein which has been shown to have strong antiviral activity that inhibits influenza 
replication (Haller and Kochs, 2002). 
 
Type I interferons also stimulate dendritic cells (DCs) which act as antigen-presenting cells 
(APCs) during influenza infection. This stimulation results in enhanced antigen presentation 
to CD4+ and CD8+ T cells (lymphocytes that mature in the thymus and express a T cell 
receptor (TCR)).  DCs  are usually situated underneath the airway epithelium barrier and are 
able to monitor the airway lumen, detecting and opsonising virions and apoptotic bodies from 
infected cells (Kreijtz et al., 2011). They can also be infected themselves, and upon infection 
migrate to the draining lymph node presenting the influenza virus-derived antigens to T cells 
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and activating them (Hintzen et al., 2006) therefore contributing to the adaptive immune 
response.  DCs degrade the viral proteins and present the immune-peptides by major 
histocompatibility complex (MHC) class I or class II molecules. MHC class I presentation 
occurs when IAV derived peptides are released in the cytosol and transported to the 
endoplasmic reticulum where they associate with MHC class I molecules.  These are then 
trafficked to the cell membrane where they are recognised by specific CD8+ cytotoxic T cells.   
MHC class II presentation occurs when IAV proteins are degraded in endosomes or 
lysosomes giving rise to peptides which associate with MHC class II molecules.  Again, these 
molecules are trafficked to the cell membrane, and recognised by CD4+ T helper cells (Kreijtz 
et al., 2011).  
 
Alveolar macrophages become activated and phagocytose influenza infected cells upon 
infection of the alveoli.   This action can limit viral spread (Tumpey et al., 2005, Kim et al., 
2008).  Conversely, following activation, alveolar macrophages produce tumour necrosis 
factor alpha (TNF-α) nitric oxide synthase 2 (NOS2) which contribute towards the virus 
induced pathology found in the lung (Jayasekera et al., 2006, Lin et al., 2008). These two 
contrasting functions of alveolar macrophages highlight the careful balancing act of responses 
during IAV infection.   Highly pathogenic avian influenza viruses such as H5N1 have been 
shown to infect both blood-derived and alveolar macrophages due to their ability to cause 
systemic infection, and are therefore more prone to causing immunopathology (Peiris et al., 
2010).   
 
Natural killer (NK) cells are important effector cells of the innate immune response.  They 
perform antibody-dependent cell cytotoxicity by recognising antibody-bound IAV infected cells 
and lysing them.  NK cells recognise IAV infected cells via two cytotoxicity receptors, NKp44 
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and NKp46.  Once bound to the IAV haemagglutinin the receptor triggers the NK cell to lyse 
the infected cell (Arnon et al., 2001, Mandelboim et al., 2001).   
 
1.4.2 The Adaptive Immune Response  
 
The adaptive immune response is responsible for eliminating pathogens from infected hosts, 
preventing pathogen replication and spread, and generating immunological memory (Bonilla 
and Oettgen, 2010).  It comprises of humoral and cellular immunity mediated by IAV specific 
antibodies produced by B cells (lymphocytes that mature in bone marrow) and T cells.  
 
B cells are activated and differentiate into antibody-secreting plasma cells or memory B cells 
following binding of antigen to membrane bound surface cell receptors. Antibodies are ‘Y’ 
shaped glycoproteins that consist of two identical heavy (H) polypeptide chains and two 
identical light (L) polypeptide chains linked by di-sulphide bonds. Different parts of the antibody 
molecule are responsible for specific functions. Antibody specificity is mediated by the binding 
of fragment antigen binding (Fab) domains of antibodies to the antigenic target. On the other 
end of the antibody is a constant region known as the fragment crystallisable (Fc) domain 
which binds to cell surface receptors providing a link between the antibody recognition of the 
infected cell and the effector cell.    Antibodies function by binding to and coating pathogens 
or cells, allowing them to be targeted for destruction by phagocytosis, death or, in the case of 
viral infection, degranulation of the pathogen infected cell which induces lysis or apoptosis of 
the target cell. This process is known as antibody dependent cellular cytotoxicity (ADCC).  In 
humans NK cells are the primary effector for ADCC, but ADCC of influenza-infected cells has 
been demonstrated in neutrophils, monocytes, lymphocytes and core blood cells (Jegaskanda 
et al., 2016). 
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There are two main classes of T cell, defined by the co-receptor they express; CD4+ or CD8+.  
Upon activation CD8+ T cells differentiate into cytotoxic T lymphocytes (CTLs), which kill 
infected cells or tumour cells by inducing apoptosis.  CD4+ cells differentiate into T helper (Th) 
cells which release cytokines that can stimulate further T cell function, macrophage activation 
or B cell antibody production.  Th cells can further be divided into Th1, Th2, Th17 and 
regulatory T (Treg) cells based on cytokine secretion profiles and functions (Bonilla and 
Oettgen, 2010).  Th1 cells are associated with the regulation of intracellular pathogens and 
produce cytokines such as interferon gamma (IFN-γ) and IL-12. Th2 cells are involved in the 
protection of the body against extracellular pathogens and helminths producing cytokines such 
as IL-4, IL-5 and IL-13.  Th17 cells are characterised by the production of IL-17 and are 
important in the defence against extracellular pathogens, and have also been linked to 
autoimmunity (Bettelli et al., 2008).  
 
 Humoral Immune Response  
 
IAV infection induces a viral-specific antibody response (Mancini et al., 2011), with the most 
significant antibodies produced against the HA and NA (Gerhard, 2001). HA specific 
antibodies can neutralise the virus as the action of binding to the trimeric globular head of HA 
inhibits viral attachment and entry into the host cell.   Antibodies against the HA are a well-
established correlate of protection providing they match the virus causing infection (de Jong 
et al., 2000).   Antibodies to NA have been shown to have protective potential.  NA antibodies 
do not directly neutralise the virus, but they have been shown to inhibit enzymatic activity 
limiting the spread of the virus. NA specific antibodies also facilitate ADCC and may also 
contribute to the clearance of virus-infected cells (Mozdzanowska et al., 1999).   Antibodies 
against the matrix (M2) protein do exist, however the protein is in such low concentrations in 
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infected cells that they are only raised to a limited extent (Kreijtz et al., 2011).  Nucleoprotein 
(NP) antibodies may also contribute to protection against influenza (Carragher et al., 2008). 
 
The main antibody isotypes in the influenza-specific humoral immune response are 
immunoglobulin A (IgA), IgM and IgG. Secretory IgA or mucosal antibodies locate to the site 
of infection affording protection by trans epithelial transport by using the mucus of the 
respiratory tract.  These antibodies are also able to neutralise intracellular virus (Mazanec et 
al., 1995).  Serum IgA antibodies are usually produced following IAV infection and the 
presence of these antibodies is a marker for recent IAV infection (Rothbarth et al., 1999), while 
serum IgG antibodies move via transudate into the respiratory tract and provide long-lived 
protection (Murphy et al., 1982). Finally, IgM antibodies are known to initiate complement 
mediated neutralisation of IAV and are a characteristic of primary infection (Jayasekera et al., 
2007).   
 
ADCC against influenza can be mediated by multiple cell types and can arise following 
infection or vaccination.  It’s thought that ADCC is primarily directed against HA, however other 
antigens to ADCC cannot be ruled out.  As stated previously, antibodies directed against the 
globular head of HA lack breadth of recognition across strains, while antibodies directed 
against the more conserved HA stem can recognise multiple strains and subtypes of HA (Air, 
2015). Antibodies with neutralisation and haemagglutination inhibition activity tend to be 
directed against the HA head domain.  
 
ADCC mediating antibodies also target other proteins on the virus surface.  NA antibody titres 
have been shown to correlate with protection against influenza (Murphy et al., 1972, Couch et 
al., 2013, Memoli et al., 2016), however NA responses are not as well documented as HA 
responses. NA is present in most vaccines originating from influenza virions, however unlike 
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HA it is not quantified for the vaccine and therefore its contribution towards protection in not 
well understood.   The highly conserved M2 antigen has also been shown to have antibodies 
to M2  mediated ADCC and shown protection in mouse studies (Von Holle and Moody, 2019). 
Additionally, the influenza nucleoprotein (NP) has been shown to mediate ADCC in vitro and 
humans vaccinated with the seasonal vaccine have demonstrated H7N9 cross-reactive ADCC 
activity that correlated with binding to NP (Jegaskanda et al., 2016).  
 
 Cell-mediated Immune Response  
 
The cellular immune response to IAV involves the activation of phagocytes, antigen-specific 
cytotoxic T-lymphocytes (CTLs), and the release of various cytokines in response to antigen.  
CD8+ and CD4+ T cells have distinct but significant roles in the control and clearance of 
influenza (Doherty and Christensen, 2000).   
 
Influenza-specific CD8+ T cells play a key role in broadly cross-reactive immunity to influenza 
viruses because they recognise small peptide fragments (8-11 amino acids) derived from 
highly conserved internal viral proteins presented as MHC class I molecules.   Influenza-
specific CD8+ T-mediated cross-protection against different influenza subtypes has been 
supported by several animal studies (Altenburg et al., 2015).  CD8+ T cells recognise the more 
conserved internal proteins of IAV allowing them to be broadly cross protective (Fig. 1.4.2.2.1).  
Therefore, pre-existing CD8+ T cell immunity cannot prevent IAV infection but are important 
in controlling an mediating recovery from infection (Wang et al., 2015).  Upon infection CD8+ T 
cells differentiate into CTLs which go on to release cytokines and effector molecules to restrict 
viral replication and kill virus-infected cells (Chen et al., 2018).  
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Figure 1.4.2.2.1. CD8+ T cells providing protection (Grant et al., 2016) (a) Infection of a naïve 
individual will elicit humoral and cellular mediated immunity.  (b) Re-infection with the same IAV strain 
reactivates immune memory and antibodies  neutralise the virus with CD8+ T cells (c)  During infection 
with a novel IAV strain neutralising antibodies will not bind, however CD8+ T cells that recognise 
conserved internal proteins will mediate immunity, still providing protection.  
 
Naïve CD8+ T cells are activated by dendritic cells that have migrated from the lungs to the 
T-cell zone of the draining lymph nodes, this leads to T cell proliferation and differentiation into 
CTLs (Ho et al., 2011).  CTLs then migrate from lymph nodes to the lungs where they can kill 
influenza infected cells. CTLs can release cytotoxic granules, such as perforin and granzymes, 
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that are able to destroy virus infect cells.    Following infection, virus-specific memory CTLs 
circulate in blood, lymphoid organs and the site of infection. Therefore they are able to respond 
to secondary influenza infection by recognising conserved influenza epitopes such as M1 and 
NP (Grant et al., 2016).   The CTL response is heterosubtypic in nature. Heterosubtypic 
immunity can be defined as cross-protection to infection with an IAV virus strain other than the 
one used for primary infection.   
 
A longitudinal study in China has shown that recovery from severe H7N9 infection in humans 
was associated with robust early CD8+ T cell responses, in contrast, patients who succumbed 
to infection had delayed and/or minimal cytotoxic CD8+ T cell responses (Wang et al., 2015).  
Influenza-specific CD8+ T cells have been found to be stable in the peripheral blood of healthy 
adults over a period of 13 years, demonstrating that CD8+ T cells are long lived (van de Sandt 
et al., 2015b).   There have been a variety of studies demonstrating that human CD8+ T cells 
specific for seasonal IAVs are cross-reactive across avian IAVs; H7N9 (Quiñones-Parra et al., 
2014, van de Sandt et al., 2014), H5N1 (Kreijtz et al., 2008, Lee et al., 2008), and the two-
lineages of IBV (van de Sandt et al., 2015a).  
 
CD4+ T cells recognise viral peptide fragments presented on MHC II molecules and perform 
an important part of promoting optimal CD8+ T cell and B cell responses during influenza 
infection.   Naïve CD4+ T cells are activated in the draining lymph node following IAV infection 
much like CD8+ T cells.  They go on to differentiate into Th1 cells following infection.  Th1 
effector CD4+ T cells produce cytokines such as IFN-γ, TNF and IL-2, and migrate to the lung 
activating alveolar macrophages (Liu et al., 2012).  
 
CD4+ T cells also differentiate into Th2, Th17 and Treg, follicular helper T cells and killer cells 
(Zhu et al., 2010).   Th2 cells have been shown to bind to virus-derived MHC class II-
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associated peptides by APCs and produce several cytokines to promote B cell responses.  
Th17 and Treg cells have been shown to be involved in regulating cellular immunity again 
influenza (Mukherjee et al., 2011) and memory CD4+ T cells can regulate early innate 
responses upon influenza infection independent of PAMP recognition (Strutt et al., 2010).  
 
T cell soluble mediators 
 
CTLs and Th cells produce a wide variety of cytokines and chemokines (Fig 1.4.2.2.2).   The 
T cell receptor (TCR) mediated production of soluble mediators is important for viral clearance 
and to minimise inflammation.   
 
 
Figure 1.4.2.2.2 T cell soluble mediators the major types of soluble T cell mediator produced by 
effector T cells during IAV infection.    
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IFN-γ 
The most well-known cytokine produced by influenza-specific Th cells and CTLs upon 
infection is interferon gamma (IFN-γ).  Peak IFN-γ production has been shown to coincide with 
the arrival of influenza-specific Th cells and CTLs into the respiratory tract (Hufford et al., 
2011). 
 
IFN-γ activates immune cells (macrophages), upregulates immunomodulating molecules 
(MHC), and modulates antibody isotype switching (the change of a B cell’s immunoglobulin 
from one type to another). IFN-γ most likely contributes to viral clearance but isn’t essential 
due to other antiviral mechanisms. It’s been demonstrated that despite its activity, IFN-γ 
deficiency was not shown to have an impact on influenza clearance (Graham et al., 1993). 
The absence of IFN-γ has also been linked to reduced tissue damage, most likely due to 
recruitment of leukocytes (Wiley et al., 2001). It’s also thought that IFN-γ may contribute to a 
patient’s susceptibility to secondary bacterial infections often seen in severe influenza 
infections (Sun and Metzger, 2008).   
 
TNF 
Tumour necrosis factor (TNF) is a pleotropic cytokine, with its functions dependent on target 
cell type as well as inflammatory environment (Parameswaran and Patial, 2010).    TNF is 
commonly produced in conjunction with IFN-γ by both influenza-specific Th cells and CTLs 
during infection.   Unlike other soluble mediators (IFN-γ) TNF release isn’t directed towards 
specific target cells and therefore allows for potent non-specific effects (Huse et al., 2006).    
TNF has also been noted to have significant impact on immune-mediated tissue damage 
during influenza infection with no discernible impact on viral clearance  (Belisle et al., 2010).  
Because of the general complexity of TNF signalling, TNF may promote anti-inflammatory 
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(diminish cytokine production, inhibit phagocytosis, trigger apoptosis) or pro-inflammatory 
(stimulate cytokine production, augment cellular proliferation, trigger cellular necrosis) 
outcomes (Hufford et al., 2011).  
 
IL-10 
Interleukin-10 (IL-10) is a regulatory cytokine which down regulates MHC and co-stimulatory 
molecule expression, modulates inflammatory cytokine expression and can inhibit cell 
proliferation.  Sources of IL-10 during infection are CTLs, Th cells and regulatory T cells; 
however, studies in mice have shown lung CTLs are the main source of IL-10, producing it in 
large amounts during infection (Sun et al., 2009).   These CTLs also have been shown to have 
the capacity to produce inflammatory cytokines such as IFN-γ, therefore associated IL-10 
production is more likely to limit inflammation than completely inhibit it (Hufford et al., 2011).  
 
MIP-1α 
Macrophage inflammatory protein (MIP) - 1α is produced by both influenza-specific Th cells 
and CTLs upon activation.  Other possible sources are B lymphocytes, NK cells and myeloid 
cells).  MIP-1α is a chemokine which, when bound to its receptors, can exert a potent 
chemotactic and pro-inflammatory effect.  It can enhance lymphocyte cytokine production and 
is an effective recruiter of  monocytes, lymphocytes, immature DCs and activated neutrophils 
(Menten et al., 2002).   Studies have shown that MIP-1α is likely a significant pro-inflammatory 
soluble mediator necessary for influenza clearance (Hufford et al., 2011).  
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IL-2 
Interleukin-2 (IL-2) is a regulatory cytokine and its main function is to promote the development 
of T regulatory (Treg) cells.   IL-2 has been shown to promote Treg cell responses while 
inhibiting T follicular helper cells (Botta et al., 2017). 
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1.5 Treatment and Prevention  
 
1.5.1 Antivirals 
 
Antivirals are important in the prevention and management of IAVs.   
 
Neuraminidase Inhibitors 
 
Neuraminidase inhibitors (NAIs) act to block the neuraminidase (NA) enzyme preventing 
ongoing viral replication by blocking budding from an infected host cell.   The NA active site is 
highly conserved amongst IAV and IBV and NAIs are effective against all currently circulating 
human influenzas. NAI compounds were designed to mimic natural substrate of the NA 
enzyme and compete for binding to the active site, with a higher binding affinity (Samson et 
al., 2013).  
 
There are currently two licensed NAIs; oseltamivir (Tamiflu) and zanamivir (Relenza), and a 
further NAI that has received approval in Japan and the US; peramivir (Thorlund et al., 2011).   
Oseltamivir is the most commonly used NAI in response to influenza infection and is often 
distributed during outbreaks, as was the case during the 2009 H1N1 pandemic.  During a 
pandemic outbreak it is recommended that a full course of oseltamivir is used alongside early 
detection for effective control of an outbreak.          
 
Influenza resistance to NAIs has been well documented.  Resistance to oseltamivir has been 
found to occur not only during treatment and prophylaxis but also in the absence of NAI 
pressure.  This was found to be the case during the 2009 H1N1 pandemic with the H274Y 
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variant. The susceptibility of oseltamivir resistance appears to differ between subtypes 
depending on the structure of their neuraminidase (Li et al., 2015).   
 
Cap-dependent endonuclease inhibitor  
 
Baloxavir marboxil (Xofluza) is a therapeutic which inhibits the cap-dependent endonuclease 
activity of the influenza polymerase.  It inhibits the process known as cap-snatching during the 
process of viral mRNA biosynthesis (DuBois et al., 2012).  Baloxavir marboxil has been 
approved since 2018 for use in adolescents and adults in the US and Japan, with antiviral 
activity against both IAV and IBV.  Clinical trials have shown that treatment with baloxavir 
marboxil significantly shortened the duration of symptoms compared with a placebo and also 
reduced infectious viral titres shed and the duration of shedding more rapidly than oseltamivir 
in healthy and high risk patients (Fukao et al., 2019). 
 
1.5.2 Vaccination 
 
Annual vaccination is currently the most effective way of controlling influenza infection and 
spread. A wide variety of vaccine platforms have been evaluated against influenza; DNA-
based vaccines, viral vectors, virus-like particles, recombinant DNA, novel live attenuated, and 
adjuvanted vaccines have all been developed to improve vaccine development and 
immunogenicity (Paules and Subbarao, 2017).  A universal vaccine that is broadly cross-
protective could potentially replace the need for an annual vaccination as well as provide 
protection against the emergence of novel strains (Hashem, 2015, Keshavarz et al., 2019).  
Currently there are only three forms of licensed vaccine used to protect individuals annually; 
inactivated, live attenuated and recombinant HA vaccines, all of which are focused on 
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producing antibodies against viral HA.   All three of these vaccines are multivalent.  This means 
that the vaccine containing multiple components which can target current globally circulating 
seasonal influenza A and B viruses. These multicomponent vaccines can either be trivalent or 
quadrivalent.  Trivalent vaccines contain both circulating A subtypes; H1N1 and H3N2, and 
one B subtype, of either Yamagata or Victoria lineage.  Quadrivalent vaccines contain both 
circulating A subtypes; H1N1 and H3N2, and both circulating B subtypes; Yamagata and 
Victoria. 
 
Inactivated Influenza Vaccine 
 
The first formulation of the inactivated influenza vaccine (IIV) was a monovalent formulation 
which contained a subtype of influenza A virus.  When influenza B was discovered in 1940 it 
was found to be antigenically distinct to the A/PR8 strain used in the monovalent inactivated 
vaccine, however it shared the ability to grow in eggs and therefore it was incorporated into 
the vaccine creating a bivalent inactivated influenza vaccine. Following this, large scale clinical 
studies with the first bivalent vaccine containing both type A and B viruses began in December 
1942 and provided researches with the first evidence that the vaccines had the capability to 
provide protection from influenza epidemics (Francis et al., 1945).  Safety and efficacy studies 
were carried out from 1942 to 1945.  
 
The current IIV is produced as a split virion or subunit vaccine which can be administered 
intramuscularly or intradermally, with 15µg and 9µg of HA protein respectively.   There is a 
higher dose of antigen (60µg) available for those aged 65 years and over.  This is designed 
to elicit an increased immune response to the vaccine (Paules and Subbarao, 2017).  The IIVs 
induced strain specific serum IgG antibody response and are licensed for individuals aged 6 
months and older.  An adjuvanted inactivated trivalent vaccine, FluAd, is also approved for 
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use in individuals over the age of 65. The adjuvanted vaccine has been shown to have a higher 
immunogenicity and effectiveness that non-adjuvented vaccines in this age group.    
 
 
Live Attenuated Influenza Vaccine 
 
Live attenuated vaccines (LAIVs) are designed to represent a natural transient influenza 
infection, therefore eliciting a longer lasting and broader immune response in recipients.  The 
first LAIV was developed in the USSR and has subsequently been used in Russia since 1987 
to vaccinate children over three years, adults and the elderly. The reassortant viruses for 
Russian LAIV are prepared by classical reassortment in eggs of chosen wild-type IAV and IBV 
viruses with one of two cold adapted (ca) master donor viruses (MDVs) as a backbone 
(A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69). Cold adapted viruses can only replicate 
at lower temperatures found in the human nasal cavity.  A/Leningrad/134/17/57 underwent 
several passages in chicken embryos at 25°C to generate the temperature sensitive 
phenotype found in LAIV.   
 
MedImmune developed the current licensed LAIV used in the UK for school aged children (2-
10) and in the US for healthy individuals between the ages of 2 and 49 (Grohskopf et al., 
2014). ca A/Ann Arbour/6/60 forms the backbone of the live attenuated quadrivalent vaccine 
and is sold under the trade name of Fluenz (Europe) and Flumist (United States).  Prior to 
license, during randomised controlled trials, the LAIV was not shown to be any more 
efficacious than the inactivated vaccine in adults.  Vaccination with the LAIV results in the 
production of strain specific IgG as well as mucosal IgA and T cell responses (Coelingh et al., 
2014).  The LAIV has also been found to be effective against some seasonally drifted strains.  
However, it has been hypothesised that an adult may have a previous immune history from 
influenza infections and therefore possess the cellular immunity to conserved internal viral 
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proteins that supress local mucosal replication of the LAIV in the nasal cavity well enough to 
prohibit a robust immune response (Sridhar et al., 2013).   
 
 
Recombinant Influenza Vaccine 
 
FluBlock is a recombinant HA vaccine.  It contains HA that has been expressed in insect cells 
using baculovirus vectors. It is currently licensed for adults aged 18 to 49 and can be used in 
individuals with an allergy to eggs (Grohskopf et al., 2014).  The manufacturing process has 
a shorter timeframe to other egg based vaccines which would be advantageous in a pandemic 
response (Paules and Subbarao, 2017). 
 
 
 
 
 
 
 
 
 
 
54 
 
1.6 Animal Models of Human IAVs 
 
Animal research and animal models are necessary tools to model the complexity of the human 
host, where in vitro and in silico models are unable to adequately simulate immunological and 
physiological response to disease.  Animal models are also essential to evaluate new 
vaccines, therapeutics and interventions to influenza before proceeding to human clinical 
trials. Animal research undergoes strict scrutiny in Europe.  In 2015 the European Commission 
underlined that while animal research remains important for improving animal and human 
health, it is committed to promoting development and validation of non-animal-based 
approaches, and to enforcing the application of the 3Rs (replacement, reduction and 
refinement) (EuropeanCommision, 2015). 
 
Animal research is conducted in compliance with strict regulatory provisions which covers the 
licensing and inspection of the premises, the training and competence of all project personnel 
and authorisation of every project by a competent Animal Welfare and Ethical Review Body 
(Barré-Sinoussi and Montagutelli, 2015).  The criteria for evaluation are based on the 3Rs. As 
well as a cost-benefit analysis that evaluates whether potential harm to the animals, which 
must be reduced to the lowest possible level, is outweighed by significant progress in terms 
of knowledge to human or animal health.   
 
Several animal models have been used in the past to assess IAV including; mice, cotton rats, 
Syrian hamsters, ferrets, dogs, cats, domestic swine and non-human primates such as rhesus, 
pigtailed and cynomolgus macaques, and marmosets (Bouvier and Lowen, 2010, Moncla et 
al., 2013, Eichelberger and Green, 2011).  The most commonly used models are the mouse, 
guinea pig and ferret models.  These are discussed below in further detail.  
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1.6.1 Mice  
 
Mice are the most widely used animal model in influenza research (Bouvier, 2015).  Practically, 
mice have inexpensive purchase and husbandry costs, they are a convenient model in terms 
of size and there is a wealth of frequently used species-specific reagents accessible to 
researchers.  When carrying out preliminary animal studies mice are the ideal animal model 
to choose. However, there are some disadvantages to the mouse model that can leave data 
obtained difficult to interpret and associate with the human situation of influenza infection.  The 
susceptibility of a mouse model to influenza and the clinical signs produced depends upon 
both the strain of mouse being used and the strain of influenza (Bouvier and Lowen, 2010, 
Margine and Krammer, 2014). Many human influenza strains must be mouse adapted which 
requires the virus to be passaged in vivo in mouse lungs. This can lead to significant amino 
acid changes which improve the receptor binding in the mouse respiratory tract allowing for 
replication and increased virulence.  However, this can mean that the adapted virus becomes 
either antigenically or phenotypically distinct from the initial strain (Margine and Krammer, 
2014), potentially producing a disease very different to human flu infection. It has also been 
noted that transmission between a donor and sentinel mouse can be difficult (Lowen et al., 
2006); therefore the mouse model is not suitable for transmission modelling investigations.  
Nonetheless, the mouse model does provide an opportunity for an in depth investigation of 
immune responses elicited by infection and vaccination and, due to their inbred nature the 
mouse model tends to mount a very reproducible response to infection (Margine and 
Krammer, 2014). 
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1.6.2 Guinea Pig 
 
The most commonly used guinea pig strain for influenza research is the outbred Hartley 
guinea pig (Bouvier and Lowen, 2010). They are susceptible to human strains of influenza, 
without need for adaptation and the virus transmits between animals with ease (Lowen et al., 
2006).  As with mice, guinea pigs are widely available, relatively cheap to acquire and house, 
and their size means that they are easy to work with. Unlike mice the strain of guinea pig used 
does not seem to alter the outcome of disease in the animal.  Viral growth occurs mainly in 
the upper respiratory tract and virus usually grows to high titres.  Growth in the lungs can be 
moderate but this is usually short lived (Lowen et al., 2006, Bouvier and Lowen, 2010).  
 
Guinea pigs can be infected with avian and swine strains of influenza without prior adaptation 
of the virus (Lowen et al., 2006) however; despite inoculation with similar virus titres, the 
resulting titres reached in the nasal passages by these viruses are not as high as when 
inoculated with human isolates.  Despite the high viral titres reached in the upper respiratory 
tract IAVs do not cause noticeable clinical disease in guinea pigs.  This is most striking when 
infecting guinea pigs with HPAI H5N1, a virus that is lethal in mice and ferrets, but only a mild 
disease is obtained following an infectious a dose of 106 EID50 (50% egg infectious dose) 
(Kwon et al., 2009) making the guinea pig model unsuitable for assessing clinical severity of 
viruses.  However, it has been demonstrated that un-adapted human influenza viruses which 
replicate in high titres in the guinea pig respiratory tract are able to be transmitted via aerosol 
from donor guinea pigs to sentinel guinea pigs (Lowen et al., 2006).  This makes guinea pigs 
a suitable small animal model in which to pilot initial transmission studies (Bouvier and Lowen, 
2010).  
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1.6.3 Non-human Primates 
 
The use of non-human primates (NHPs) in the investigation of influenza dates to the 1890s.  
Researchers attempted to infect NHPs with “bacteria” recovered from influenza patients, this 
produced a mild illness (Davis et al., 2015). One of the key advantages of NHP models is their 
close genetic and physiological match to humans when compared to other mammalian models 
(Moncla et al., 2013).  However, it is important to note that there is variability in suitability 
amongst species.  For example it has been found that cynomolgus macaques have 50-73 
times higher expression levels of α 2, 6-linked sialic acid receptors in their respiratory tracts 
compared to rhesus macaques which could cause a difference in the replication of the virus 
(Mooij et al., 2015).  It is thought that NHPs are able to model the human immunological 
response to IAV infection much more strongly than seen in rodent and ferret models (Mooij et 
al., 2015).  A wide range of NHP species have been shown to be susceptible to influenza A 
virus infection (Davis et al., 2015), however, they develop varying clinical signs and 
histopathological changes which are not always characteristic of human H1N1 or H3N2 
infection (Bouvier and Lowen, 2010).   
 
Some studies have shown successful infection of NHPs comparable to human infection; 
marmosets infected with a pandemic H1N1 isolate resulted in virus replication, antibody 
response, symptom development and transmission which are all typical of human influenza 
infection (Moncla et al., 2013, Mooij et al., 2015). A comparison study between rhesus and 
cynomolgus macaques showed that rhesus macaques exhibited the most easily observed 
clinical symptoms of the two sub-species when infected with a pandemic H1N1 virus.  
 
A review of the literature in this area shows that researchers still need to establish the optimal 
route of infection to simulate a reproducible human influenza infection in NHPs.  Researchers 
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usually inoculate animals via multiple routes ensuring that infection takes place, this, however 
does not mirror natural exposure seen in humans (Davis et al., 2015).   Introduction of the 
virus directly into the lower respiratory tract maximises the severity of the disease, 
consequently this method is less optimal for modelling typical seasonal infections.  
Investigations have found that the respiratory tract of NHPs differ from that in humans, with a 
greater affinity for avian influenza viruses compared to human influenza viruses (Davis et al., 
2015).   The NHP model comes with high costs and complex husbandry needs that only a 
small number of researchers can accommodate. This coupled with the low availability of NHPs 
mean that this animal model is less accessible than other animal models used to study IAV.  
 
1.6.4 Ferret  
 
Ferrets are small carnivorous mammals from the mustelid family.  Due to their small size and 
comparable physiology, anatomy and metabolism to humans they are considered a more 
suitable animal model for the study of influenza virus infection when compared to larger animal 
models such as pigs, dogs and NHPs (Enkirch and von Messling, 2015).  The ferret model for 
IAV was first characterised in 1933 (Smith et al., 1933) following exposure of two ferrets to 
filtered throat washings from human patients infected with influenza.  Since then it has been 
established that ferrets are susceptible to a wide variety of human influenza isolates without 
need for prior adaptation of the virus, as well as avian and swine viruses.  Consequently, 
ferrets are widely considered the gold standard for influenza infection and the ferret model has 
made a remarkable contribution to our current understanding of influenza.  
 
Early experiments with ferrets showed that they produced similar symptomology to humans 
when infected with influenza; such as sneezing, lethargy, fever, nasal discharge and anorexia.  
As with humans, ferrets inoculated with influenza present a primarily upper respiratory tract 
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infection due to humans and ferrets having a similar distribution of sialic acid receptors in their 
respiratory tracts.  In the upper respiratory tract of both species there is an abundance of alpha 
2,6- linked sialic acid receptors, while both alpha 2,6- linked and alpha 2,3-linked sialic acid 
receptors are present in the lower respiratory tract.  As in humans, ferrets infected with 
seasonal H1N1 and H3N2 strains usually produce mild clinical symptoms with widespread 
infection of the upper respiratory tract due to the viruses high affinity for alpha 2,6- linked sialic 
acid receptors while tissues in the lower respiratory tract are decreasingly affected (Enkirch 
and von Messling, 2015). In contrast, both humans and ferrets infected with pandemic strains 
of influenza experience extensive infection throughout the lung with associated pneumonia 
due to the highly pathogenic influenza viruses increased affinity (with respect to seasonal 
strains) for alpha 2,3-linked sialic acid receptors. Because ferrets show symptoms to IAV 
infection they are often used in studies to look at the efficacy of antiviral agents in preventing 
disease.  In addition, the ferret remains the primary animal model for assessing the efficacy of 
new antiviral drugs and vaccine strategies (Bodewes et al., 2010). 
 
The initiation of IAV infection in the ferret model, and indeed other animal models as well as 
humans, is most routinely carried out by instilling virus via the intranasal route.  It is the most 
straightforward procedure compared to other methods of infection.  Figure 1.6.4.1 illustrates 
other inoculation route commonly used in the ferret influenza model.   The choice of which 
route to use is dependent on the stain of virus used and the question being posed.  For 
example, with avian influenzas such as H5N1 and H7N9 intratracheal instillation is used to 
allow the virus direct access to the lower respiratory tract inducing a more severe clinical 
disease.  This is with the view to produce a more severe pneumonia which represents the 
pathogenesis seen in humans infected with these viruses (Bodewes et al., 2011, Kreijtz et al., 
2013). 
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Figure 1.6.4.1 Contribution of inoculation route contributes to ferret pathogenesis (Belser et al., 
2016) Contribution of inoculum volume and route of infection to influenza virus virulence in the ferret.  
This figure illustates the variance in location and viral load between multiple different inoculum routes 
employed in the ferret. Shading indicates locations with high viral loads. Selected advantages and 
disadvantages for each inoculum route are highlighted. 
 
Ferrets are commonly infected with seasonal IAVs via the intranasal route.  It has been noted 
that the clinical severity of influenza infection caused by intranasal infection can vary 
depending on the volume of virus given to the ferret (Moore et al., 2014).  It has been shown 
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(Fig 1.6.4.1) that smaller volumes of inoculum (0.2ml and 0.5ml) remained in the upper 
respiratory tract of the ferret whilst larger volumes of inoculum (1.0ml) resulted in the delivery 
of the virus to the lower respiratory tract.  The larger volume (1.0ml) of incoula also gave the 
ferrets more severe clinical signs and lung histopathology when compared to ferrets infected 
with smaller volumes (0.5ml and 0.2ml) (Moore et al., 2014).  The Influenza Group at Public 
Health England routinely infect their ferrets with an inoculum volume of 0.2ml (Marriott et al., 
2014) (Ryan et al., 2018) (Gooch et al., 2019). 
 
One criticism of intranasal infection is that it does not represent a ‘natural’ route of infection. 
Past investigations into more ‘natural’ routes of influenza infection in the ferret model have 
included; contact (Yen et al., 2001, Frise et al., 2016) and non-contact transmission 
experiments (Koster et al., 2012) (Otte et al., 2016), aerosol exposure of animals using a 
plethysmography chamber (Gustin et al., 2011), aerosol-ocular exposure (Belser et al., 2012) 
and nose inhalation exposure system (Lednicky et al., 2010).  These ‘natural infection’ models 
often provide a more clinically relevant route of transmission.  However, none of these studies 
have made any comparison between all three methods of experimental infection: intranasal, 
aerosol and transmission cage.  
 
The model is a valuable tool for assessment of the acute phase of infection as there are 
numerous samples that can be collected from the ferrets without termination of animals (Fig. 
1.6.4.2).    Successful virus infection is largely assessed based on quantification of virus shed 
from the respiratory tract.    Nasal washes can be collected frequently to allow titration of the 
virus from the upper respiratory tract.  Additionally, bronchiolar lavage (BAL) washes have 
been used to allow for consecutive quantification of influenza virus replication in the lower 
respiratory tract of living ferrets (Lee et al., 2014).   Swabbing at specific sites in the upper 
respiratory can provide an alternative to nasal washing.  Swabbing can also be carried out 
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rectally to assess the presence of virus in the gastrointestinal tract.  These samples can then 
be titrated for the presence of virus.  Collection of peripheral blood samples during the infection 
and at cull allows observation of viremia and antibody titres throughout infection.   
 
When ferrets are terminated, tissues can be collected for virus quantification, and the extent 
of virus burden throughout the ferret can be determined.  Collection of tissue samples from 
throughout the upper and lower respiratory tract can provide more specific location of viral 
replication in the ferret than nasal or BAL washes, which are more likely to be inclusive of most 
or all the respiratory tract.    
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Figure 1.6.4.2 Influenza virus sample collection sites (Belser et al., 2016) Frequently collected 
samples from the ferret respiratory tract during the acute phase of infection. Examples of variance in 
location precision and viral load between different sites and types of samples collected during influenza 
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virus infection in the ferret, and different viral loads and pathology present between mild/seasonal and 
virulent/avian influenza virus infection, are shown. Green shading indicates locations of high viral loads 
in nasal and tracheal samples. Sites sampled during nasal wash collection may extend beyond the 
upper respiratory tract. 
 
Despite criticisms, the majority of ferret influenza studies use intranasal infection and inoculate 
with high viral titres (104-6 plaque forming units (PFU) per ferret) which allows many infectious 
particles to infect the upper respiratory tract in a short period of time. Ferrets infected with 
these titres often experience their highest shedding titres at 1dpi (day post infection) (Marriott 
et al., 2014). In contrast, ferret infected with lower doses (102 PFU) appear to more closely 
resemble a ‘natural infection’ where nasal wash viral titres gradually rise, peak and then fall 
(Marriott et al., 2014), (Oh and Hurt, 2016).   Higher viral titres are often used to infect ferrets 
to guarantee infection and to increase pathogenicity, however this may not be necessary as a 
low dose intranasal infection has been shown to be reproducible and show comparable 
disease severity in ferrets (Marriott et al., 2014), (Oh et al., 2015). 
  
The draft of the ferret genome was published in 2014 (Peng et al., 2014) and has provided 
researchers with the opportunity to improve the sophistication of ferret respiratory disease 
models, particularly in overcoming the lack of immunological reagents.  Analysis of the ferret 
genome revealed a high protein-sequence similarity and shared tissue expression patterns 
with humans (Peng et al., 2014), reiterating the ferret’s suitability as an effective model for 
human influenza.  Despite the ferret’s ability to demonstrate a very similar disease to humans, 
the model still lacks appropriate reagents required to carry out in depth immunological studies 
(Thangavel and Bouvier, 2014) and remains inaccessible to some researchers due the cost, 
size and husbandry requirements of the animals.    
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1.7 Summary 
 
For this set of studies the ferret has been chosen as the most appropriate animal model for 
the following reasons:  
 
1. The ferret model for human IAV is widely used in then influenza research field and has 
several advantages over other animal models such as comparable symptomology, 
similar receptor distribution in the respiratory tract to humans. 
 
2.  The ferret has the ability to be infected with human isolates without the need for prior 
adaptation unlike other animal models.    
 
3. At PHE Porton Down there is extensive experience of performing studies on ferrets 
using H1N1 influenza strains. This body of work hopes to build on this experience, by 
developing a H3N2 ferret model by evaluating routes of transmission, and the viral 
kinetics and cellular immune response induced by these routes.  
 
It is already known that the seasonal H3N2 virus is able to successfully cause disease in 
ferrets following infection, however the vast majority of these experimental models have been 
carried out using high titres of virus.     There are several gaps in knowledge surrounding the 
H3N2 virus in the ferret model, for example, the robustness and reproducibility of a low dose 
of infection and the effect of a low dose of infection on the viral kinetics in the ferret model and 
the cellular immune response seen as a result.  
 
The H3N2 strain that was chosen for this piece of work was A/Perth/16/2009.  The 
A/Perth16/2009 strain was initially chosen as this was the most up to date H3N2 strain 
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available for testing at the start of this piece of work.  As the work progressed the question of 
whether the H3N2 strain should be updated from A/Perth/16/2009 to a more recent strain to 
make it more relavent and comparable to the current H3N2 circulating strains was posed.   It 
was decided that this was not the best course of action.  Many models of influenza use older 
strains that have been well characterised and updating the strain could potentially cause 
unforeseen problems with assays that have been used to evaluate results from the pilot 
studies of the model.  It would be difficult to select the most up to date strain of H3N2, as the 
following year the strain would no doubt change due to antigenic drift. As such, the 
A/Perth/16/2009 of H3N2 was worked with throughout this piece of work.    
 
 These studies are important because they will enhance the ferrets model’s applicability when 
assessing vaccine strategies and therapeutics. For this reason, it is also important to 
understand the similarities and differences between seasonal H3N2 and H1N1 infection in the 
ferret as these differences can most likely be translated to human disease.   
 
1.8 Hypothesis 
 
 
The following hypotheses were investigated:  
 
1. That the pathogenesis of disease following different infection delivery models is similar 
despite the route of delivery and that pathogenesis is a property of the virus receptor rather 
than delivery route. 
 
2. That influenza infection results from a combination of both droplet (fomite) and aerosol 
particles and that both particle types contribute to transfer. 
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Aims: 
a. Developing and comparing intra-nasal, natural transmission and aerosol modes of 
experimental infection.  
 
b. Investigating the robustness of the three infection models in terms of reproducibility 
and reliability. 
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2 Material & Methods 
 
2.1 Cell & Virus Culture 
 
2.1.1 Media  
 
Cell Culture Media for Resuscitation 
500ml of DMEM + GlutaMAX™ (Gibco, Loughborough, United Kingdom) supplemented with 
100ml of (20% (v/v)) Foetal Calf Serum (FCS) (Sigma- Aldrich, Dorset, United Kingdom) and 
5ml of 1x PenStrep (100 U/ml penicillin and 100μg/ml streptomycin) (Gibco, Loughborough, 
United Kingdom). 
 
Cell Culture Media for Cell Maintenance 
500ml of  DMEM + GlutaMAX™ (Gibco, Loughborough, United Kingdom) supplemented with 
50ml of (10% (v/v)) FCS, (Sigma- Aldrich, Dorset, United Kingdom) and 5ml of 1x PenStrep 
(100U/ml penicillin and 100 μg/ml streptomycin) (Gibco, Loughborough, United Kingdom). 
 
Influenza Growth Media 
500ml of DMEM + GlutaMAX™ (Gibco, Loughborough, United Kingdom), 13ml of BSA 
Fraction V (Gibco, Loughborough, United Kingdom) and Trypsin TPCK (-1-Tosylamide-2-
phenylethyl chloromethyl ketone) (Sigma- Aldrich, Dorset, United Kingdom).  The trypsin 
TPCK value is based on a titrated value and varies from one batch to another therefore exact 
volumes cannot be supplied.  
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Plaque Assay Overlay Media 
100ml of 10x MEM (Gibco, Loughborough, United Kingdom), 20ml of 7.5 % NaHCO3 (Sigma- 
Aldrich, Dorset, United Kingdom), 10ml of 1M HEPES (Sigma- Aldrich, Dorset, United 
Kingdom), 28ml of 7.5% BSA fraction V (Gibco, Loughborough, United Kingdom), 5ml of 1% 
DEAE (diethylaminoethyl) Dextran (Sigma- Aldrich, Dorset, United Kingdom), 10ml of 100x 
Anti-Anti (Fisher Scientific UK Ltd, Loughborough, United Kingdom), 10ml of 100x L-
Glutamine (Fisher Scientific UK Ltd, Loughborough, United Kingdom) and 517ml of Irrigation 
H2O (water) (PamSupplies). 
 
2.1.2 Cells  
 
Madin-Darby canine kidney cells (MDCK cells Fig. 2.1.2.1) were originally isolated from a 
cocker Spaniel in 1958. MDCK cells are an adherent cell line and like most epithelial cell lines 
exhibit strong contact inhibition when grown in cell culture. MDCK cells are permissive and 
support the growth of influenza virus (Green, 1962), making them suitable for influenza 
research.  MDCK cells were obtained from The European Collection of Authenticated Cell 
Cultures (ECACC, Porton Down, United Kingdom).  
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Figure 2.1.2.1 Image of MDCK Cell Line (ECACC) Healthy, normal confluent MDCK cells.  
 
2.1.3 Cell Resuscitation 
 
The appropriate number of vials were removed from liquid nitrogen and defrosted in a 37ºC 
water bath for approximately 1 to 2 minutes until no more than two ice crystals remain.  Rapid 
thawing in this manner was required to minimise the damge to cells.   Cells were removed 
from water bath and transferred to a sterile centrifuge tube containing 12ml of cell culture 
media.  Cells were washed by centrifugation at 200 g for 5 minutes and resuspended in 12ml 
of fresh cell culture media. The centrifugation step was repeated, and cells were resuspended 
in 10ml of media and seeded into a 175cm2 flask with an additional 20ml of cell culture media.  
Cells were incubated overnight at 37ºC at 5% CO2 to allow cell attachment.  The following day 
cell debris and dead cells were removed by changing cell culture media and replacing with 
30ml of cell culture media.  
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2.1.4 Cell Maintenance 
 
MDCK cells were passaged at approximately 80% confluency.  Media was removed, and cells 
were washed twice with sterile PBS pH 7.4 (Gibco, Loughborough, United Kingdom).  After 
the second wash was discarded 2ml of 1 x Trypsin-EDTA (ethylenediaminetetraacetic acid) 
(0.05% Trypsin, 0.02% EDTA) was added to evenly cover the cell monolayer.  Trypsin is used 
to detach the cell monolayer from the flask. The flask was placed at 37ºC, 5% CO2 for 5-10 
minutes to aid detachment of the monolayer.  Detachment of the monolayer was confirmed as 
the trypsin solution becomes visibly opaque and cells move upon rocking the flask.  Following 
cell detachment 10 ml of cell culture media was added to stop trypsinisation and to resuspend 
cells.  Long term incubation of cells with a high concentration of trypsin damages cells by 
stripping cell surface proteins and eventually killing the cells. Vented 175cm2 flasks were 
typically seeded with 0.75 -1.5ml of resuspended cells (exact volume depended on cell 
confluency, Figure 2.1.4.1, gives an example, and time to next passage) and 30ml of cell 
culture media was added.    
 
2.1.5 Virus 
 
Passages of IAV A/Perth/16/2009 (H3N2) used during this piece of work were either; 
propagated in Madin-Darby Canine Kidney (MDCK) cells (Section 2.1.2) or propagated in 
specified pathogen free (SPF) hens eggs (Charles River Ltd, Wisconsin, United States).  The 
passage batch: P+2A of A/Perth/16/2009, propagated in MDCK cells, was used for all animal 
infections during this piece of work.  The identity of passage batch: P+2A was confirmed by 
sequencing of the HA and NA genes.   Passage batches: P+3B and P+3A were propagated 
in SPF hens’ eggs were used for immunological assays. 
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2.1.6 Virus Propagation in Cell Culture 
 
MDCK cells are used to grow influenza virus due to its high susceptibility to infection with 
various influenza strains. MDCK cells are widely used for influenza virus isolation and vaccine 
production (Seitz et al., 2010).  
 
MDCK cells were grown to 90 – 100% confluency. Media was removed, and cells were 
washed twice with sterile PBS pH 7.4 (Gibco, Loughborough, United Kingdom). Virus was 
removed from storage and diluted appropriately in influenza growth media. Diluted virus was 
added to cells and incubated for 1 hour at 37ºC, 5% CO2.  Following incubation 25ml of virus 
growth media was added and flasks were incubated until at least 75% of the cell monolayer 
displayed cytopathic effect (CPE). Cytopathic effect describes the structural changes that take 
place in the cell following viral infection.  This is usually lysis of the cell or where the cell dies 
due to an inability to reproduce.   Media were harvested and centrifuged at 750g for 5 minutes 
to remove cell debris.  Virus was aliquoted and frozen at -70±10ºC for long term storage. 
 
2.1.7 Virus Propagation in Eggs  
 
Eggs are commonly used to grow influenza viruses.  Eggs often provide a high yield of 
influenza virus and allow for large volumes of virus to be produced.   
 
Eggs were set for primary incubation at 37 °C, 40- 80% Relative Humidity (RH) and rocking 
for 9 – 11 days.  Prior to inoculation eggs were candled using a LED (light-emitting diode) 
lamp to visualise the chicken embryo in the egg and ensure the embryo was alive (Fig. 
2.1.7.1). A mark was placed on the egg above the air sack, opposite the embryo and avoiding 
major blood vessels to indicate where the site of inoculation should be. Any unfertilised, 
73 
 
cracked, or dead eggs were not suitable for inoculation and were placed in the fridge overnight 
prior to discarding. 
 
 
Figure 2.1.7.1 Normal viable egg.  (a) Well defined vein structure and (b) fixed air sack at the top pole 
of the eggs.  Upon candling the chicken embryo, a mark is placed just above the air sack (c) to indicate 
where the egg should be inoculated. 
 
A lancet was used to create a hole in the egg between 2 and 5mm above the mark made on 
the egg and another hole approximately 5mm was made above the first hole.  Virus was diluted 
in PBS pH 7.4 (Gibco, Loughborough, United Kingdom) to approximately 103 PFU (plaque 
forming units) per egg.  100μl of virus inoculum was injected into each egg.  Eggs were sealed 
with a glue stick and incubated 37±1°C for 48 h or at 33±1°C for 72 hours.  
 
c 
a 
b 
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Following secondary incubation, eggs were chilled at 5 ±3°C for a minimum of 4 hours.  
Disposable forceps were used to crack the top of the egg and peel back the membrane. 
Allantoic fluid (AF) was collected with a pipette into a sterile tube. AF was clarified by 
centrifugation at 1000g for 5 minutes prior to aliquoting and long-term storage at -70±10ºC. 
The number of PFU/ml was assessed by performing a plaque assay. 
 
2.1.8 Haemagglutination (HA) Assay 
 
The HA assay is a method used to titre influenza viruses based on their ability to attached to 
the sialic acid receptors present on the surface of red blood cells (RBCs) via their HA receptor.  
 
A 0.5% blood suspension chicken RBCs (Envigo, Huntingdon, United Kingdom) was prepared 
on the day of the HA assay. Virus to be assayed was thawed and serially diluted 1:2 across a 
96 v-well plate in triplicate (50µl of stock virus added to 50µl of PBS pH 7.4 (Gibco, 
Loughborough, United Kingdom)).  An appropriate volume (usually 50µl) of 0.5% blood was 
added and the plate was incubated at room temperature for 45-60 minutes.   It was determined 
whether wells showed no haemagglutination (red blood cells formed a button) or 
haemagglutination (red blood cells formed a latticework) (Fig. 2.1.8.1).  The highest dilution 
of the virus antigen showing complete agglutination was the end point of the titration; 
containing one HA unit in 50µl. The virus was then diluted appropriately with PBS pH 7.4 
(Gibco, Loughborough, United Kingdom) to 4 HA units per 25µl for use in the 
haemagglutination inhibition (HAI) assay (Section 2.3.8).  A back titration of the diluted virus 
was then performed to ensure correct dilution.   
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Figure 2.1.8.1 The HA Assay (adapted from (CDC, 2017))  The assay involves the interaction of red 
blood cells (RBCs) with influenza virus. Row A illustrates in the absence of virus, RBCs in a solution 
will sink to the bottom of a v-well microtitre plate well and look like a red button. Row B shows that 
influenza viruses will bind to red blood cells when placed in the same solution. This is called 
hemagglutination and is represented by the formation of the latticework structure, as shown in “result”.  
 
2.1.9 Plaque Assay 
 
The plaque assay is a cell culture-based technique and is used to quantify the amount of live 
virus in a sample.  
 
MDCK cells were seeded into 12 well cell culture plates at a density 4x105 cells/ml and 
incubated overnight to be used the following day.  Samples to be titrated were diluted 
appropriately with serum free DMEM + GlutaMAX™ (Gibco, Loughborough, United Kingdom).   
Serum is omitted because it contains inhibitors of trypsin.  Many influenza strains are trypsin 
dependent for replication in cell culture.  The trypsin cleaves the HA on the virus, so it becomes 
fusion competent.  Cells were washed with PBS 7.4 (Gibco, Loughborough, United Kingdom), 
and incubated with 200μl of sample for 1 hour at 37°C, 5% CO2.   Overlay media (21ml) was 
Components Interaction Result 
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used with 2% Agar Overlay (9ml) (melted and maintained at 55°C) (Oxoid, Basingstoke, 
United Kingdom) and 1.6 mg/ml TPCK Trypsin (Sigma- Aldrich, Dorset, United Kingdom).  
Plates were incubated for 3 days at 37°C, 5% CO2.  Agar was removed after three days and 
plates were fixed and stained with Crystal Violet Stain; 40ml 2.5 % Crystal Violet stock (Sigma- 
Aldrich, Dorset, United Kingdom), 80ml Methanol, 300ml Irrigation H2O (PamSupplies). 
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2.2 Molecular Virology  
 
2.2.1 Generation of synthetic standard curve used during qRT-PCR 
 
A synthetic T7 transcript of full length M gene for A/Perth/16/2009 was generated for use as 
standard curve during quantitative RT-PCR. 
 
 Complementary DNA (cDNA) Generation 
 
Viral RNA was extracted from virus stock P+2A using QiaAmp Kit (Qiagen, Manchester, 
United Kingdom). cDNA was transcribed using Superscript III RT kit (Invitrogen).   
 
Table 2.2.1.1.1 Primer Sequence  
Primer Sequence 5’ 3’ 
Uni-12 AGC AAA AGC AGG  
 
For a 32.5µl reaction 25µl viral RNA was mixed with 5µl of primer (Table 2.2.1.1.1) and 2.5µl 
of 10mM dNTP mix (Invitrogen, Fisher Scientific, Loughborough, United Kingdom).  The 
reaction was heated in a water bath to 65oC for 5 minutes and then snap-cooled on wet ice.  
To the same reaction tube, 10µl of 5xFS buffer + 2.5µl 0.1M DTT + 2.5µl RnaseOUT 
(Invitrogen, Fisher Scientific, Loughborough, United Kingdom) + 2.5µl Superscript III enzyme 
was added.  This reaction was incubated at 50oC for 60 minutes followed by 70oC for 15 
minutes and the held at 4ºC until the cDNA was stored at -20oC. 
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 PCR 
 
The GRAM-1Fw and GRAM-1027Rv sequences (Table 2.2.1.2.1) amplified all IAV subtypes.  
PCR was carried out using Phusion High-Fidelity PCR kit (Fisher Scientific, Loughborough, 
United Kingdom).  A master mix (x1) was made as follows: 10 µl 5x Phusion High-Fidelity 
buffer + 0.4µl 25mM dNTPs + 2.5µl GRAM-1Fw (20 µM) + 2.5µl GRAM-1027RvwT7 (20 µM) 
+ 2µl cDNA + 0.5 µl Phusion DNA Polymerase + 34.6µl RNase-free water.   This reaction was 
incubated in a 3Prime Thermal Cycler (Techne, Stone, United Kingdom) at 98oC for 30 
seconds followed by 35 cycles of 98oC for 10 secs, 63.5oC for 20 secs and 72oC for 55 secs, 
finishing with 72oC for 8 min, finally being held at 10oC until removal from the PCR machine.  
 
Table 2.2.1.2.1 Primer Sequence  
Primers Sequence 5’ 3’ 
GRAM-1Fw AGC AAA AGC AGG TAG ATA TAT TGA  
GRAM-1027Rvw/T71 GAA ATT AAT ACG ACT CAC TAT AGG GAG 
TAG AAA CAA GGT AGT TTT TTA CTC  
1Reverse primer GRAM-1027vw/T7 has T7 promoter attached 
 
To confirm presence of the correct amplicon gel electrophoresis was performed.  Buffer was 
1x TAE (from 10x TAE stock) (Invitrogen, Fisher Scientific, Loughborough, United Kingdom). 
Gel was 1.2 % agarose (Invitrogen, Fisher Scientific, Loughborough, United Kingdom) in 1x 
TAE containing 3µl per 30ml SYBR Safe (Invitrogen, Fisher Scientific, Loughborough, United 
Kingdom).  5µl of PCR product with 1µl dye (10x Blue Juice, Invitrogen) was loaded onto gel 
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alongside 10µl Size Standard from Phusion kit.  Gel was electrophoresed at 100V ~1 hr and 
visualised on Geldoc. Product was a single band of 1027bp.  Remaining sample was stored 
at -20ºC. 
 
 Transcription 
 
Once amplicon product was confirmed transcription with MEGAscript kit (Ambion Fisher 
Scientific, Loughborough, United Kingdom) was carried out. The MEGAscript Kit is used to 
generate large amounts of RNA from linearized DNA template. 
 
The following reaction was assembled at room temperature:   5µl PCR product + 3µl water 
(from kit) + 2µl each of 4 rNTPs (75mM, from kit) + 2µl 10x Megascript buffer + 2µl T7 enzyme 
mix.  Reaction was incubated in an incubator 37°C for approximately 4 hours.  Following 
incubation sample was stored at -20oC. 
 
 RNA Clean Up and Quantitation 
 
Product was purified using Qiagen RNeasy Kit (Qiagen, Manchester, United Kingdom).  The 
RNA was eluted into RNase-free water and quantified spectrophotometrically using a 
NanoDrop™ Lite Spectrophotometer (ThermoFisher Scientific, Loughborough, United 
Kingdom).  The number of M segment copies per µl was calculated using the concentration 
ascertained from the nanodrop as follows:  
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The rNTP molecular weight (assumed) is 320.5 and the M segment of IAV has 1027 bases. 
M.W. of ssRNA = (# nucleotides x 320.5) + 159.0  
M.W. = (1027 x 320.5) + 159.0 = 329312.5 
(X-9g/µl)/ 329312.5 = (answer) x (6.022 x 1023*) 
*Avogadro’s Number – defines the amount of substance in on mole. 
 
2.2.2 Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction 
 
qRT-PCR was used to quantify the amount of virus present in a sample.  qRT-PCR is unable 
to differentiate between live and dead virus, it is only able to indicate the presence of a specific 
part of the virus genome.  
 
The target for this qRT-PCR was the consereved M (matrix) segment found in the influenza 
virus genome. 
 
Total RNA was extracted from ferret tissues (lung, trachea and nasal turbinate) which had 
been collected into RNALater (Qiagen, Manchester, United Kingdom) and stored at -20°, using 
the Qiagen RNeasy Mini kit (lung) or RNeasy Fibrous kit (trachea, nasal turbinates). Lung 
samples were taken from the upper left lobe in each case. RNA was quantified 
spectrophotometrically using a NanoDrop™ Lite Spectrophotometer (ThermoFisher Scientific, 
Loughborough, United Kingdom). RNA quality was assessed using an Agilent 2100 
Bioanalyzer. Absolute quantification of influenza virus M segment was determined using a 
quantified, negative-sense synthetic T7 RNA polymerase transcript, from either a synthetic T7 
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transcript of A/Perth/16/2009 M segment (Section 2.2.1.4) or a full-length plasmid clone of 
A/California/04/2009 M segment, to construct a standard curve. Reactions used primers 
(M+24, M-124, M-124Mod) and probe (M+64 with 5’-FAM and 3’-BHQ1)  (Table 2.2.2.1) with 
the Superscript III Platinum One-Step qRT-PCR kit (Invitrogen, Fisher Scientific, 
Loughborough, United Kingdom), and were analysed using the ABI Prism 7900HT and SDS 
2.4 software (Applied Biosystems, Fisher Scientific, Loughborough, United Kingdom). 
 
Table 2.2.2.1 Primer Sequences 
Primers Sequence  5’ 3’ 
M+64  (6FAM)TCAGGCCCCCTCAAAGCCGA(BHQ1) 
M+24 AGATGAGTCTTCTAACCGAGGTCG  
M-124mod TGCAAAGACACTTTCCAGTCTCTG 
M-124 TGCAAAAACATCTTCAAGTCTCTG 
 
The master mix (x100) comprised of 546µl water (RNase-free, Ambion AM9937 or AM9906 
(DEPC-treated)) + 1ml 2 x Reaction mix + 50µl Enzyme mix + 100µl M+24 primer (6 µM) + 
100µl M-124mod (6µM) or M-124 primer (6µM) + 100µl M+64 probe (FAM-BHQ1) (5µM) + 4µl 
ROX dye.  Each reaction used 19µl of master mix and 1µl or RNA.  The standard plate layout 
comprised of 7 serial 10-fold dilutions of standard (107-101 copies/µl) in triplicate, a no template 
control (NTC) in triplicate, and up to 36 unknowns in duplicate. 
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2.3 In vivo work 
 
2.3.1 Ferrets 
 
Ferrets (Mustela putorius furo) were obtained from Highgate Farm, United Kingdom, and 
Marshalls Bio Resources, Hull, United Kingdom.  All ferrets were confirmed as seronegative 
for influenza antibodies by haemagglutination-inhibition (HAI) assay (Section 2.2.7) prior to 
study commencement. Identifier chips (Bio-Thermo®, iDENTICHIP®, Cambridge, United 
Kingdom) were inserted subcutaneously into the dorsal cervical region of each animal.  The 
ferrets were housed in cages or floor pens which were designed in accordance with the 
requirements of the United Kingdom Home Office Code of Practice for the Housing and Care 
of Animals Used on Scientific Procedures (1989).   
 
2.3.2 Virus Preparation 
 
Virus was typically diluted in either PBS pH 7.4 (Gibco, Loughborough, United Kingdom) or 
DMEM with GlutaMAX (Gibco, Loughborough, United Kingdom). For intranasal inoculations a 
total volume of 200µl challenge material was administered and distributed evenly between 
both nares. This procedure was performed slowly, ensuring each droplet was absorbed into 
the nasal cavity of the ferret before releasing another. 
 
2.3.3 Sedation 
 
Animals were sedated by intramuscular injection of ketamine/xylazine (17.9 mg/kg and 3.6 
mg/kg bodyweight). 
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2.3.4 Clinical Monitoring 
 
Ferrets were typically monitored for the following signs of disease twice daily (approximately 
8 hr apart); appetite loss, sneezing, nasal discharge, diarrhoea and activity level.   Information 
was recorded as yes or no for all metrics excluding activity level, which was scored as 0 for 
normal, 1 for reduced activity and 2 for inactive.  Weight was recorded in grams once daily.  
 
2.3.5 Nasal Wash 
 
Nasal washes were obtained (Fig. 2.3.5.1) using 2 ml PBS pH 7.4 (Gibco, Loughborough, 
United Kingdom).   
 
Figure 2.3.5.1 Images of a ferret undergoing nasal washing.  Each ferret was anaesthetised prior 
to nasal washes being carried out.  A 20G x 30mm blunt ended needle attached to a 2ml syringed filled 
with PBS was used to flush the ferrets nose.  Ferrets were placed on their backs with nostrils facing 
down toward a plastic cup and petri dish.  The PBS was divided between each nostril equally.  The tip 
of the needle was held just above the nostril (a) and the plunger slowly depressed to administer the 
PBS.  The PBS was the allowed to drip into the cup and collection dish (b).  Using the same blunt ended 
syringe, the PBS was drawn back up and dispensed into appropriately labelled tubes.    
 
a
b 
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Nasal washes were stored on ice.  A one in 10 dilution of nasal wash to Trypan Blue solution 
(Sigma- Aldrich, Dorset, United Kingdom) was carried out, mixed and loaded onto a C-Chip™ 
disposable haemocytometer (NanoEnTek, Seoul, Korea). Trypan Blue solution is a live/dead 
stain which dead cells dark blue, with live cells staying white. The haemocytometer contained 
four quadrants with a grid of nine with each quadrant.  The live cells were counted in each 
quadrant and then divided by four to obtain an average.  This number was then multiplied by 
104 (as the total volume of the quadrant is 0.0001ml) to give number of cells per ml. The nasal 
washes were aliquoted and frozen at -80°C prior to plaque assay analysis.  Alternatively, cell 
counts were carried out using a NucleoCounter® NC-200™ (ChemoMetec, Allerod, Denmark). 
 
2.3.6 Blood Sampling 
 
Blood samples were taken from the cranial vena-cava vessel of ferrets using a needle and 
syringe into either BD Vacutainer® Heparin Blood Collection tubes for whole blood immune-
phenotyping, peripheral blood mononucleocyte (PBMC) collection or interferon gamma 
enzyme linked immunosorbent assay (IFN-γ ELISA) or BD Vacutainer® SST™ tubes for serum 
collection.  
 
Blood taken for serum in BD Vacutainer® SST™ tubes was left to clot at room temperature for 
at least 30 minutes.   BD Vacutainer® SST™ tubes were then placed into a centrifuge a spun 
at 1000g for 10 minutes to separate serum.  Serum was removed and aliquoted into cryovials 
(Nunc, Roskilde, Denmark) and stored at -70±10°C for long term storage. 
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2.3.7 Ferret Sera Preparation 
 
Ferret sera were diluted 1:3 with Receptor Destroying Enzyme (RDE, Denka Seiken, Japan) 
and incubated for 18-20 hours in a 37±1°C incubator.  Following incubation, the RDE is 
inactivated in a 56±1ºC water bath for 45-50 minutes.  RDE treated sera was then frozen at -
20ºC until use. 
 
2.3.8  Haemagglutinin Inhibition (HAI) Assay 
 
The HAI assay is a simple assay used to assess the presence of antibodies to a specific strain 
of influenza in sera (Fig. 2.3.8.1). 
 
A 0.5% blood suspension with appropriate red blood cells was prepared on the day of the HAI 
assay. RDE treated sera (50µl) to be assayed were placed on a 96 v-well plate (Invitrogen, 
Paisley, United Kingdom) and serially diluted (1:2) with PBS pH 7.4 (25µl) (Gibco, 
Loughborough, United Kingdom). Diluted virus (from HA assay 2.1.8) was added to the plate 
and incubated for 30 minutes at room temperature.  Following incubation 0.5% blood (50µl) 
was added to the plate and incubated for 45-60 minutes. The HAI titre of sera was read by 
determining which wells showed complete inhibition of haemagglutination (red blood cells 
formed a teardrop shape) or haemagglutination (red blood cells formed a latticework). The 
HAI titre was read as the well which showed the last complete inhibition of haemagglutination 
for each serum sample. Serum from infected animals with known HAI titre were used as 
positive controls during the HAI assay.    
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Figure 2.3.8.1 The HAI Assay (CDC, 2017) The HAI assay involves the interaction of red blood cells 
(RBCs), antibody and influenza virus. Row A illustrates in the absence of virus, RBCs in a solution will 
sink to the bottom of a v-well microtitre plate well and look like a red button. Row B shows that influenza 
viruses will bind to red blood cells when placed in the same solution. This is called hemagglutination 
and is represented by the formation of the latticework structure, as shown in “result”. Row C shows how 
antibodies that are antigenically like a virus being tested will recognise and bind to that influenza virus. 
This prevents the virus and RBCs from binding, and therefore, haemagglutination does not occur 
(haemagglutination inhibition occurs instead). 
 
2.3.9 Terminal Anaesthesia and Necropsy 
 
Animals were sedated (Section 2.3.3).  If taking whole blood for immuno-phenotyping and 
whole blood stimulation this was carried out prior to terminal euthanisation.  Ferrets were 
euthanised by using a lethal dose of sodium pentobarbitone.   If required, the remainder of the 
blood was collected after overdose into BD Vacutainer® Heparin Blood Collection tubes for 
whole blood and/or BD Vacutainer® SST™ tubes for serum. 
Components Interaction Result 
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2.4 Immune Cell Isolation 
 
2.4.1 Media  
 
R10 Medium 
500ml of RPMI 1640 medium (Sigma-Aldrich, Dorset, United Kingdom) with the addition of 
5ml of  L-glutamine (2mM) (Sigma-Aldrich, Dorset, United Kingdom), 0.5ml of 0.05mM 2-
mercaptoethanol (Invitrogen, Paisley, United Kingdom), 15ml of 25mM HEPES buffer (Sigma-
Aldrich, Dorset, United Kingdom), and 50ml of (10%) heat inactivated foetal bovine serum 
(Sigma-Aldrich, Dorset, United Kingdom). 
 
R2 Medium  
500ml of RPMI 1640 medium (Sigma-Aldrich, Dorset, United Kingdom) with the addition of 
5ml of L-glutamine (2mM) (Sigma-Aldrich, Dorset, United Kingdom), 0.5ml of 0.05mM 2-
mercaptoethanol (Invitrogen, Paisley, United Kingdom), 15ml of 25mM HEPES buffer (Sigma-
Aldrich, Dorset, United Kingdom), and 10 ml of (2%) heat inactivated foetal bovine serum 
(Sigma-Aldrich, Dorset, United Kingdom). 
 
2.4.2 Isolation of Peripheral Blood Mononuclear Cells 
 
Fresh heparin anti-coagulated blood was layered on room temperature Histopaque 1083 
(Sigma-Aldrich, Dorset, United Kingdom) in 15ml ACUSPINTM tubes (Sigma-Aldrich, Dorset, 
United Kingdom) and a density separation carried out at 800g for 20 minutes.  The buffy coat 
(Fig. 2.4.2.1), the fraction of anticoagulated blood containing most of the white blood cells and 
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platelets following density gradient centrifugation, was collected for each sample and washed 
with R2 medium cells were pelleted by centrifugation at 400g for 10 minutes.   
 
 
Figure 2.4.2.1 PBMC Isolation.  The diagram illustrates where the buffy coat forms following 
centrifugation on the Histopaque 1083 gradient.  The buffy coat is located in the same place during 
splenocyte and BAL isolation. 
 
2.4.3 Isolation of Splenocytes  
 
Spleens were removed whole from each ferret.  Spleen were cut up using disposable scissors 
and placed into gentleMACS C-tubes and dissociated using a gentleMACS Tissue Dissociator 
(Miltenyi Biotec, Surrey, United Kingdom) with R2 medium. The tissue solution was passed 
through two cell sieves (100µm then 70µm) and then layered on room temperature Histopaque 
1083 (Sigma-Aldrich, Dorset, United Kingdom) in 15ml ACUSPINTM tubes (Sigma-Aldrich, 
Dorset, United Kingdom) and a density separation carried out at 800g for 20 minutes.  The 
blood 
histopaque 1083 
centrifuge 
fret 
buffy coat 
plasma 
red cells 
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buffy coats containing lymphocytes were collected and washed with R2 medium and cells 
were pelleted by centrifugation at 400g for 10 minutes.   
 
2.4.4 Isolation of Bronchoalveolar Lavage (BAL) Immune Cells 
 
Bronchoalveolar lavage washes were performed post overdose, prior to removal of lungs. BAL 
washes with sufficient R2 medium were layered on room temperature Histopaque 1083 
(Sigma-Aldrich, Dorset, United Kingdom) in 15ml ACUSPINTM tubes (Sigma-Aldrich, Dorset, 
United Kingdom) and a density separation carried out at 800g for 20 minutes.  The buffy coats 
containing lymphocytes were collected and washed with R2 medium and cells were pelleted 
by centrifugation at 400g for 10 minutes.  
 
2.4.5 Isolation of Lung Mononuclear Cells 
 
Whole lungs were removed from each ferret.  The lungs were dissected into small pieces and 
placed into a 25ml solution of collagenase (715 collagenase units/ml) (Sigma-Aldrich, Dorset, 
United Kingdom) and DNase (350 DNase units/ml) (Sigma-Aldrich, Dorset, United Kingdom).  
Lungs were vigorously shaken whilst in a 37±1oC incubator for 1 hour. Partially digested lung 
tissue was then placed into gentleMACS C-tubes and dissociated using a gentleMACS Tissue 
Dissociator (Miltenyi Biotec, Surrey, United Kingdom).    The tissue solution was passed 
through two cell sieves (100µm then 70µm) and then layered on room temperature Histopaque 
1083 (Sigma- Aldrich, Dorset, United Kingdom).  A density separation was carried out at 400g 
for 30 minutes.  The buffy coats containing lymphocytes were collected (Fig. 2.4.5.1) and 
washed with R2 medium by pelleting cells by centrifugation at 400g for 10 minutes. 
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Figure 2.4.5.1 Lung MNC Isolation.  The diagram illustrates where the buffy coat forms following 
centrifugation on the Histopaque 1083 gradient.   
 
2.4.6 Red Blood Cell Removal Using ACK Lysis Buffer 
 
Red blood cells were lysed from PBMC, spleen, lung MNC and BAL sample preparations by 
re-suspending cell pellets in 5ml of ACK Lysing Buffer (Gibco, ThermoFisher Scientific, United 
Kingdom).  The cells were incubated at room temperature with manual gentle agitation for 5 
minutes.  The ACK Lysing Buffer was inactivated by the addition of an excess of R2 medium.  
Cells were pelleted by centrifugation at 400g for 10 minutes to remove lysis buffer.  If lysis of 
the red blood cells were incomplete, then the treatment was repeated. 
 
 
 
centrifuge lung MNCs 
histopaque 1083 
red cells 
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2.4.7 Immune Cell Counting 
 
Cell pellets were resuspended with an appropriate volume of R2 medium. Cell counts were 
carried out using a NucleoCounter® NC-200™ (ChemoMetec, Allerod, Denmark). 
 
2.4.8 Immune Cell Cryopreservation  
 
Cells were pelleted by centrifugation at 400g for 5 minutes and resuspend in the appropriate 
volume of cryomedia (90% FCS + 10% DMSO). DMSO was added as a cryoprotectant to 
avoid damage to the cells during freezing.   Cells were frozen in cryovials (Nunc, Roskilde, 
Denmark) in 1ml aliquots of concentrations between 3 x 106 and 1.3 x107 cells per ml.  
Cyrovials were placed in a Mr Frosty™ Freezing Container and transferred to a -70ºC freezer. 
The Mr Frosty™ Freezing Container allowed for a rate of cooling of approximately -1ºC/minute 
allowing for slow freezing of the cells which prevents intracellular ice crystals from forming.  
After freezing at  -70ºC  vials were transferred to liquid nitrogen storage. 
 
2.4.9 Immune Cell Resuscitation 
 
The appropriate number of vials were removed from liquid nitrogen and placed in a 37°C water 
bath until visually defrosted.  Cells were immediately placed into R10 medium with benzonase. 
Cells were washed by centrifugation at 400g for 5 minutes and re-suspending in R10 + 
benzonase twice.  Cells were then resuspended and rested for at least 1.5 hours or at most, 
overnight by incubation at 37±1°C, 5% CO2 in 50ml sterile centrifuge tubes with loosened lids 
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to allow gas exchange. Following incubation cells were washed by centrifugation at 400g for 
5 minutes and re-suspended in 5ml R10 without benzonase for a viable count. 
 
2.4.10 Quantification of influenza-specific Interferon-gamma (IFN-γ) production by 
enzyme linked immunosorbent assay (ELISA)  
 
The IFN-γ ELISA (fig 2.4.10.1) is used to assess the longitudinal influenza-specific IFN-
response in circulating peripheral blood of the ferret. High level production of IFN-γ is typically 
associated with effective host defence against intracellular pathogens. The small volumes of 
blood (approximately 400µl depending on the number of antigens used for stimulation) 
required for this assay means samples can be taken from ferrets on a frequent basis.    
 
Heparinised whole blood was diluted 1:10 with serum free RPMI 1640 medium and incubated 
with A/Perth/16/2009 (H3N2) at a multiplicity of infection (MOI) of 0.8. MOI refers to the 
number of virions that are added per cell during infection. Phytohemagglutinin PHA-M (PHA) 
(Sigma-Aldrich, Dorset, United Kingdom) was used as a positive control as it is a potent 
mitogen used to stimulate cell proliferation in lymphocyte cultures. Egg allantoic fluid was used 
as a negative control as viruses used were grown in eggs. Blood was stimulated by incubation 
for 4 days in a 37°±C, 5% CO2 incubator after which plasma supernatants were collected and 
cryopreserved at -80 ºC. The Ferret IFN-γ ELISA Development Kit (ALP) (Mab Tech, Nacka. 
Sweden) was used to determine the quantity of IFN-γ secreted by cells in the blood in 
response to influenza-specific stimulations.  ELISA plates were read using the VersaMax 
ELISA Microplate Reader (Molecular Devices, Sunnyvale, CA, USA) with SoftMaxTM PRO 
software (Molecular Devices, Sunnyvale, CA, USA). Unknowns were calculated from the 
standard curve on each plate.  
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Figure 2.4.10.1 ELISA Overview (Mab Tech, Nacka. Sweden).   a Antibody Coating: IFN-γ specific 
monocolonal capture antibody (mAb MTF14) immobilised on high protein binding plates. b  Protein 
Capture: Samples and standard dilutions are added to wells and are captured by the bound 
antibodies  c Detection Antibody: biotinylated IFN-γ specific detection antibody is added to wells to 
enable detection of captured IFN-γ  d  Streptavidin-enzyme Conjugate:  Streptavidin conjugated 
with alkaline phosphatase is added to the wells and bind to biotinylated antibody. e Colourimetric 
substrate is added to the wells an forms a coloured solution when catalysed by the enzyme.  f 
Absorbance is measured  using using the VersaMax ELISA Microplate Reader (Molecular Devices, 
Sunnyvale, CA, USA) with SoftMaxTM PRO software (Molecular Devices, Sunnyvale, CA, USA) and the 
amount of IFN-γ in samples is detected. 
 
 
 
a b c 
d e f 
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2.4.11 Interferon-gamma (IFN-γ) Enzyme Linked Immuno-Spot Assay (ELISpot) 
 
The influenza-specific IFN-γ ELISpot assay was performed with PBMC, spleen, lung MNC and 
BAL sample.  The ELISpot (fig. 2.4.11.1) allows determination of the production capacity of 
influenza-specific T cells in various tissues using a ferret specific IFN-γ kit (Mab Tech, Nacka. 
Sweden).  PBMC, spleen, lung MNC and BAL were resuscitated as described (Section 2.4.9). 
Cells were rested for 2 hours prior to use.  PBMC, spleen, lung MNC and BAL were assessed 
for responses to IAV A/Perth/16/2009 (H3N2).  A/Perth/16/2009 was used at multiplicity of 
infection (MOI) of 0.08.  The passage of A/Perth/16/2009 used was egg grown, therefore, egg 
allantoic fluid was used as a negative control throughout all the ELISpot assays.  Phorbol-12-
myristate PMA) (100ng/ml; Sigma-Aldrich, Dorset, United Kingdom) and ionomycin (1µg/ml; 
Merck, Watford, United Kingdom) were combined and used as a positive control.  PMA and 
ionomycin used in combination can stimulate the intracellular production of cytokines. Pre-
coated (mAb MTF14) plates (Mab Tech, Nacka. Sweden) were used. A range of cell 
concentrations were seeded (depending on cell origin) per well in 50µl of R10, with or without 
antigen, in duplicate and incubated overnight at 37±1ºC. Following culture, plates were 
washed and incubated for 2 hours with biotinylated anti IFN-γ IgG.  Spots were developed by 
the addition of streptavidin-alkaline phosphatase and 5-bromo-4-chloro-3-indoly phosphate 
(BCIP)-Nitro Blue tetrazolium (NBT) substrate. Results from duplicate tests were averaged. 
Data were analysed by subtracting the mean number of spots in the cells and allantoic fluid 
control wells from the mean counts of spots in wells with cells and antigen. ELISpot plates 
were scanned on the C.T.L ELISpot Plate Reader using ImmunoSpot 5.0 Analyzer Software 
and counted using ImmunoSpot 5.1 Counting Software. Plates underwent manual quality 
control following automatic counting.  
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Figure 2.4.11.1 ELISpot Overview (Mab Tech, Nacka. Sweden).   a Antibody Coating: IFN-γ specific 
monocolonal capture antibody (mAb MTF14) immobilised on an ethanol-treated PVDF membrane 
plate. b  Cell Incubation: Cells are added to the wells in the prescence or absence of stimuli and 
then incubated to allow IFN-γ secretion.  c Cytokine Capture: Secreated IFN-γ binds to the capture 
antibodies on the membrane immediately surrounding the activated cells.  d  Detection Antibody:  
Following removal of cells and washing of plates, biotinylated IFN-γ specific detection antibody is 
added to wells. e Streptavidin-enzyme Conjugate: To enable the formaton of spots on the 
membrane, a streptavidin enzyme conjugate is added to wells.  f Addition of Substrate: Colorimetric 
substrate is added to the wells and forms an insoluable precipitate when catalysed by the enzyme; 
this provides a visable representation of IFN-γ release by a single activated cell. g Analysis:  Spots 
are counted using a The C.T.L ELISpot Plate Reader and the frequency of secreating cells is 
calculated.    
 
 
 
 
a b c d 
e f g 
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2.4.12 Whole Blood Immunophenotyping – Antibody labelling 
 
Whole Blood Immunophenotyping was used to identify T cell populations in whole circulating 
blood to determine the number of cells per ml.  Two antibodies (Table 2.4.12.1), each 
conjugated with a different fluorochrome, were used in these experiements.  The first was a 
phycoerythrin (PE)-conjugated anti-ferret CD4 (Sino Biological, Bejing, China).  This antibody 
was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells 
obtained from a mouse immunized with purified, recombinant Ferret CD4. The second was a 
Alexa Fluor™ (AF) 700-conjugated anti-human CD8a Clone: OKT8 (eBiosciences, San Diego, 
USA).  This antibody has previously been reported to work well with the ferret model (Reber 
et al., 2018).    
 
Table 2.4.12.1 Antibodies 
Antibody Manufacturer Lot number 
CD4 PE  Sino Biological 60003-MM02-P-SIB 
CD8 AF700  eBiosciences 56-0086-42 
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The following antibodies were used to determine the compensation setting: 
 
Table 2.4.12.2 Compensation Antibodies  
Antibody Manufacturer Lot number 
IgG PE (anti-
human) 
eBiosciences 3298651 
IgG AF700 (anti-
human) 
eBiosciences 94762813 
 
Compensation is the process of correcting the spill over from the primary signal in each 
secondary channel it is measured in.  The emission spectra of fluorescent dyes are broad.  
The peak emission is usually clearly separated for each dye, but there can be considerable 
overlap between the dyes.  Using FITC and PE as examples, Figure 2.4.12.1 illustrates 
spectral overlap; where some of the light emitted by the FITC will pass through the filter for 
PE.  This means that some of the cells labelled with the FITC will appear to have PE 
fluorescence. 
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Figure 2.4.12.1 An example of spectral overlap (Omerod, 2008). FITC and PE with two bandpass 
(BP) filters superimposed.  Some of the light from the FITC will pass through the filter used to collect 
the light from PE.  
 
To obtain a true representation of the data colour compensation needs to be applied.  
Compensation for spectral overlap can be done by subtracting a fraction of the FITC signal 
from the PE signal.  Compensation has to be applied in both directions to represent the data 
correctly (Omerod, 2008).   
 
Two tubes were prepared, one for each antibody to be used during compensation. 
Compensation beads (lot: 3316686) were placed into each tube and treated the same as 
samples going forward.   
 
spectral 
overlap 
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All antibodies were added in excess (5μl of each in each tube). Antibodies were only mixed 
and aliquoted into tubes once blood was available to avoid complexes forming between the 
antibodies.  50μl of fresh heparinised blood was added to each tube.  Samples were vortex 
mixed for 5-10 seconds and incubated at room temperature for 30 minutes with light excluded.  
Light was excluded because fluorophore attached the antibody was light sensitive. 
 
Following incubation 50μl of Uti-Lyse™ Reagent A (Dako, Agilent, Stockport, United Kingdom) 
was added to tubes.  Samples were vortexed for 5-10 seconds.  Samples were covered and 
left to incubate at room temperature for 10 minutes. Red blood cells were then lysed by adding 
500μl of Uti-Lyse™ (Dako, Agilent, Stockport, United Kingdom) Reagent B to tubes and mixing 
with a vortex.  Samples were left covered for up to 3 hours or until RBC lysis was completed.  
To fix samples 38μl of 16% methanol free formaldehyde was added to each tube achieving a 
1% formaldehyde solution.  Samples were left for a minimum of 10 minutes prior to flow 
cytometric acquisition.   
 
Immediately prior to flow cytometric acquisition, 50µl of Flow Count (Becton Dickinson, New 
Jersey, United States) beads were added to each tube to enable counts to be carried out. 
 
2.4.13 Whole Blood Immunophenotyping – Flow Cytometric Acquisition 
 
All flow cytometric acquisition of whole blood immune-phenotyping was carried out using a BD 
LSRFortessa™ and BD FACSDiva™ software.  Acquisition was stopped after 15,000 
lymphocyte events were collected in the lymphocyte region.  Flow cytometric analysis was 
carried out within 24 hours of fixing.   Compensation was always performed each time 
acquisition of the FSC files took place.  
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BD™CS&T (Cytometer Set-up & tracking) beads (Becton Dickinson, New Jersey, United 
States) are used on BD flow cytometers to provide a standardised method to perform a quality 
control of the instruments optics, electronics and fluidics and for adjusting fluorescence 
compensation.  They are a suspension of fluorospheres with uniform and stable size and 
fluorescence intensity. BD™CS&T (Becton Dickinson, New Jersey, United States) beads were 
run on each occasion that the Fortessa was used to provide a performance check.  The beads 
were re-suspended by inverting the bottle prior to use.  The performance check was run on a 
medium flow rate. DIVA Software was put into cytometer set up and tracking mode prior to 
running the BD™CS&T (Becton Dickinson, New Jersey, United States) beads.  The 
administrator will have installed details for the current bead batch prior to use.  In a 5ml flow 
cytometer tube one drop of BD™CS&T (Becton Dickinson, New Jersey, United States) beads 
were added to 350µl of PBS.  The tube of diluted beads was applied to the probe and run.  
Following acquisition, the flow cytometer was returned to Standby mode.  A CS&T report was 
produced and any out of specification values were highlighted. 
 
Data analysis was carried out using FlowJo (FlowJo LLC, Ashland, Oregon, United States).  
Granulocyte and lymphocyte populations were identified on pseudo dot plots (FSC vs SSC) 
and gated as shown in the example below (Fig. 2.4.13.1). 
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Figure 2.4.13.1 Identification of granulocyte and lymphocyte populations.  Gates were drawn 
around the lymphocyte and granulocyte populations by selecting the polygon shape. These gates were 
applied to all samples being analysed. Each sample was then QC checked to ensure the gates were in 
the correct place as populations can appear slightly differently across ferrets.  
 
CD4+ and CD8+ T cell populations were identified by isolating the lymphocyte population on 
the plot and changing the axis to show the PE (CD4) and AF700 (CD8) detectors.  A quad 
region was drawn as shown below (Fig. 2.4.13.2).  
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Figure 2.4.13.2 Identification of CD4+ and CD8+ populations.  CD4+ and CD8+ T cells within the 
lymphocyte population were identified using a quad region.  
 
Results were presented as the percentage change in cell per ml from values obtained prior to 
challenge.  This was calculated by dividing the cell per ml of blood after challenge by the mean 
cells per ml value prior to challenge.   The value obtained was multiplied by 100 to calculate 
the percentage and 100 was subtracted to calculate if the change was positive or negative.  
 
2.5 Statistical Analysis 
 
To compare the amount of virus shed in infected animals the area under the curve (AUC) for 
each animal was calculated using GraphPad Prism, version 7.0 (GraphPad Software Inc, La 
Jolla, California, USA).  Where animal numbers were sufficient, the AUCs calculated in each 
test group were compared to those animals in other test groups with a Mann Whitney test 
using GraphPad Prism, version 7.0 (GraphPad Software Inc, La Jolla, California, USA).   
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To compare the amount of IFN-γ responses detected by ELISA in circulating blood infected 
animals the AUC for each animal was calculated using GraphPad Prism, version 7.0 
(GraphPad Software Inc, La Jolla, California, USA).  The Mann Whitney test was used to 
determine if there were any differences between influenza-specific IFN-γ responses seen in 
PBMC and lungs of ferrets inoculated with different strains of influenza.  The Spearman 
correlation test was used to determine the level of correlation between study parameters using 
GraphPad Prism, version 7.0 (GraphPad Software Inc, La Jolla, California, USA).   
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3 Characterisation and Development of the Intranasal Low 
Dose model in Ferrets 
 
3.1 Introduction  
 
The purpose of developing a low dose intranasal model with H3N2 is to provide a baseline 
comparative model to run alongside the development of two other models: the nose-only 
aerosol delivery and the respiratory droplet transmission cage model.  Intranasal inoculation 
is the most commonly used method for infection of ferrets with influenza virus inoculation 
(Belser et al., 2011, Enkirch and von Messling, 2015).  The infection of ferrets with seasonal 
H3N2 influenza via the intra-nasal route causes a characteristically mild to moderate, non-
lethal infection resulting in weight loss, brief fever and upper respiratory tract infection.  
Previous studies have inoculated animals with high doses of influenza to ensure that animals 
have been infected and induce a clear response.  This, however, doesn’t provide a true 
representation of human infection who can be infected with doses as low as 100 TCID50 intra-
nasally and 0.6-3.0 TCID50 via the aerosol route (Nikitin et al., 2014) 
 
Intranasal infection of ferrets with 106 plaque forming units (pfu, Section 2.1.9) and TCID50 of 
A/California/04/2009 has been widely reported to produce a mild to moderate respiratory 
response (Maines et al., 2009, Huang et al., 2011, Munster et al., 2009). The PHE Influenza 
Research Team, however, developed a low dose H1N1 ferret model with A/California/04/2009 
and have demonstrated that reducing the challenge dose to 102 pfu delays the onset of clinical 
signs by 1 day and results in a modest reduction in clinical signs and a slowed nasal cavity 
innate immune response (Marriott et al., 2014).  A delay in virus production in the upper 
respiratory tract (URT) and prolonged virus shedding was also seen. These delayed disease 
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kinetics are much more similar to the course of influenza disease in humans than those 
observed with a higher challenge dose (Marriott et al., 2014). 
 
A series of studies were completed evaluating the viral kinetics and pathology in the ferret 
following intranasal inoculation.   
 
3.2 Chapter Aims 
 
The overall objective of this chapter was to assess the low dose intranasal ferret model for 
H3N2 A/Perth/16/2009.  Specific objectives were to:  
 
 Evaluate and compare the high and low dose intranasal inoculation of ferrets with 
A/Perth/16/2009  
 To confirm that a dose of 102 pfu per ferret provides a robust and reproducible model 
of infection 
 To investigate, compare and contrast the cellular immune response seen in ferrets 
when infected with a high and low dose of A/Perth/16/2009 
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3.3 Initial Intranasal Dose Pilot Study  
 
The first study designed was a high dose (HD) and low dose (LD) inoculation of ferrets was 
carried out in study 4965 (see appendix 1). This pilot study was carried out using a stock of 
A/Perth/16/2009 that was identity confirmed by sequencing of the HA and NA genes. 
Previously A/Perth/16/2009 had been reported in the literature to cause observable, non-lethal 
illness in ferrets when delivered intra-nasally at 106 PFU/ferret (Maines et al., 2009). Upon 
commencing this pilot no data was available for lower doses of the virus.  
 
3.3.1 In vivo Study Outline  
 
As a first step in developing an H3N2 ferret model for this project, 4 ferrets were used to 
perform a pilot dose-ranging study. Doses of 102 and 106 PFU/ferret were tested, as these 
values spanned the range known to efficiently infect ferrets when using H1N1 
(A/California/04/2009) virus (Marriott et al., 2014). Ferrets were monitored for clinical signs 
and virus shedding, as well as sero-conversion, to inform future studies using an H3N2 
challenge.  
 
3.3.2 Ferrets 
 
Ferrets were obtained from Highgate Farm, UK and were 4-6 months at the time of the study.  
A total of 4 ferrets were used, 2 were allocated to the HD group and 2 to the LD group as 
shown in Table 3.3.2.1. Ferrets were group housed in floor pens designed in accordance with 
the requirements of the United Kingdom Home Office Code of Practice for the Housing and 
Care of Animals Used on Scientific Procedures (1989). 
107 
 
 
Table 3.3.2.1 Ferret Identification Numbers 
High Dose (HD) Group Low Dose (LD) Group 
 
27043 (m), 30654 (f) 
 
47575 (m), 27027(m) 
 
3.3.3 Prior to Viral Inoculation 
 
At three days prior to inoculation, ferrets were fully anaesthetised using Ketamine/Xylazine 
(1ml Ketamine plus 0.4ml Xylazine) given at a dose of 0.25ml/Kg bodyweight. A nasal wash 
was performed on each ferret to act as a baseline nasal wash count prior to inoculation. 
Baseline blood samples were taken from the anterior vena-cava vessel of each ferret, 500 µl 
blood was collected into SST tubes for sera isolation. Sera were tested by HAI (Section 2.3.8) 
for the presence of any pre-existing antibodies to influenza H3N2 A/Perth/16/2009 to ensure 
ferrets were not previously exposed to this strain of influenza.  Sera with an HAI titre equal to 
or less than 8 was deemed to be seronegative. All baseline sera samples had HAI titres of 
less than 4 to H3N2 A/Perth/16/2009. It was deemed that these ferrets had no previous 
exposure to H3N2 and so were suitable for challenge. 
 
3.3.4 Virus 
 
Ferrets were inoculated intranasally with H3N2 A/Perth/16/2009 P+2A challenge stock virus 
diluted in PBS to provide a stock of 1x106 pfu/ferret (HD group) or 10x102 pfu/ferret (LD group). 
The dose was confirmed on day of administration by back-titration. The challenge materials 
were given to each animal in a volume of 0.2ml by the intranasal route. 
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3.3.5 Sample Collection 
 
Following virus inoculation, ferret weight was recorded daily, and clinical signs of influenza 
infection were recorded twice daily.  From 1 to 4 dpi and on 7, 9, 11 days post infection (dpi) 
nasal washes were collected from animals.  Nasal washes were counted and frozen to be 
titred at a later date. At day 14 ferrets were culled. Ferrets were sedated by intramuscular 
injection of Ketamine/Xylazine (1ml Ketamine plus 0.4ml Xylazine) given at a dose of 
0.25ml/Kg bodyweight. Following overdose samples were collected from each ferret; nasal 
wash and blood in SST for serum.  Nasal washes and serum were aliquoted and stored at -
70±10ºC for analysis at a later date. 
 
3.3.6 Results 
 
 Nasal wash cell counts and titres in HD and LD groups 
 
Nasal wash cell counts were collected for both groups at 1- 4, 7, 9, 11 and 14 days post 
infection (dpi) (Fig. 3.3.6.1.1).  Cell counts for the HD group ferrets, 27043 and 30654, both 
increased at 2 dpi, indicating successful infection.  The nasal wash cell count for 30654 then 
steadily decreased over the sampling period, while ferret 27043 appeared to have a second 
peak at 7 dpi with a decrease to baseline levels in nasal wash cell counts by 14 dpi. The LD 
group appeared to have a slower rise in nasal wash cells counts following infection. Ferret 
47575 peaked at 3 dpi and a slight second peak at 9 dpi with a decrease to baseline level by 
14 dpi.  Ferret 27027 had a slower but steady rise in nasal wash cell counts not peaking until 
around 9 dpi.  By 14 dpi nasal wash cell counts were decreasing but not back down to baseline 
levels. 
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Figure 3.3.6.1.1 Nasal wash cell counts HD Group: 27043, 30654.  LD Group: 27027, 47575. Nasal 
washes were collected at +1 to +4, +7, +9, +11 and +14 dpi. All nasal washes were counted to ascertain 
the number of cells being shed from each ferret at each timepoint.   A rise in nasal wash cells from 
baseline indicates successful infection.  Plots represent individual counts.  Single counts were 
performed on each nasal wash sample from each ferret on each day.  
 
Nasal wash samples were titred to ascertain live viral titres being shed from the ferrets (Fig. 
3.3.6.1.2). The first peak in the HD group appeared at 1 dpi for both ferrets, 27043 and 30654.  
This was followed by a fall in titre, with a smaller, lower peak at 4 dpi.  Both ferrets stopped 
shedding virus by 7dpi.  The ferrets in the LD group began shedding virus at one (47575) and 
two (27027) days post infection.  Ferrets 47575 and 27027 had peak shedding titres at 3 and 
4 dpi, respectively.  Ferret 47575 stopped shedding virus by 7 dpi and ferret 27027 stopped 
shedding virus by 9 dpi.   These results are as expected, ferrets successfully infected with 
influenza virus should start to shed live virus at approximately 1 dpi, but it is expected that 
these results will differ with inoculation titre.  
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Figure 3.3.6.1.2. Nasal wash titres HD Group: 27043, 30654.  LD Group: 27027, 47575.  Nasal 
washes were collected at +1 to +4, +7, +9, +11 and +14 dpi. Nasal washes were plaque assayed to 
ascertain viral titres shed from ferrets at all timepoints. Plaque forming units (PFU) per millilitre (ml) of 
nasal wash represent a direct relationship to the amount of live virus in a sample. Plots represent 
individual assay results.  Single plaque assays were performed on each nasal wash sample from each 
ferret on each 
 
 Clinical signs of infection in HD and LD groups  
 
Weight was monitored once daily throughout the study.  Both HD group ferrets initially 
experienced a drop in percentage weight from baseline following inoculation at 2 dpi.  They 
both recovered by 3dpi and began to put on weight.  Ferret 30654 experienced another 
decrease in percentage weight from baseline at 6 dpi, which appears to coincide with the 
second peak in nasal wash cell counts identified in Figure 3.3.1 All four ferrets on the study 
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gained weight over the course of the study (Fig. 3.3.3), showing that the virus had no impact 
on the ferrets’ ability to gain weight overall.  
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Figure 3.3.6.2.1 Weight percentage change from baseline. HD Group: 27043, 30654.  LD Group: 
27027, 47575.  Percentage weight changes from day of infection for all ferrets (n=4). 
 
Table 3.3.6.2.1.  Cumulative incidence of nasal discharge and sneezing 
Ferret Incidence 
27043 
 
5 
30654 
 
3 
47575 
 
2 
27027 
 
2 
 
The cumulative incidences for nasal discharge and sneezing, recorded 1-14 dpi, in the HD 
group were higher when compared to the LD group (Table 3.3.6.2.1). Appetite loss was noted 
for both animals in the HD group, 27043 and 30654, at 7 dpi for two instances.  There were 
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no instances of reduced activity or diarrhoea recorded for any of the animals in either the HD 
or LD group.   
 
 Evidence of seroconversion in HD and LD groups  
 
The HAI assay confirmed ferrets from both the HD and LD groups seroconverted (Fig. 
3.3.6.3.1).  Seroconversion is the period during which specific antibodies to A/Perth/16/2009 
develop to become detectable in the ferret blood.  When these antibodies become detectable 
the ferret blood the ferret is deemed to have seroconverted.  Seroconversion is measured by 
HAI titre. Both the groups show similar HAI titres. It is not expected that the HAI titre would be 
different depending on titre of virus inoculated with, and therefore between groups.  Rather 
the HAI titre shows that the humoral immune response to influenza infection was successfully 
elicited. These results confirm, along with the nasal wash titre results, that all the ferrets were 
successfully infected and produced a robust antibody response.  
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Figure 3.3.6.3.1 Haemagglutination Inhibition (HAI) titres of high and low dose infected ferrets 
to A/Perth/16/2009. HD Group: 27043, 30654.  LD Group: 27027, 47575. All pre-infection titres were 
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<4.  The cut off limit designates the titre under which ferrets are deemed seronegative.  Titres above 20 
HAI are deemed to show seroconversion.  
 
3.3.7 Discussion  
 
This study was designed to be a preliminary investigation into the immunogenicity and viral 
kinetics of H3N2 A/Perth/16/2009 in ferrets.  This study confirmed that ferrets were able to be 
successfully inoculated with high (1x106 PFU/ferret) and low (1x102 PFU/ferret) dose 
concentrations of A/Perth/16/2009.   Nasal wash cell counts indicated that ferrets had been 
infected, and plaque assays on those nasal wash samples allowed titres of virus being shed 
by the ferrets to be calculated. Clinical monitoring suggested that infection with H3N2 
A/Perth/16/2009 had no significant effect on the weight of animals, all the ferrets gained weight 
from baseline measurements for the duration of the study.  The HAI results show that both 
titres of virus caused seroconversion in the ferrets.  This suggests that the humoral immune 
response to a low dose of influenza is like that stimulated by a high dose influenza infection. 
There was a higher incidence of nasal discharge and sneezing in the two ferrets inoculated 
with the high dose of H3N2 A/Perth/16/2009 when compared to the two ferrets inoculated with 
the low dose.   
 
3.3.8 Further Work 
 
The results from this small-scale study indicate that ferrets were successfully infected with 
both 1x102 and 1x106 PFU/ferret dose of A/Perth/16/2009. Using a low dose model is 
preferential as the dose presents a more “true to life” representation of a natural dose.  These 
results show there are some differences between the high and low dose inoculated ferrets but 
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demonstrates that a low dose causes mild symptoms, viral shedding, increased numbers in 
nasal cell wash counts and elicits a humoral immune response triggering seroconversion. 
 
Therefore, this study provided the confidence to move forward with a low dose (102 pfu/ferret) 
to look at: 
 
 The presence of virus in the respiratory tract of the ferret  
 The reproducibility of the viral shedding in the ferret 
 The cellular immune response of ferrets using influenza-specific IFN-γ as a readout  
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3.4 Serial Cull Study  
 
This section describes a low dose inoculation study, designated study number 5087 (appendix 
1). To elucidate the viral kinetics of the H3N2 A/Perth/16/2009 in the ferret model a serial cull 
study was designed collecting samples which allowed the determination of the kinetics of virus 
replication and pathogenesis along the length of the respiratory tract. This study was carried 
out using the same stock of A/Perth/16/2009 used during the initial pilot study, with identity 
previously confirmed by sequencing of the HA and NA genes. Ferrets were inoculated 
intranasally with a low dose of 102 PFU/ferret. Ferrets were culled from the study 2 at a time  
at pre-determined time points, with tissues being taken for qRT-PCR.  Additionally, they were 
monitored for clinical signs, virus shedding and sero-conversion as was carried out previously. 
 
3.4.1 In vivo Study Outline  
 
Ferrets were inoculated intranasally with 1x102 PFU of A/Perth/16/2009. Ferrets were culled 
out 2 at a time at 2, 3, 4 and 8 days post infection (Table 3.4.2). A total of 8 ferrets were used.   
These time points were chosen based upon the virus titres shed by low dose inoculated ferrets 
in the previous study (Section 3.3).  Both ferrets were shedding live virus by 2 dpi, and peak 
titres were shed between 3 and 4 dpi.  Results from these three timepoints should provide a 
picture of what is happening in the ferret during the first several days of influenza infection.   
Based on the previous study day 8 was chosen as the final timepoint because this was around 
the time of viral clearance.   
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3.4.2 Ferrets 
 
Ferrets were obtained from Highgate Farm, UK and were 9.5-14.5 weeks at the time of the 
study.   
 
Table 3.4.2.1 Ferret Identification 
Day of Cull Ferrets 
2 26166 (f), 27207 (f) 
3 18992 (m), 26624 (f) 
4 76400 (f), 31048 (m) 
8 33920 (f), 86670 (f) 
 
Ferrets were group housed in floor pens designed in accordance with the requirements of the 
United Kingdom Home Office Code of Practice for the Housing and Care of Animals Used on 
Scientific Procedures (1989). 
 
3.4.3 Prior to Viral Inoculation 
 
At three days prior to inoculation, ferrets were fully anaesthetised using Ketamine/Xylazine 
(1ml Ketamine plus 0.4ml Xylazine) given at a dose of 0.25ml/Kg bodyweight. Baseline blood 
samples were taken from the anterior vena-cava vessel of each ferret, 2ml blood collected into 
SST tubes for sera isolation and a baseline nasal wash was performed. Sera were tested by 
HAI for the presence of any pre-existing antibodies to influenza H3N2 A/Perth/16/2009.  All 
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baseline sera samples had HAI titres of less than 4 to H3N2 A/Perth/16/2009, and it was 
deemed that these ferrets had no previous exposure to H3N2 and so were suitable for 
challenge. 
 
3.4.4 Virus 
 
Ferrets were inoculated intranasally with H3N2 A/Perth/16/2009 P+2A challenge stock virus 
diluted in PBS to provide 1x102 PFU/ferret. The dose was confirmed on day of administration 
by back-titration. Each animal was inoculated with a volume of 0.2ml by the intranasal route. 
 
3.4.5 Sample Collection 
 
Following challenge, weight was recorded daily, and clinical signs recorded twice daily.  Nasal 
washes were collected from 1 to 8 days post infection.  Ferrets were culled from the study two 
at a time (see table 3.4.1) on 2, 3, 4 and 8 days post infection. Ferrets were sedated by 
intramuscular injection of Ketamine/Xylazine (1ml Ketamine plus 0.4ml Xylazine) given at a 
dose of 0.25ml/Kg bodyweight. Following overdose samples were collected from each ferret; 
nasal wash, blood in SST for serum. Key tissues from the respiratory tract were collected to 
assess viral load. Nasal turbinate, trachea and lung were taken and placed into RNALater for 
RNA extraction. Samples of nasal cavity, trachea and lung were fixed in 10% neutral buffered 
formalin for pathology analysis. 
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3.4.6 Results 
 
 Nasal wash cell counts and titres  
 
Nasal wash counts were performed on all nasal washes (Fig. 3.4.6.1.1).  Counts for all animals 
began to increase at around 2 dpi, indicating successful infection.  Counts continued to rise 
for animals that had not been culled until 5 dpi when they plateaued and then began to slowly 
decline at around 7dpi, in line with previous results.  
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Figure 3.4.6.1.1 Nasal Wash Cell Counts Nasal washes were collected at +1 to +8 dpi. All nasal 
washes were counted to ascertain the number of cells being shed from each ferret at each timepoint.   
A rise in nasal wash cells from baseline indicates successful infection.  Plots represent individual counts.  
Single counts were performed on each nasal wash sample from each ferret on each day.  
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All ferrets began to shed detectable virus titres in their nasal washes at 1 dpi (Fig. 3.4.6.1.2).  
Ferrets 26166 and 27207 were culled at 2 dpi. Ferret 18992 was culled at 3 dpi with ferret 
26624.  The peak nasal wash viral titre for ferret 18992 was recorded as 3 dpi. Ferrets 76400 
and 31048 were culled at 4 dpi. Ferrets 33920 and 86770 had a ‘double peak’ in in their nasal 
wash titres, the first peak being at 2 dpi and the second, lower peak being at 6 dpi.   These 
results show the same pattern of shedding as seen in the pilot (Section 3.3), however 
sampling is more frequent in this study. 
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Figure 3.4.6.1.2 Nasal Wash Titres Nasal washes were collected at +1 to +8 dpi.  Nasal washes 
were plaque assayed to ascertain viral titres shed from ferrets at all timepoints. Plaque forming units 
(PFU) per millilitre (ml) of nasal wash represent a direct relationship to the amount of live virus in a 
sample. Plots represent individual assay results.  Single plaque assays were performed on each 
nasal wash sample from each ferret on each day. 
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 Clinical signs of infection in ferrets 
 
It must be noted that the ferrets that were kept alive for the longest (8 dpi) has the higher 
incidences of sneezing and nasal discharge.  The earlier the ferrets were culled, the less 
incidences of sneezing and nasal discharge that occurred.  
 
Table 3.4.6.2.1 Cumulative incidence of nasal discharge and sneezing 
Ferret Incidence 
26166 0 
27027 0 
18992 1 
26624 1 
76400 4 
31048 2 
33920 5 
86670 4 
 
 
 Evidence of seroconversion in ferrets 
 
HAI assays were performed on ferrets culled at 8 dpi; 33920 and 86670.  39920 gave a titre 
of 64 and 86670 had a titre of 32.  These values are above the HAI titre cut of value of 20 
suggesting that these ferrets have seroconverted.  HAI assays were not performed on the 
ferrets culled at 2, 3 and 4 dpi as it was highly unlikely that seroconversion would have 
occurred. 
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 Viral burden detected in ferret tissues  
 
 
Viral RNA (vRNA) was extracted from nasal turbinate, trachea and upper and lower right lung 
lobes to assess viral burden following inoculation with a low dose of A/Perth/16/2009.  Tissues 
had been collected into and stored in RNAlater -20ºC. The H3N2 M gene was used for 
standard curve and H3N2-specific primers were used as described in Chapter 2 Materials & 
Methods. Upper right and lower right lung lobes were analysed separately and averaged.  
 
The highest viral burden was found in the nasal turbinate tissue, where the highest amount of 
vRNA was detected.  This was consistent for all ferrets across all four cull time points when 
compared to the viral burden of other tissues (Fig. 3.4.6.4.1 a, b, c).   The greatest amount of 
RNA was detected at 2 dpi in ferrets 26166 and 27207. The vRNA copies then declined 
progressively from day 2 to 8 in the ferrets.  
 
The viral burden in the trachea was variable across the cull days (Fig. 3.4.6.4.1b).  One ferret 
culled at 2 dpi (27207) had no vRNA detected in trachea samples. Ferret 31048, culled at 4 
dpi, had the highest vRNA detected at 3460 copies per milligram detected. There was a very 
low amount vRNA detected at 8 dpi for ferrets 33920 and 86670.  
 
Ferret 31048 had the highest amount vRNA present in lung samples with 2381 copies per 
milligram detected (Fig. 3.4.6.4.1c).  The remaining ferrets had extremely low vRNA detected 
in the lung samples of below 50  copies per milligram. 
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Figure 3.4.6.4.1.  Viral burden in ferret tissues.  a Nasal turbinates, b trachea and c lung lobes were 
collected into RNALater for each ferret at cull (n=8).  Copies per milligram were calculated by using a 
standard curve as detailed in Chapter 2 Materials and Methods.    c the data points shown above 
were calculated as the arithmetic mean of the upper right and lower right lobes of lung.   
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 Histopathology of nasal cavity, trachea and lung 
 
Samples of nasal cavity, trachea and lung were fixed in 10% neutral buffered formalin and 
sent to the Histology Department at PHE, Porton Down.  Fixed tissues were processed to 
paraffin wax.  Sections, approximately 3-5µm thick, were stained with haematoxylin and eosin 
(HE) for examination.  Haematoxylin stains the nucleus of cells blue, and eosin stains the cell 
cytoplasm pink.  HE stain is a gold standard tissue stain used in histology and provides the 
pathologist with a general overview of the tissue sample’s structure.  Tissues were examined 
by light microscopy and evaluated subjectively by the pathologist at PHE Porton Down. 
 
Following infection, the most pronounced histopathological changes were observed in the 
nasal cavity (Fig. 3.4.6.5.1).  Changes including inflammatory cell infiltration and occasional 
oedema of the propria mucosa; epithelial loss, occasional necrosis and prominent attenuation; 
and suppurative exudation, were detected in the animals.  Minimal changes were seen at two 
days post infection (Fig. 3.4.6.5.1a), with severity increasing at three days post infection (Fig. 
3.4.6.5.1b), with most of moderate changes recorded (Fig. 3.4.6.5.2).  Marked changes were 
found to present at 8 dpi (Fig. 3.4.6.5.1c). 
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Figure 3.4.6.5.1 HE Staining of the Nasal cavity a Nasal cavity from ferret 26166, culled at 2 dpi.  The 
image shows minimal epithelial attenuation (red arrow) and suppurative exudate (commonly referred to 
as pus), black arrow shows normal epithelium. b Nasal cavity from ferret 26624, culled at 3 dpi.  The 
image shows moderate epithelial attenuation (black arrow) and the normal epithelium remains opposite. 
c Nasal cavity from ferret 33920, culled at 8 dpi.  The image shows marked epithelial inflammation, with 
some attenuation (black arrow). Images provided and analysed by the Histology Department, Public 
Health England, Porton Down. 
 
 
a b 
c 
125 
 
2 3 4 8
 
Figure 3.4.6.5.2 Frequency of pathological changes in the nasal cavity Cumulative frequency of 
pathology seen at each time point (n=2 per time point). 
 
Changes seen in the trachea were sporadic, and minimal for all animals and therefore 
considered too few to draw any firm conclusions.  Figure 3.4.6.5.3. shows clear mononuclear 
inflammatory cell infiltrate (in blue) in both a (ferret culled at 2 dpi) and b (ferret culled at 8 
dpi).  The Pathologist interpreting these slides concluded that these images only showed 
minimal mononuclear inflammatory cell infiltrate.  Furthermore, only minimal pathology was 
observed in the lungs of all ferrets (Fig 3.4.6.5.4).This correlates with the low level viral burden 
present in the lung.  
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Figure 3.4.6.5.3 HE Staining of Lung Tissue a Lung tissue from ferret 27207, culled at 2dpi.  The 
image shows minimal, parenchymal, mononuclear inflammatory cell infiltrate. b Lung tissue from ferret 
33920, culled at 8 dpi.  The image shows minimal, parenchymal, mononuclear inflammatory cell infiltrate 
as seen in the sample from 2 dpi. Images provided and analysed by the Histology Department, Public 
Health England, Porton Down. 
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Figure 3.4.6.5.4 Frequency of pathological changes in the lung Cumulative frequency of 
pathology seen at each time point (n=2 per time point). 
 
a b 
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 Influenza-specific interferon gamma responses detected in the spleen 
 
Spleens were collected from all ferrets at cull.  Splenocytes were isolated from each spleen 
and the frequency of influenza-specific IFN-γ secreting cells was quantified by ferret specific 
IFN-γ ELISpot.  Responses were seen in all eight ferrets (Fig. 3.4.6.6.1).  Ferrets culled at 8 
dpi showed the highest influenza-specific IFN-γ responses when compared to the ferrets 
culled at 2, 3 and 4 dpi.  Ferrets culled at 4 dpi had the lowest influenza-specific IFN-γ 
responses.  This increase by 8 dpi could be due to the time it takes for the cellular immune 
response to be triggered. Carrying out in study sampling of circulating peripheral blood and 
assessing the influenza-specific IFN-γ responses would help to gauge if this result is expected.    
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Figure 3.4.6.6.1.  Cellular immune response of ferrets infected with A/Perth/16/2009.  Spleens 
were collected from all animals (n=8).  Results were normalised by subtracting allantoic fluid control 
values from virus stimulated samples. Influenza-specific IFN-γ responses were quantified in the spleen 
samples from all ferrets.  The values measured for each ferret are plotted as spot forming units (SFU) 
per million cells.  Bars show standard deviation and mean for each group.  
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3.4.7 Discussion 
 
This study had a total of eight ferrets inoculated intranasally with a low dose (1x102 PFU/ferret) 
A/Perth16/2009. All ferrets were successfully infected, as shown by virus shedding and sero-
conversion. A serial cull was performed with two ferrets being culled on days two, three, four 
and eight post infection. The results from two animals per day was not enough to give any 
statistical significance to the data when comparing animals across timepoints.  It did however 
allow elucidation of the viral kinetics occurring over the first eight days of infection in the ferret 
model, paired results per day allowed for more robust data. 
  
Seven of eight ferrets had shed peak viral titres at two days post infection. Viral titres for ferret 
18992 peaked at three days post infection.  The kinetics of viral shedding for ferrets 33920 
and 86670 had a distinctive ‘double peak’ of virus shedding that was not identified in the 
previous pilot low dose study. However, this could be due to the limited sampling days used 
in the first study.  Ferret 31048 was the only animal to have vRNA present in lung, this 
correlated with 31048 having the highest amount of vRNA found in the trachea.  Strangely no 
histopathological changes were noted in the lung at four days post infection, the day ferret 
31048 was culled out of the study. The low viral RNA copies detected in the lungs of the ferrets 
(Fig. 3.4.6.4.1c) corresponds with the minimal pathology recorded by the Pathologist (Fig. 
3.4.6.5.3).  This suggests that A/Perth/16/2009 may not travel to the lungs as well as the other 
seasonal circulating IAV, H1N1pdm (Music et al., 2014, Roberts et al., 2012, Carolan et al., 
2014, Roberts et al., 2011).  These observations are consistent with A/Perth/16/2009 having 
a tropism for the upper respiratory tract (Ryan et al., 2018).  
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The high influenza-specific IFN-γ response seen at two days post infection would need to be 
confirmed with a larger number of animals as it is unlikely that a robust T cell response would 
present at two days post infection (Ryan et al., 2018).   However, the higher influenza-specific 
IFN-γ responses seen at eight days post infection was in line with similar studies looking at 
influenza-specific IFN-γ responses to influenza infection in the ferret (Music et al., 2014) and 
to further studies carried out in this body of work. 
 
3.4.8   Further Work 
 
Additional work with more ferrets is required to look at the distinctive ‘double peak’ of virus 
shedding identified in the two ferrets culled at day eight. This will be addressed in the next 
piece of work (Section 3.5).   
 
Further work will need to be carried out on the influenza-specific IFN-γ responses that were 
identified in the spleen during this study. Looking at additional tissues as well as the spleen, 
for example circulating blood, bronchiolar lavage fluid (BAL) or lung, could help to build a 
clearer picture of the cellular immune response to influenza infection in the ferret.   
Development of a method to look at the influenza-specific IFN-γ response of infected ferrets 
without having to cull animals would be advantageous. This would provide an adequate 
number of animals for statistical analysis and enable a longitudinal time course of the cellular 
immune response to influenza infection in the ferret. 
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3.5 Study to Demonstrate the Reproducibility and Reliability of the Low Dose 
Intranasal Inoculation 
 
This low dose inoculation study, 5256 (appendix 1), was designed to develop the intranasal 
delivery ferret model further.  This study was intended to confirm the double peak of virus 
shedding observed in study 5087 (Section 3.4, Fig. 3.4.6.1.2).   
 
3.5.1 In vivo Study Outline  
 
The study was carried out using the same stock of A/Perth/16/2009 used during previous 
studies. To clarify the viral kinetics of the H3N2 A/Perth/16/2009 seen previously in the ferret 
model, six ferrets were infected with a low dose of 1x102 PFU/ferret intranasally (Table 
3.5.2.1).  Ferrets were followed throughout the study until 8 days post infection where they 
were all culled.   This allowed for samples to be collected from all ferrets throughout the study.  
This meant that vRNA and cellular immune responses were not able to be measured during 
this study.   Ferrets were monitored for clinical signs and virus shedding, as well as sero-
conversion as was done previously. 
 
 
3.5.2 Ferrets 
 
Ferrets (Table 3.5.2.1) were obtained from Highgate Farm, UK and were 10+ weeks at the 
time of the study.  A total of 6 ferrets were used.  All ferrets were culled at eight days post 
infection.  Ferrets were group housed in floor pens designed in accordance with the 
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requirements of the United Kingdom Home Office Code of Practice for the Housing and Care 
of Animals Used on Scientific Procedures (1989). 
 
Table 3.5.2.1 Ferret Identification Numbers 
Ferrets  Dose 
57277(m), 80693(f), 87677(f), 93202(m), 
55702(m), 88448(m) 1x10
2 PFU/ferret 
 
 
3.5.3 Prior to Inoculation 
 
 At one day prior to inoculation ferrets were fully sedated by an intramuscular injection of 
Ketamine/Xylazine (1ml Ketamine (100mg/ml) plus 0.4ml Xylazine (20mg/ml) given at a dose 
of 0.25ml/Kg bodyweight). Baseline blood samples were taken from the anterior vena-cava 
vessel of each ferret, 2ml blood collected into SST tubes for sera isolation and a baseline 
nasal wash was performed. Sera were tested by HAI for the presence of any pre-existing 
antibodies to influenza H3N2 A/Perth/16/2009.  All baseline sera samples had HAI titres of 
less than 4 units to H3N2 A/Perth/16/2009, and it was deemed that these ferrets had no 
previous exposure to H3N2 and so were suitable for challenge. 
 
3.5.4 Virus 
 
Ferrets were fully sedated by an intramuscular injection of Ketamine/Xylazine (1ml Ketamine 
(100mg/ml) plus 0.4ml Xylazine (20mg/ml) given at a dose of 0.25ml/Kg bodyweight).  Ferrets 
were inoculated intranasally with H3N2 A/Perth/16/2009 P+2A challenge stock virus diluted in 
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PBS to provide 1x102 PFU/ferret. The dose was confirmed on day of administration by back-
titration. Each animal was inoculated with a volume of 0.2ml by the intranasal route.  
 
3.5.5 Sample Collection 
 
Post inoculation, weight was recorded daily, and clinical signs recorded twice daily.  Nasal 
washes were collected from 1 to 8 dpi.  Ferrets were culled at 8 dpi. Ferrets were sedated by 
intramuscular injection of Ketamine/Xylazine (1ml Ketamine plus 0.4ml Xylazine) given at a 
dose of 0.25ml/Kg bodyweight. Following overdose samples were collected from each ferret; 
nasal wash and blood in SST for serum. 
 
3.5.6 Results 
 
 Nasal wash cell counts and titres  
 
Nasal wash cell counts began to increase (Fig. 3.5.6.1a) between two and three days post 
infection indicating that all six ferrets had successfully been infected.   Counts remained high 
for all ferrets until they were culled at eight days post infection.  The nasal washes were also 
assessed for replicating virus by plaque assay (Fig. 3.5.6.1b).  Virus shedding began in nasal 
washes at one day post infection for all ferrets.  The first peak was recorded at two days post 
infection for ferrets 80693 and 88448, and at three days post infection for ferrets 57277, 87677, 
93202 and 55702. This was followed by a decrease in viral load for all ferrets before a second 
smaller peak at five days post infection for ferrets 80693 and 57277 and at six days post 
infection for 88448, 87677, 93202 and 55702.  All ferrets had stopped shedding detectable 
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virus by eight days post infection.   The peak shedding titre of the ferrets was found to have a 
strong positive correlation and significance (R +1.00, P 0.0028) with the total amount of virus 
shed from each ferret (area under the curve).   
 
Figure 3.5.6.1 Nasal wash collection. Nasal washes were collected at +1 to +8 dpi. (a) All nasal 
washes were counted to ascertain the number of cells being shed from each individual timepoint (n=6). 
(b) Nasal washes were subsequently plaque assayed to ascertain the titre of virus being shed from 
each individual ferret (n =6) at these timepoints.    
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3.5.7 Clinical signs of infection 
 
Weight was monitored daily throughout the study. Weight loss from baseline (Fig 3.5.7.1) was 
seen for four of the ferrets; 57277, 87677, 80693 and 93202.  These four ferrets dropped 
below baseline between one and two days post infection, with their highest percentage loss 
recorded at two days post infection in each case.  Following this all ferrets began to gain 
weight and their weight remained above baseline from four days post infection onwards. 
Ultimately all six ferrets had gained between 8 and 14% of weight from baseline during the 
study. 
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Figure 3.5.7.1 Weight percentage change from baseline. Percentage weight change from day of 
infection for all ferrets (n=6). 
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All ferrets were monitored for sneezing, nasal discharge, inactivity, diarrhoea and loss of 
appetite. The ferrets presented with sneezing and nasal discharge only. The cumulative 
incidences of sneezing and nasal discharge were recorded during the study (Table 3.5.7.1), 
with the number of incidences varying from 1 to 7.  The day of onset also varied widely from 
day 3 to day 7. This shows that while clinical signs are helpful in determining whether a ferret 
may be infected, their severity and day of onset for this virus can vary greatly between ferrets 
and doesn’t appears to correlate with virus shedding or nasal wash cell counts. 
 
Table 3.5.7.1 Cumulative incidence of nasal discharge and sneezing. 
Ferret Incidence  Day of Onset 
57277 6 4 
80693 1 7 
87677 4 5 
93202  5 3 
55702 7 4 
88448 2 5 
 
 
 Evidence of seroconversion 
 
Serum was collected at eight days post infection when the ferrets were culled. All ferrets 
showed seroconversion when they were assayed against A/Perth/16/2009 (HAI titres greater 
than 256). These results confirm, along with the nasal wash titres that all ferrets were 
successfully infected. 
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3.5.8 Discussion 
 
This study was designed to identify the double peak that had been seen during study 5087 in 
the two ferrets culled at eight days post infection.  The double peak was seen in all ferrets in 
this study. The double peak has been seen previously in this body of work (Sections 3.3 and 
3.4) and in other published studies (Frise et al., 2016, Dimmock et al., 2012, Marriott et al., 
2014, Roberts et al., 2012, Gooch et al., 2019).  The double peak could be due to the immune 
response in the ferrets, with a viral peak followed by an initial clearance of the virus from the 
nasal cavity by the innate immune response.  This could be followed by a second wave of 
virus production in the nasal cavity ultimately concluding in total viral clearance. 
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3.6 Low Dose Model to Investigate Cellular Immune Response 
 
 
This final study combines two groups of ferret studies, 5549 and 5719 (appendix 1), utilising 
key techniques identified in earlier studies and expanding on the investigation of the cellular 
immune response seen in the ferret model.   A PBS group was included to compare the cellular 
immune responses seen in infected ferrets with mock ferrets. 
 
3.6.1 In vivo Study Outline  
 
Ferrets were inoculated intranasally with low dose of A/Perth/16/2009.  Small volume 
sequential blood samples were taken through the study to assess the longitudinal influenza-
specific IFN-γ response in the periphery circulating blood.  Whole blood and lung were taken 
at study termination to assess influenza-specific IFN-γ responses in specific tissues. 
 
3.6.2 Ferrets 
 
Female ferrets (Table 3.6.2.1) were obtained from Highgate Farm, UK and were 4-6 months 
at the time of the study.  A total of 12 ferrets were used.  All ferrets were culled at 14 days post 
infection.  Ferrets were group housed in floor pens designed in accordance with the 
requirements of the United Kingdom Home Office Code of Practice for the Housing and Care 
of Animals Used on Scientific Procedures (1989). 
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Table 3.6.2.1 Ferret Identification Numbers 
H3N2 Low Dose (5719) Mock (5549) 
86654, 86811, 86809, 86659, 86812, 86660 55432, 45891, 53132, 49686, 52094, 45627 
 
 
3.6.3 Prior to Inoculation 
 
At seven and three days prior to inoculation ferrets were fully sedated by an intramuscular 
injection of Ketamine/Xylazine (1ml Ketamine (100mg/ml) plus 0.4ml Xylazine (20mg/ml) 
given at a dose of 0.25ml/Kg bodyweight).  At -7 dpi whole blood samples were collected from 
all ferrets. At -3 dpi whole blood samples were collected from all ferrets. These two whole 
blood samples were used to calculated baseline values for the IFN-γ ELISA. Additional 
baseline blood samples were taken at -3 dpi from the anterior vena-cava vessel of each ferret, 
2ml blood collected into SST tubes for sera isolation and a baseline nasal wash was 
performed. Sera were tested by HAI for the presence of any pre-existing antibodies to 
influenza H3N2 A/Perth/16/2009.  All baseline sera samples had titres of less than 4 HAI units 
to H3N2 A/Perth/16/2009, and it was deemed that these ferrets had no previous exposure to 
H3N2 and so were suitable for challenge. 
 
3.6.4 Virus 
 
Ferrets were fully sedated by an intramuscular injection of Ketamine/Xylazine (1ml Ketamine 
(100mg/ml) plus 0.4ml Xylazine (20mg/ml) given at a dose of 0.25ml/Kg bodyweight).  Ferrets 
were inoculated intranasally with H3N2 A/Perth/16/2009 P+2A challenge stock virus diluted in 
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PBS to provide 100 PFU/ferret. The dose was confirmed on day of administration by back-
titration. Each animal was inoculated with a volume of 0.2ml by the intranasal route.  Mock 
ferrets were intranasally inoculated with 0.2ml of PBS. 
 
3.6.5 Sample Collection 
 
Post inoculation, weight was recorded daily, and clinical signs recorded twice daily.  
Temperatures were not recorded.  Nasal washes were collected from 1 to 8 days post 
infection.  Whole blood samples were collected from all ferrets at 2, 5, 8 11 and 14 days post 
infection. Ferrets were sedated by intramuscular injection of Ketamine/Xylazine (1ml Ketamine 
plus 0.4ml Xylazine) given at a dose of 0.25ml/Kg bodyweight. Following overdose, samples 
were collected from each ferret; nasal wash, blood in SST for serum and blood into heparin 
tubes for PBMCs.  Lungs were collected into RPMI 1640 media. 
 
3.6.6 Results 
 
 Nasal wash cell counts and titres 
 
Nasal wash counts were performed on all nasal washes (Fig 3.6.6.1.1).  Counts for ferrets 
infected with A/Perth16/2009 began to increase between two to three days post infection 
indicating successful infection. Nasal washes from ferrets inoculated with PBS remained at a 
baseline level throughout the study.  
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Figure 3.6.6.1.1 Nasal wash cell counts.  Nasal washes were collected at +1 to +8 dpi. All nasal 
washes were counted to ascertain the number of cells being shed from each individual ferret at each 
time point (n=12). The area under the curve (AUC) was calculated for both the H3N2 (n=6) and mock 
group (n=6). The area under the curve represents the total amount of virus shed by the ferrets over the 
timecourse. A Mann-Whitney test was performed and a statistical difference (P=0.022) was found 
between ferrets intranasally inoculatedwith A/Perth/16/2009 (H3N2 group) and PBS (mock group). 
 
As carried out previously, the nasal washes were tested for the presence of replicating virus 
by plaque assay (Fig 3.6.6.1.2).  4 out of 6 ferrets inoculated with H3N2 began to shed 
detectable virus at 1 dpi.  The remaining two ferrets, 86654 and 86660, began to shed 
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detectable virus at 2 dpi.  Viral shedding peaked at 3 dpi, this was followed by a decrease in 
virus load and a subsequent smaller, second peak that has been seen previously.  The smaller 
second peak was not found to be statistically significant but this has been noted by others 
previously (Roberts et al., 2012, Gooch et al., 2019, Marriott et al., 2014, Dimmock et al., 
2012).  As seen previously the smaller second peak cannot be identified in the nasal wash cell 
count.  Again, as seen previously the peak shedding titre was found to have a strong positive 
correlation (Spearman) and significance (R +0.9429, P 0.0167) with the total virus shed.  
Plaque assays for the mock group were carried out. As anticipated no virus was being shed 
from these animals and therefore the data was not included in Figure 3.6.6.1.2. 
 
Figure 3.6.6.1.2 Nasal wash titres.  Nasal washes were subsequently plaque assayed to ascertain 
the amount of virus being shed from each individual ferret at all time points collected.    
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 Clinical signs of nasal infection 
 
Disease progression was monitored up to 14 days post infection (Table 3.6.6.2.1).  The 
mock group showed no clinical signs of infection.   
 
Table 3.6.6.2.1 Cumulative incidence of nasal discharge,sneezing and inactivity 
Group Total Nasal Discharge Total Sneezing Inactivity 
H3N2 
 
0 24 0 
Naïve  
 
0 0 0 
 
 
 Evidence of seroconversion in ferrets 
 
HAI assays were performed on the terminal bleeds of all ferrets.  All ferrets inoculated with 
virus gave titres of ≥512 confirming all ferrets were successfully infected and had 
seroconverted.  Ferrets in the mock group inoculated with PBS had titres <4, confirming they 
were not infected.  
 
 Longitudinal time course of influenza-specific IFN-γ responses in the periphery 
 
Small volumes of heparinised whole blood were collected at the days shown in Figure 
3.6.6.1.1 to assess the influenza-specific IFN-γ responses in peripheral blood.   This was 
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carried out as described in Materials and Methods (Section 2.4.10) using homologous virus.   
Samples from each ferret were assessed by ELISA and a longitudinal time course was 
created.  Two samples were collected seven and one day’s pre-infection. This was to 
demonstrate that there were low influenza-specific IFN-γ responses in the ferrets prior to 
infection.  If the influenza-specific IFN-γ responses were found to be high the ferrets may have 
been exposed to influenza previously.  All ferrets were found to have responses below 270 
pg/ml of IFN-γ in pre-infection samples.  These responses were averaged and represent the 
0 time point.  Following infection with A/Perth/16/2009 low level influenza-specific IFN-γ 
responses were detected in ferrets from five days post infection and increased at eight to 11 
days post infection, peaking between 11 and 14 days post infection.  At 14 days post infection 
some of the responses peak while other begin to decrease, this variation could be due to the 
outbred nature of ferrets.   Ferrets in the mock group inoculated with PBS had responses 
below 270 pg/ml over the 14 days. 
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Figure 3.6.6.4.1 Quantification of influenza-specific IFN-γ production by ELISA Diluted whole 
blood samples were collected from all ferrets at -7, -1, 2, 5, 8, 11, and 14 days post infection, stimulated 
with appropriate antigens (whole virus) and the supernatants harvested. Supernatants were used in the 
Ferret IFN-γ ELISA Development Kit (ALP).  Influenza-specific IFN-γ responses became detectable at 
5 days post infection with a peak at 11-14 days post infection for all virus infected animals.  No 
responses were detected in the mock group.  
 
 Cellular immune responses measured by ferret specific IFN-γ enzyme linked 
immunospot assay (ELISpot)  
 
Animals were culled at 14 days post infection, lymphocytes isolated from whole lung (lung 
MNCs, Section 2.4.5) and whole blood (PBMCs, Section 2.4.2) and the frequency of the IFN-
γ secreting cells were quantified by ferret-specific IFN-γ ELISpot (Fig. 3.6.6.5.1).  Virus 
infected ferrets showed a significant (P 0.0022) increase in the number of influenza-specific 
IFN-γ secreting PBMCs when compared to mock infected ferrets at 14 days post infection 
(Fig. 3.6.6.5.1a).   A very low influenza-specific IFN-γ response was detected in the PBMCs 
of one of the mock ferrets, none of the remaining PBMCs of the mock ferrets had any 
detectable influenza-specific IFN-γ responses. No influenza-specific IFN-γ responses were 
seen in the lung MNCs of mock ferrets or the majority of those infected with virus.  Only one 
ferret, 86659, had a recorded influenza-specific IFN-γ response in lung MNCs. This suggests 
that the virus did not travel to the lungs of all the ferrets.  This is in line with previous 
observations seen in the serial cull study (Section 3.4) where there was a low amount of viral 
RNA found in the lung suggesting that A/Perth/16/2009 is not lung trophic in the ferret model.  
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Figure 3.6.6.5.1 Cellular immune responses in ferrets infected with A/Perth/16/2009 PBMCs (a) 
and Lung MNCs (b) were collected from all animals (n=12) at 14 dpi.  Results were normalised by 
subtracting the individual sample allantoic fluid control values from virus stimulated sample values 
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3.6.7 Discussion  
 
This study demonstrates it is possible to successfully evaluate cellular immune responses to 
seasonal influenza infection over a time-course in the ferret.   By sequentially taking low 
volumes of heparinised blood samples from individual animals and detecting influenza-specific 
IFN-γ as measured by ELISA, a pictureof what occurs in the periphery throughout infection 
was formed. Furthermore, when the animals were sacrificed, influenza-specific IFN-γ 
secreting cells in tissues of interest were quantified. Using these complementary techniques, 
it has been demonstrated that the response to a low dose H3N2 infection in the lung is minimal, 
and which complements data that was gathered earlier in the chapter with regards to lung 
pathology and vRNA present in the lower respiratory tract.  These results help to enhance the 
applicability of the ferret model to study acquired immunity and vaccination strategies to 
influenza.  
 
Ferret 86659 was found to have high influenza-specific IFN-γ response in lung MNCs and in 
peripheral circulating blood.  Although ferrets are outbred and therefore some variation would 
be expected, these results were particularly unusual when compared to the other five ferrets 
infected with low dose H3N2.  
 
3.7 Conclusions  
 
 
These combined studies have shown that a reproducible and reliable low dose intranasal 
model for H3N2 A/Perth/16/2009 has been successfully set up.   
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 The high and low dose intranasal inoculations were evaluated and compared in Section 
3.3.  This study highlighted the differences in pathogenesis between the doses, as well as 
confirming that ferrets could be successfully infected with a low dose of H3N2 
A/Perth/16/2009. 
 Viral kinetics and pathogenesis seen in ferrets inoculated intranasally with low dose H3N2 
A/Perth/16/2009 has been shown to be reproducible across studies conducted at different 
timepoints.  All ferrets were successfully infected.  
 The cellular immune response to a low dose intranasal infection was investigated in 
Section 3.6.  An understanding of the longitudinal influenza-specific IFN-γ response in the 
periphery was established.  In addition, the influenza-specific IFN-γ responses in two key 
samples, circulating blood and the lungs, were established. 
 
This low dose intranasal model can now be used to compare to the nose-only aerosol model 
and droplet transmission cage models which are discussed in the next two chapters.  
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4 Nose-only Aerosol Infection Model 
 
4.1 Introduction  
 
The intranasal droplet route is the most frequently used route of experimental infection when 
delivering influenza virus to the ferret model.  As previously demonstrated, this allows for a 
controlled titre of virus to be delivered to the nasal cavity of the animal, ensuring successful 
infection even at lower titres of virus.   It can be argued that this method of infection does not 
accurately reflect a “natural” influenza virus infection in humans; therefore, it is necessary to 
explore alternative models of infection.    Transmission of influenza between individuals occurs 
via contact (fomite/direct) and non-contact (droplet) routes:  
 
i. Contact transmission; fomites  
ii. Large droplet transmission; particles ≥5µm 
iii. Droplet nuclei transmission; particles <5µm (Gustin et al., 2011)  
 
The individual contribution of these modes of transmission to the spread of influenza in the 
population is dynamic and still not well understood, and although infection via the aerosol route 
has been shown to cause influenza virus infection in both humans and ferrets, the relative 
importance of contact and airborne transmission remains unknown in both (Bouvier, 2015). 
Studies of influenza infected patients found low viral titres in the aerosol generated by 
sneezing, coughing and breathing (Milton et al., 2013). Similar results have been recorded in 
ferrets, where animals have been successfully infected with less than 10 PFU (Gustin et al., 
2015). Following visits to live bird markets it was shown that even though no direct contact 
was made with poultry, cases of human H7N9 infection have been recorded.  Suggesting that 
inhalation of aerosols containing the virus was the primary mode of infection in these cases 
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(Li et al., 2014, Liu et al., 2014).  Additionally, detection of H7N9 in the air sampled from live 
poultry markets (Zhou et al., 2016) suggests that there is a possibility that zoonotic infection 
can also occur with a low level of aerosolised virus (Creager et al., 2017).  Past studies that 
have used human volunteers have shown a role for aerosols in influenza virus transmission 
(Milton et al., 2013, Lindsley et al., 2010). 
 
Airborne transmission of influenza can be considered as two types.  Droplet spray 
transmission is when an infected individual coughs or sneezes, expelling respiratory droplets 
that contain contagious viral particles, impacting directly upon the nasal mucosa of a 
susceptible person. Aerosol (droplet nuclei) transmission occurs when an infected individual 
exhales virus laden respiratory droplets, coughs and sneezes (Tellier, 2006a).  Aerosols are 
suspensions in air (or a gas) of liquid or solid particles minute enough that they remain airborne 
for a period of time due to their low settling velocity (Tellier, 2009), and influenza laden 
respiratory droplets have been found to remain suspended in air for several hours. Particles 
of between 5µm and 10µm are able to reach the trachea and particles of ≤5µm have the 
capability to infiltrate the respiratory tract all the way down to the alveolar region (Tellier, 
2006b) causing infection.   
 
In the past, aerosol infection of ferrets has been achieved in two ways; exposure to infected 
donors (Herfst et al., 2012, van der Vries et al., 2011) and exposure to a nose-only aerosol 
system (Tuttle et al., 2010a, Lednicky et al., 2010, Gustin et al., 2011) which allows for a 
calculated and precise dose of virus inoculum to be delivered.   It has previously been reported 
that ferrets exposed to aerosolised H3N2 (A/Panama/2007/99)  were infected with 
approximately 1 TCID50 (Gustin et al., 2011).   The generation of small particle aerosols with 
specialised equipment allows the virus to reach the lungs of the animals, whereas intranasal 
infection, depending on the volume of the dose (Belser et al., 2016) might not enable the virus 
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to successfully reach the lower respiratory tract.  The following in vitro and in vivo studies 
provided the opportunity to examine the impact of delivery H3N2 A/Perth/16/2009 to the lungs 
of ferrets. 
 
4.2 Aims of the Studies  
 
A small number of studies have been published looking at the mechanical aerosolisation of 
influenza into ferrets (MacInnes et al., 2011, Lednicky et al., 2010, Turgeon et al., 2019, Gustin 
et al., 2013, Gustin et al., 2011).  Thus far no studies have examined and explored the effect 
of an aerosol H3N2 subtype of IAV infection upon the cellular immune response of the ferret.    
This study hopes to:  
 
 establish an effective and robust low dose method of nose-only aerosol 
challenge in ferrets   
 evaluate the viral kinetics and the cellular immune responses of ferrets infected 
via the aerosol route  
 successfully deliver H3N2 A/Perth/16/2009 to the lungs of the ferret  
 compare and contrast these results to animals infected via the intranasal route 
as well as a naïve group 
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4.3 In vitro Studies 
 
 
The nose-only aerosol model was utilised to provide a more accurate experimental 
representation of natural influenza infection than intranasal inoculation; that could be 
controlled within defined working constraints, such as exposure time, humidity and presented 
dose.  The nose-only aerosol model acts as a particle delivery system which can deliver 
droplet nuclei particles to the upper and lower respiratory tract of ferrets.  Prior to animal work 
taking place, an in vitro study was carried out to ensure a reproducible spray factor and 
presented dose could be achieved, identifying the lowest dose that can reliably infect all 
animals.  The spray factor is calculated by dividing the viable aerosol concentration by the 
inoculum concentration; this is important to help determine the presented dose given to each 
animal.  
 
The following factors are considered important when considering exposure dose: 
 Respiratory function of the ferret at time of exposure 
 Aerosol concentration in the test atmosphere 
 Duration of exposure  
 Deposition and retention of aerosol once inhaled 
 
Inhalation exposures involving biologically active materials, such as influenza virus, pose  
several specialised considerations on top of this (Hartings and Roy, 2004).   
 
Known concentrations of A/Perth16/2009 P+2A were aerosolised using a mobile form of the 
Henderson apparatus (Fig. 4.3.1) in conjunction with Biaera Technologies Aerosol 
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Management Platform (Hartings and Roy, 2004).  This was carried out to assess the in vitro 
characteristics of A/Perth/16/2009 prior to use in the in vivo challenge studies.  Aerosol 
generation and sampling was performed in a flexible film isolator to provide primary 
containment against operator exposure to the aerosolised virus inoculum.    
 
 
Figure 4.3.1 Mock ferret aerosol exposure system set up Small particle aerosols, which are 
predominantly <2µm Mass Median Aerodynamic Diameter (MMAD), were produced using a Collison 
six-jet nebulizer (8) (May, 1973) operating at 15L/min for 10 minutes.  The MMAD defines the size at 
which 50% of the particles by mass are larger and 50% of the particles are smaller.  The concentration 
of A/Perth/16/2009 in the aerosol was determined by collecting samples directly from the exposure 
system (4) (post sow) using a glass impinger (2) (AGI30 AceGlass Inc.) operating at 6 L/min for 10 
minutes and containing 20ml DMEM.  MMAD was measured using an aerodynamic particle sizer (3) 
(TSI Instruments). The aerosol stream was conditioned and maintained at room temperature and a 
relative humidity of 65 ± 5%.  
 
Virus was provided in three 20ml nebuliser aliquots at a titre of 1.1x106 pfu/ml diluted in 
Dulbecco’s Modified Eagle Medium (DMEM). This titre was confirmed by back titration.  Each 
aliquot corresponded to the spray runs as follows:  
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Nebuliser 1 = Spray 1, 2 & 3 
Nebuliser 2 = Spray 4, 5 & 6 
Nebuliser 3 = Spray 7, 8, 9 & 10 
 
Following aerosolisation the remaining liquid from each nebuliser sample was collected and 
plaque assayed for live viral titre.  The live viral titres of the nebuliser samples are shown in 
Table 4.3.1.  The remainder of each sample was frozen for further analysis if required.  There 
appears to be have been roughly five-fold knock down from the amount of virus put into the 
nebuliser compared to the amount of virus recovered from the nebuliser.  This could be due 
to the violent nature in which the aerosol is generated.  Compressed air is passed through a 
six-jet nebuliser to aerosolise the virus in DMEM.  Influenza is an enveloped virus and is 
relatively vulnerable to damaging environmental impacts (Arbeitskreis Blut, 2009). Therefore 
this process could conceivably damage the envelope of the virus, preventing its ability to enter 
host cells.   
 
During aerosolisation each spray run was collected into 20ml of DMEM in the impinger. 
Samples from the impingers of the ten aerosol runs were then immediately plaque assayed 
for live viral titre, the results are shown in Table 4.3.1.  Impinger samples were plaque assayed 
immediately to prevent loss of virus titre from the process of freeze thawing. The remainder of 
each sample was frozen for further analysis if required. A target flow rate of 6 lites per minute 
was set, however, as is shown in Table 4.3.1 the flow rate can vary during the spray.  
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Table 4.3.1 Viral titres in spray samples 
Nebuliser 1 2 3 
Cneb 
(pfu/ml) 
1.23E+05 2.25E+05 2.75E+05 
Spray 1 2 3 4 5 6 7 8 9 10 
Impinger 
Titre 
(pfu/ml) 
2.50E+03 3.25E+03 2.25E+03 3.75E+03 5.25E+03 3.25E+03 3.25E+03 1.33E+03 3.75E+03 4.00E+03 
Sample 
Volume 
(ml) 
20 20 20 20 20 20 20 20 20 20 
Sample 
Flow 
(L/min) 
5.9 5.9 5.7 5.5 5.8 4.8 5.2 5 4.9 4.9 
Caero 
(pfu/ml) 
8.5E-01 
 
1.1E+00 
 
7.9E-01 
 
1.4E+00 
 
1.8E+00 
 
1.4E+00 
 
1.3E+00 
 
5.3E-01 
 
1.5E+00 
 
1.6E+00 
 
Spray 
Factor 
6.9E-06 
 
8.9E-06 
 
6.4E-06 
 
6.2E-06 
 
8.0E-06 
 
6.2E-06 
 
4.7E-06 
 
1.9E-06 
 
5.5E-06 
 
5.8E-06 
 
Mean 
Caero 
1.2E+00 
 
Mean 
Spray 
Factor 
 
 
6.1E-06 
 
 
As well as the live viral titres from the impinger, Table 4.3.1 lists the aerosol concentration 
(Caero) and spray factors of each ‘spray run’. A mean spray factor of 6.1x10-6 was calculated..   
The spray factor is a measurement of of the efficiency of aerosolising the virus from the starting 
solution.  A figure of 10-5 to 10-6 is normally expected. The presented dose represents the 
potential amount of virus inhaled by the ferret, therefore giving an approximate titre of virus 
with which the ferrets are exposed to.  
 
Presented Dose = (1.2)*(3730) = 4476 PFU 
 
This in vitro spray illustrates that A/Perth/16/2009 was  able to be aerosolised through the 
Henderson apparatus successfully. Recovery of live virus from the impingers indicates that 
when ferrets are introduced into the system they will be successfully inoculated with a reliable 
dose of virus.  
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4.4 In vivo Study Outline 
 
The results discussed here are from study 5530, where an aerosol infected group was 
compared alongside high dose and low dose intranasal infected groups and a mock (intranasal 
PBS) group.    In vivo work was carried out on 12 female ferrets aged 4-6 months from 
Highgate Farm.   
 
 
 
Figure 4.4.2 Study timeline Whole blood for IFNγ ELISA andimmune phenotypingwas taken at -7, -1, 
+2, +5, +8, +11 and +14 dpi. Baseline bleeds for serum were taken from all ferrets at -3 dpi. At 0 dpi 
donor ferrets were sedated and challenged via intranasal (I.N) (4.4.4) or aerosol (4.4.3) and placed into 
group floor pens. Nasal washes were collected in PBS from +1 dpi to +8 dpi. At cull (+14 dpi) lung, 
156 
 
spleen, bronchiolar lavage (BAL) and whole blood (PBMCs) were taken for the evaluation of the cellular 
immune response. Blood for serum was also taken to evaluate the humoral immune response. 
 
4.4.1 Ferrets 
 
Female ferrets (Table 4.4.1.1) were obtained from Highgate Farm, UK and were 4-6 months 
at the time of the study.  A total of 12 ferrets were used.  All ferrets were culled at 14 dpi.  
Ferrets were group housed in floor pens designed in accordance with the requirements of the 
United Kingdom Home Office Code of Practice for the Housing and Care of Animals Used on 
Scientific Procedures (1989). 
 
Table 4.4.1.1 Ferret Identification Numbers 
Aerosol Low Dose  High Dose Mock 
40761, 47791, 
49800 
53177, 51352, 
46171 
50706, 46313, 
46392 
46476, 48186, 
41787 
 
4.4.2 Prior to Challenge  
 
At seven and one days prior to inoculation ferrets were fully sedated by an intramuscular 
injection of Ketamine/Xylazine (1ml Ketamine (100mg/ml) plus 0.4ml Xylazine (20mg/ml) 
given at a dose of 0.25ml/Kg bodyweight).  Baseline whole blood samples were taken from 
the anterior vena-cava vessel of each ferret into heparin microtainers using syringes pre-
treated with heparin.  These whole blood samples were used to ascertain baseline data for 
whole blood immune phenotyping and IFN-γ ELISA.  At three days prior to challenge ferrets 
were anaesthetised as previously described. The baseline blood samples were taken from the 
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anterior vena-cava vessel of each ferret, 500 µl blood collected into SST tubes for sera 
preparation and a baseline nasal wash was performed. Sera were tested by HAI for the 
presence of any pre-existing antibodies to influenza H3N2 A/Perth/16/2009. All baseline sera 
samples had HAI titres of less than 4 to H3N2 A/Perth/16/2009, and it was deemed that these 
ferrets had no previous exposure to H3N2 and so were suitable for challenge. 
 
4.4.3 Nose-only aerosol infection of ferrets 
 
 
On the day of challenge ferrets were fully sedated by an intramuscular injection of 
Ketamine/Xylazine (1ml Ketamine (100mg/ml) plus 0.4ml Xylazine (20mg/ml) given at a dose 
of 0.25ml/Kg bodyweight). Ferrets received a presented aerosol dose of H3N2 
A/Perth/16/2009 (approximately 3x102 PFU/ferret) using the Collison nebuliser and Henderson 
apparatus.  The stock A/Perth/16/2009 P+2A was provided at a concentration of 1.1x107 
pfu/ml diluted to a concentration of 3x104 pfu/ml in serum free DMEM + GlutaMAX™. 10ml of 
challenge material was aerosolised over a five-minute exposure time.  A reduced exposure 
time of five minutes was implemented for ethical reasons due to the introduction of live animals 
into the system.  Ferrets were removed and placed back into their housing. Ferrets were group 
housed in floor pens designed in accordance with the requirements of the United Kingdom 
Home Office Code of Practice for the Housing and Care of Animals Used on Scientific 
Procedures (1989).  
 
4.4.4 Intranasal infection of ferrets 
 
Ferrets were fully sedated by an intramuscular injection of Ketamine/Xylazine (1ml Ketamine 
(100mg/ml) plus 0.4ml Xylazine (20mg/ml) given at a dose of 0.25ml/Kg bodyweight).  Ferrets 
158 
 
were inoculated intranasally with H3N2 A/Perth/16/2009 P+2A challenge stock virus diluted in 
PBS to provide 1x102 PFU/ferret for the low dose group and 1x106 PFU/ferret for the high dose 
group. The mock group was also sedated as above and were given sterile PBS. The dose 
was confirmed on day of administration by back-titration. Each animal was inoculated with a 
volume of 0.2ml by the intranasal route.  
 
4.4.5 Sample collection 
 
Following challenge, weight was recorded daily, and clinical signs recorded twice daily.  From 
one to eight days post challenge nasal washes were collected from animals. At days two, five, 
eight and eleven whole blood samples were taken from the anterior vena-cava vessel of each 
ferret into heparin microtainers using syringes pre-treated with heparin. At day 14 ferrets were 
culled. Ferrets were sedated by intramuscular injection of Ketamine/Xylazine (1ml Ketamine 
plus 0.4ml Xylazine) given at a dose of 0.25ml/Kg bodyweight. Prior to overdose, 500 µl of 
whole blood was taken from the anterior vena-cava vessel of each ferret into heparin 
microtainers using syringes pre-treated with heparin. Following overdose, the following 
samples were collected from each ferret; nasal wash, blood in SST for serum, remaining whole 
blood in heparin for PBMC isolation, spleen, BAL and whole lung. Immune cells were 
immediately isolated from whole blood, spleen, BAL and whole lung. 
 
4.4.6 Results 
 
 Back titration of aerosol spray  
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Virus diluent was prepared on the day of the spray; a stock volume of virus was prepared at a 
titre of 3x104 PFU/ml which should have given an approximate presented dose of around 
3x102 PFU to each ferret.  Following preparation, the stock was plaque assayed on the same 
day and the titre was recorded as 1.74x104 PFU/ml.  Therefore, it was anticipated, based on 
previous calculations, that there would be an presented dose of around 200 PFU.  However, 
the impinger titre was 2.5 PFU/ml, which equates to a presented dose of 0.8 PFU, 250-fold 
lower than expected. 
 
4.4.7 Nasal wash cell counts and titres in ferrets following infection 
 
Nasal wash cell counts for animals in the high and low dose intranasal and aerosol groups 
increased during the study indicating that all animals had become infected (Fig. 4.4.7.1a).  
The nasal wash cell counts for the mock group remained at baseline levels, as expected.   As 
seen in a previous study (Section 3.3) the high dose intranasally infected animals had raised 
nasal cell wash counts and began to shed virus prior to the low dose intranasally infected 
group.  The nasal wash cell counts for both the aerosol and low dose groups began to increase 
after 2 dpi rising above the mock group baseline. The nasal wash cell counts (Fig. 4.4.7.1a) 
for the low dose group began to decline at 8 dpi and appeared to plateau just above baseline 
until 14 dpi. The nasal wash cell counts for the aerosol group remained above baseline until 
14 dpi. All ferrets in the low dose group became infected at the same time and this is apparent 
in the nasal wash cell counts and the amount of virus shed of the course of the study.  The 
low dose results are in line with what has previously been seen in this work and in other 
published low dose work (Marriott et al., 2014, Ryan et al., 2018, Gooch et al., 2019). 
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In comparison the aerosol group had an extended high nasal wash cell counts, coupled with 
a variable amount of virus shed from each ferret within the group. Nasal cell shedding for the 
aerosol group was anticipated to be in line with the low dose intranasal group, however, as 
the results were collected it became apparent that two of the animals, 49800 and 40761, were 
not following the predicted viral kinetics.  Animal 47791 nasal wash counts began to increase 
at 3 dpi with a definite peak seen at 4 dpi. A delay in the increase of cells in 49800 and 40761 
in the nasal wash was seen, with counts only increasing at 5 dpi for animal 49800 and at 6 dpi 
for animal 40761.  
 
All infected ferrets began to shed detectable virus titres in their nasal wash (Fig. 4.4.7.1a).  
Ferrets inoculated intranasally with a high dose began shedding at one day post infection, 
where they peaked, with a lower, second peak titre at 5 dpi.   Viral titres were no longer 
detected beyond 6 dpi in the high dose group.  Peak viral titres were seen in the low dose 
group at 3 dpi.     A delay in virus shedding was seen in the aerosol group when compared to 
the two intranasal groups. It was expected that the aerosol group ferrets would begin to shed 
virus at roughly the same time point as ferrets infected intranasally with a low dose of virus. 
Ferret 47791 began to shed detectable virus at two days post infection, in line with this theory, 
however ferrets 49800 and 40761 began to shed virus at five and six days post infection 
respectively.    
 
Unfortunately, it’s difficult to compare the aerosol group directly with the low dose group as 
only ferret 47791 is thought to have been truly infected via the aerosol route. The remaining 
two ferrets in the aerosol group, 49800 and 40761, most likely became infected by either 
contact or non—contact transmission from ferret 47791 when it began to shed live virus at 2 
dpi.   Ferret 47791 had a peak in shedding at 4 dpi while in comparison the low dose ferret 
peaked at 2 dpi (51352) or 3 dpi (53177, 46171).    All the low dose ferrets experienced a 
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‘second peak’ in nasal wash titre, at 7 dpi (51352) or 6 dpi (53177, 46171), which has been 
identified in low dose infected ferrets previously.   Ferret 47791 also appeared to have a 
second peak at 8 dpi, however as no nasal washes were taken beyond this point until sacrifice 
at day 14 this cannot be proven.  Generally, it appears as through viral kinetics observed in 
an aerosol infected animal are like those in a low dose (1x102 PFU) infected ferret, however 
there is a time delay from the day of infection, possibly due to the lower presented dose of 3.2 
PFU. Ferrets 49800 and 40761 both had delayed viral kinetics compared to the low dose 
group, however it is difficult to compare the two directly as the route and time point at which 
these two ferrets became infected is impossible to clarify.    
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Figure 4.4.7.1 Nasal wash collection. Nasal washes were collected at +1 to +8, +11 and +14 dpi. (a) 
All nasal washes were counted to ascertain the number of cells being shed from each individual ferret 
at each time point (n=12).  (b) All nasal washes were subsequently plaque assayed to ascertain the 
titre of virus being shed from each ferret (n=12). 
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4.4.8 Clinical signs of infection found in ferrets  
 
Weight loss was observed in all groups infected with H3N2, in comparison mock infected 
ferrets gained weight (Fig 4.4.8.1).  Of all the infected ferrets the low dose group experienced 
the greatest mean percentage weight loss and remained below the baseline of percentage 
change for most of the study.       
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Figure 4.4.8.1 Weight percentage change from baseline. Mean percentage weight change of ferrets 
infected with H3N2 at high (n=3) and low (n=3) dose intranasally, by nose-only aerosol (n=3) and PBS 
(n=3).   
 
The high dose group also experienced percentage weight loss below baseline, however the 
ferrets appeared to gain weight from 9 dpi onward.  The aerosol group initially appeared to 
gain weight.  At 7 dpi the percentage weight change dropped below 0 and the ferrets appeared 
to start to lose weight.  This delayed weight loss correlated with the delayed viral shedding 
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seen in the aerosol group.   The mock group of ferrets gained weight over the course of the 
study.  This is expected in ferrets that didn’t receive virus.  
 
Table 4.4.8.1 Clinical sign observations. 
Group N Total Sneezing Total Nasal Discharge Total Inactivity Mean Score per ferret 
Low 3 10 3 0 4.3 
High 3 15 8 0 7.7 
Aero 3 10 3 0 4.3 
Mock 3 0 0 0 0 
Total instances of clinical observations. N, number of ferrets per group. 
 
Table 4.4.8.1 shows the cumulative incidence of nasal discharge, sneezing and total inactivity 
recorded over the course of the study for each ferret in all the groups.  These results are in 
line with what was seen in the previous high and low dose intranasal comparison (Section 
3.3). All ferrets infected with virus experienced either sneezing or nasal discharge over the 
course of the study. Animals in the high dose group experienced the highest incidence of nasal 
discharge and sneezing of all the groups with a mean ferret score of 7.7.   Ferrets in the low 
dose and aerosol group had the same mean ferret score of 4.3, with the same incidence of 
sneezing and nasal discharge recorded across ferrets, with increased sneezing and nasal 
discharge seen over 2 dpi to 6 dpi.  No clinical signs were recorded in the mock group.  
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4.4.9 Whole blood immunophenotyping  
 
 
Peripheral circulating whole blood was labelled to determine the number and percentage of T 
cells and T cell subsets in the blood of ferrets and analysed by using two colour flow cytometry.  
Sampling for whole blood immunophenotyping (Section 2.4.12)was carried out post infection 
on days 2, 5, 8, 11 and 14.  Whole blood samples were also taken at -7 and -1 before 
inoculation to form baseline data.  Data was analysed as detailed in the materials and 
methods.  
 
The granulocyte population (Fig. 4.4.9.1) of ferrets in the high dose group showed a general 
increase for two out of three above baselines in cell numbers over the time course.    The 
granulocyte population for the low dose and mock groups appeared to fluctuate around 
baseline for the duration of the study.  Granulocyte cell numbers for ferrets 47791 and 49800 
in the aerosol group peak at 5 dpi, while ferret 40761 remained below 50% change from 
baseline, in line with the low dose and mock group results.   This is consistent with viral 
shedding results for ferret 40761 which began to shed virus at 6 dpi and therefore was most 
probably infected last out of the three animals.     A decline of cell numbers to baseline for 
ferrets 47791 and 49800 was seen at 8 dpi. 
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Figure 4.4.9.1 Percentage change from baseline in granulocyte population Percentage change 
from baseline was calculated using raw granulocyte cell data. Raw cell data was calculated using the 
following calculation; (A/B) x (C/D) = concentration of samples as cells/µl. Where A = number of cell 
events, B = number of bead events, C = Assigned bead count of the lot (beads/50 µl) and D = volume 
of sample (µl). 
 
The high dose group (Fig. 4.4.9.2) group showed a steep decline in the lymphocyte population 
(above 50%) at 2 dpi for all ferrets.  This percentage change slowly decreases across the 
remaining sample days until the population returned to baseline levels at 14 dpi. One ferret, 
50706 showed a further decrease percentage change from baseline at 14 dpi.  The low dose 
group had a decline in lymphocyte population following infection, with peak decline at 5 dpi 
followed by a recovery in numbers.  This most likely occur due to cells being sequestered 
away from the peripheral blood to the site of infection.     This early dip is known a lymphopenia, 
and has been described in influenza-infected patients (Criswell et al., 1979).  A decrease in 
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both T and B cells during experimental inoculation of humans has also been recorded (Dolin 
et al., 1977).  The aerosol group declined from baseline for all three ferrets occurring at 5 dpi, 
with a peak decline at 8 dpi.  Cell numbers appeared to rebound returning to pre-challenge 
levels or above pre-challenge levels by 11 dpi. These responses are similar, although slightly 
later, to those observed for the high and low dose group.  Ferret 47791 appears to act 
differently to rest of the aerosol group with a higher percentage change from baseline at 11 
and 14 dpi.  Ferret 47791 is the individual from the aerosol group that most likely became 
successfully infected from the aerosol inoculation. It should be noted that two of the three 
animals in the mock group also have a decline from baseline at 8 dpi.  
 
 
Figure 4.4.9.2 Percentage change from baseline in lymphocyte population Percentage change 
from baseline was calculated using raw lymphocyte cell data. Raw cell data was calculated as described 
above in Fig. 4.4.9.1. 
168 
 
Results seen in the CD4+ T cell population (Fig. 4.4.9.3) were comparable to those seen in 
the lymphocyte population (Fig. 4.4.9.2) with a decline in cell numbers observed at two days 
post-challenge in the high dose group.  The decline in cell numbers occurred later in the low 
dose group at approximately 5 dpi.  Numbers of CD4+ cells of both groups continued to 
recover to baseline levels for the majority of animals towards the end of the time course.  A 
decline in CD4+ cells also occurred in the aerosol group at 8 dpi, though not as sharply as the 
high and low dose groups.  Numbers returned to baseline by 14 dpi.    
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Figure 4.4.7.3 Percentage change from baseline for CD4+ T cells following influenza infection 
Percentage change from baseline was calculated using raw CD4+ T cell values. Raw cell data was 
calculated as described above in Fig. 4.4.9.1. Data were not analysed at 11 dpi due to an incorrect 
batch number of PE CD4+ antibody being used for the whole blood phenotyping; this batch number 
had been found previously to not work and was used in error; results from 11 dpi were therefore omitted 
from analysis.  
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A similar decline was observed in infected groups in the CD8+ T cell population, however it 
was not as marked as in the lymphocyte (Fig 4.4.9.2) or CD4+ T cells (Fig 4.4.9.3). An 
increase in the number of CD8+ T cells was observed at eight days post challenge in the high 
dose group of animals, a similar increase was also observed in the low dose and aerosol 
group of animals.   There appears to be a decline from baseline in all animals at 11 dpi.  Ferret 
41787 in the mock group appears to be to be an outlier, as the increase in CD8+ T cells is 
much higher than expected in the mock group and when compared to other infected ferrets. 
 
 
Figure 4.4.7.4 Percentage change from baseline for CD8+ T cells following influenza infection 
Percentage change from baseline was calculated using raw CD8+ T cell values. Raw cell data was 
calculated as described above in Fig. 4.4.9.1. 
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4.4.10 Comparison of cell types producing influenza-specific IFN-γ response  
 
 
All cells used in the assay were isolated at necropsy and assessed for influenza-specific IFN-
γ responses (Fig 4.4.10.1) in PBMC (a), spleen (b), Lung MNCs (c) and BAL wash (d).  Results 
were analysed to look at the number of spot forming units per 1x106 cells, which represents 
the quantity of cells expressing influenza-specific IFN-γ responses.  
 
The cellular immune response seen in PBMCs (Fig 4.4.10.1.a) appears to be the highest for 
the low dose group, with the high dose and aerosol groups appearing to have comparable 
influenza-specific IFN-γ response.  No response was detected in the mock group.   Influenza-
specific IFN-γ responses seen in splenocytes (Fig. 4.4.10.1.b) were only determined for two 
out of three ferrets in the low dose group.  These results were quite variable, as one ferret had 
very low spot forming units detected whilst the other had the highest detected of all the ferrets 
assayed.    The high dose and aerosol group ferrets showed similar influenza-specific IFN-γ 
responses detected with each of their groups in splenocytes.  Low responses were detected 
in the mock group, as expected.  Variable influenza-specific IFN-γ responses were detected in 
the low dose group in lung MNCs (Fig. 4.4.10.1.c).  The ferret with the high influenza-specific 
IFN-γ response seen in the lung MNCs for the low dose group was not the same ferret with 
the high influenza-specific IFN-γ response detected in the splenocytes. 
 
In the aerosol group the highest influenza-specific IFN-γ responses in animal 40761 were 
found in the PBMCs and in contrast, the lung MNC influenza-specific IFN-γ responses in this 
ferret were relatively low (Fig. 4.4.10.1). Comparatively low influenza-specific IFN-γ responses 
were seen in the PBMCs of ferrets 47791 and 49800.  This corresponds with the sequestering 
of immune cells to the lung – the primary site of infection.  When considering the spot size of 
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the spot forming units, similar results are seen.  Both ferrets 47791 and 49800 have slightly 
higher influenza-specific IFN-γ responses in lung MNCs than animal 40761 however all of their 
repsonses are relatively similar.  
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Figure 4.4.10.1 Cellular immune response (a) PBMCs (whole blood), (b) splenocytes (spleen), (c) 
lung mononucleocytes (MNCs) and (d) bronchiolar lavage (BAL) wash were collected from all animals 
(n=12, results for splenocytes for ferret 46171 in the low dose group were not able to be reported due 
to assay failure).  Results were normalised by subtracting allantoic fluid control values from virus 
stimulated samples.  Bars show standard deviation and mean for each group.   
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4.4.11 A longitudinal time course of circulating IFN-γ in nose-only aerosol challenged 
ferrets 
 
Observation of the ongoing cellular immune response to influenza challenge was performed 
by monitoring influenza-specific IFN-γ responses in circulating blood.  Small volumes of 
heparinised blood were collected at -7, -1, 2, 5, 8, 11 and 14 days post challenge, diluted and 
stimulated with A/Perth/16/2009.  Ferrets in the low dose group acted as previously described 
in Chapter 3, Section 3.6.6.4 with influenza-specific IFN-γ responses detected as early as 5 
dpi (Fig. 4.4.11.1).  This increased at 8 and 11 dpi, peaking between 11 and 14 dpi.    The 
high dose group had more variable influenza-specific IFN-γ responses.  One ferret (46392) 
didn’t produce detectable levels of influenza-specific IFN-γ until 11 dpi.  It’s not clear why this 
happened, as the remaining two produced detectable levels of influenza-specific IFN-γ at 5 
dpi, as seen previously in low dose infected animals.  However, the amount of influenza-
specific IFN-γ detected (pg/ml) was, at times, double the amount detected in the low dose 
group. 
 
The levels of influenza-specific IFN-γ detected in the aerosol group was also variable between 
ferrets and the delayed detection of responses corresponds with the hypothesis that some of 
the ferrets were unsuccessfully inoculated via the nose-only aerosol route.   Ferret 47791 
began to show influenza-specific IFN-γ response on 5 days post challenge, while the 
remaining two ferrets did not begin to show influenza-specific IFN-γ responses until 11 days 
post challenge.  Ferret 47791 shows a similar longitudinal time course of influenza-specific 
IFN-γ responses as those seen in ferrets infected intranasally with a low dose of influenza. As 
proposed previously, it is likely that ferrets 49800 and 40761 were infected through natural 
transmission after coming into close contact with 47791, this could be the reason for the 
apparent delayed influenza-specific response observed in these ferrets. As samples were only 
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collected until 14 days post challenge it is impossible to tell if these responses would continue 
to rise, however based on the evidence from the low dose inoculated ferrets it could be 
assumed that this would be the case.  
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Figure 4.4.11.1. Quantification of influenza-specific IFN-γ production by ELISA Diluted whole 
blood samples were collected all groups (n = 12) at -7, -1, +2, +5, +8, +11 and +14 dpi, stimulated with 
appropriate antigens and the supernatants harvested.  Supernatants were used in the Ferret IFN-γ 
ELISA Development Kit (ALP). Influenza-specific IFN-γ responses became detectable at 5 dpi.  No 
responses were detected in PBS ferrets.  12000 pg/ml was the upper limit of detection for the ELISA. 
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4.5 Discussion 
 
The viral kinetics of the low dose and high dose groups were consistent with those seen in 
Chapter 3. The immunological readouts for the low dose and mock groups were as 
established previously and provided a good baseline comparison for the high dose and aerosol 
groups.   
 
The inoculation of the high and low dose groups appeared to be successful. The nose-only 
aerosol inoculation only appeared to be successful in 1 out of 3 of the ferrets infected via this 
route. As results were collected from this study it became apparent that two of the three 
animals that were challenged via the nose-only aerosol route did not respond as anticipated. 
It is thought that animal 47791 was successfully infected via the nose-only aerosol route; while 
it appears animals 40761 and 49800 were not. In this study the three ferrets from each group 
were housed together, therefore it can be concluded that ferret 47791 most probably infected 
the two other ferrets via a route of natural transmission. From the viral shedding results it can 
be confirmed that ferrets 40761 and 49800 eventually became infected with A/Perth/16/2009.  
 
This conclusion was initially drawn from the nasal wash counts and viral shedding data due to 
the differences in the timings of when animals started to shed an excess of nasal wash cells 
and virus, respectively. Upon further analysis of cellular immune response results it can be 
seen that there is a delay in the appearance of responses in the longitudinal time course of 
influenza-specific IFN-γ responses. This seems to confirm that animals 40761 and 49800 were 
infected later to animal 47791.  
  
175 
 
ELISpot data suggests that there was a successful infection in the lungs of ferrets 47791 and 
49800 as high influenza-specific IFN-γ responses were detected in lung MNCs. Influenza-
specific IFN-γ responses seen in the lung MNCs of ferret 40761 were very low compared to 
ferrets 47791 and 49800 and fell within baseline responses seen in the mock infected, naïve 
PBS inoculated ferrets.  These results suggest that the virus did not successfully reach the 
lungs of ferret 40761 and therefore it is highly likely that this ferret was not successfully infected 
via the aerosol route and rather by direct contact transmission.   This influenza-specific IFN-γ 
response seen in lung MNCs was not seen in the majority of ferrets infected intranasally. 
 
4.6 Further Work 
 
The results from this study suggest one of the animals that were challenged via nose-only 
aerosol became infected.  The remaining two animals becoming infected through contact 
transmission.   Analysis of the results identified a range of reasons for why two out of three of 
the animals may not have been successfully infected during challenge.   
 
1. Re-evaluation of the in vitro spray factor using the aerosol delivery system to 
ensure accuracy and reproducibility 
 
Would the addition of protein, such as bovine serum albumin, make a difference to the 
survival of influenza particles during the nebulisation process?   
 
Presence of protein is thought to have a protective effect on the virus during aerosolisation 
(Tuttle et al., 2010b), though many of the studies where this is reported are investigating 
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aerosol survival rather than aerosol delivery to animals, therefore not taking into account the 
introduction of a live animal into the aerosol system.   A range of studies have been identified 
using several different diluents including; PBS + 0.5% BSA fraction V  (Lednicky et al., 2010) 
PBS + 0.5% BSA fraction V + molecular-grade antifoam agent B added at 0.25% (v/v) (Tuttle 
et al., 2010b) and MEM, 0.2% NaHCO3, 20mM HEPES, 1% Antibiotic/Antimycotic, 20mM L-
Glutamine, 0.001% BSA, and 100µl of Antifoam A (MacInnes et al., 2011). 
 
The act of nebulising the inoculum is violent and the protein could afford a protective effect on 
the aerosolised virus particles. A small amount of preliminary in vitro aerosol data was 
generated prior to the start of this body of work with a H1N1 influenza strain comparing the 
spray factor with and without protein (0.5% BSA).  However, there was an insufficient number 
of replicates, and samples were frozen prior to performing plaque assays.  The results from 
this small study suggested there was little difference between nebulising the inoculum with or 
without protein (BSA Fraction V), therefore, when designing the set up and testing parameters 
during in vitro testing for A/Perth/16/2009 the addition of protein was not explored.  The 
inclusion of protein needs to be properly evaluated to see if this has an effect upon the survival 
of influenza once nebulised. This would include running more replicates than were previously 
carried out during in vitro studies as well as carrying out sprays on different days to ensure it 
was carried out consistently.  Beginning with 1x106 PFU of A/Perth/16/2009, aerosols would 
be generated and collected, and plaque assays will be used to evaluate the amount of virus 
present in the impinger sample. Virus would be diluted in media (DMEM) with and without 
protein to identify if BSA Fraction V should be included in the virus diluent in future studies or 
not.  A range of protein concentrations should be included. Following the first experiment, it 
will be repeated to evaluate if there is any day to day variation in the spray factor using the 
aerosol delivery system. Three impinger samples will be collected from each Collison run to 
identify any degradation in the virus suspension.  
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2. Ensuring the spray factor is correct when using a range of virus dilutions as a 
starting point  
 
Does the spray factor change across a range of starting dilutions or does it remain the 
same? 
 
A lower concentration of virus was recovered from the impinger than expected during the 
aerosol challenge of ferrets with A/Perth/16/2009. The spray factor used to calculate the 
presented dose was based on in-vitro spray data when virus was aerosolised at a starting 
concentration of 1x106 PFU/ml. The starting concentration in the Collison for the H3N2 
inoculum was approximately 2x104 PFU/ml and therefore around 1x102 PFU was expected to 
be recovered from the impinger (based on an expected 2 log drop seen in previous in vitro 
studies).  Considerably less was recovered from the impinger and based on that value the 
calculated presented dose for the study was 0.8 PFU. Therefore, different starting 
concentrations of virus should be aerosolised to ensure that dropping the initial concentration 
of virus in the nebuliser does not have influence on the spray factor and therefore the 
presented dose. This should be repeated to ensure the consistency of the results. The 
outcome of the experiment should identify if using different dilutions of virus results in different 
spray factors. 
 
 
 
 
178 
 
 
3. Repeating in-vivo work 
 
How does the introduction of animals into the system affect the spray factor and 
presented dose?   
 
Following the full evaluation of aerosols generated in-vitro, assuming the presented dose is 
robust, reproducible and reliable, in-vivo work can begin. In the first instance a series of dose 
titration studies should be performed with pre-determined target doses; this will ensure the 
addition of ferrets to the system does not have an effect upon the spray factor and presented 
dose calculated in prior in vitro studies. Ferrets would need to be housed individually to ensure 
none became infected via the natural transmission route, and potentially confusing the results. 
The dose to be used in any future ferret studies can then be identified as the lowest dose that 
reliably infects all ferrets. The starting dose chosen would be dependent upon the outcome of 
any additional spray factor work carried out.   During this study only 1/3 ferrets were 
successfully infected when the presented dose of 3x102 PFU was used with a spray factor 
6.1x10-6.  Therefore, a dose range of 2x102, 4x102 and then 8x102 PFU presented dose would 
be sensible to evaluate in the ferret model.  
 
Ultimately completing further nose-only aerosol study with the above parameters would 
provide a much clearer picture for the evaluation of cellular immune responses.  However, as 
animal studies are very expensive and time consuming, as well as considering ethical 
considerations around using more ferrets, it was not possible to complete within the confines 
of this project.   
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4.7 Summary 
 
 Virology and cellular immune readouts work successfully and were observed in all 
animals  
 Assays were able to identify differences between groups of animals 
 Responses appeared similar to those seen in the low dose intranasally inoculated 
animals 
 Nose-only aerosol inoculation of ferrets with A/Perth/16/2009 is currently unreliable 
and requires further optimisation to reliably infect all exposed animals 
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5 Transmission Cage Model  
 
5.1 Introduction  
 
Human to human transmission of IAV occurs either through contact (direct or indirect) or 
respiratory droplet (droplet or droplet nuclei) transmission (Bridges et al., 2003).  As stated 
previously, dissociating these transmission routes is complicated, and it is difficult to determine 
the exact contribution of each of these modes of transmission to infection.  However, the 
transmission of respiratory droplets when an infected individual coughs or sneezes is likely to 
be a major mode of sustained virus spread in the community setting during seasonal 
epidemics and occasional pandemics (Maines et al., 2006).    
 
Detection of infectious airborne IAV in clinical settings is limited and lacks sensitivity (Blachere 
et al., 2011).  There are several challenges that are encountered when culturing airborne IAV; 
low concentrations of virus, damage to virus during sampling and interference by 
environmental contaminants (bacteria, mould, dust) (Turgeon et al., 2019).  
 
In the laboratory setting several animal models have been used to investigate IAV 
transmission via respiratory droplets (Lowen et al., 2006, Maines et al., 2009, Maines et al., 
2006), including ferrets  (Maines et al., 2006, Munster et al., 2009). Ferrets have already been 
shown to be an ideal candidate to investigate human IAV transmissibility and shed a light on 
the pandemic potential of emerging zoonotic viruses.   Ferret transmission studies provide an 
important insight into host, viral and environmental factors affecting the transmission of IAV 
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(Nishiura et al., 2013), with basic analysis in typical ferret experiments being the presence or 
absence of transmission from an infected ferret to a susceptible ferret.     
 
Transmission of respiratory droplets of IAV from infected donor ferrets to naïve recipients is 
an effective method of evaluating the ability of the virus to transmit via ‘naturally’ generated 
aerosols.  Unlike the aerosol exposure system where the presented dose can be calculated, 
the presented aerosol dose to the naïve recipient would be difficult to calculate.  Air sampling 
in and around transmission cages could help to establish insight into how the virus is shed 
and at what stages, post infection, the virus is transmitted.  Previous investigations showed 
that influenza transmission amongst ferrets via the air was positively associated with the 
number of infectious particles exhaled by the infected donor (Lakdawala et al., 2011).   
However, another investigation with pre-2009 seasonal H1N1 and pandemic H1N1 showed 
that high viral RNA levels in the air surrounding animals in transmission cages did not predict 
efficiency of transmissibility of individual virus strains (Koster et al., 2012).  This study also 
showed that as time passed following the initial infection of the donor ferret the less efficient 
the transmission of virus became between it and its recipient pair despite viral RNA levels 
staying similar throughout the initial time period of the investigation (Koster et al., 2012).  It 
has been suggested that this may be due to a robust inflammatory response that reduced the 
viability of the virus, but does not affect the level of viral RNA exhaled (Thangavel and Bouvier, 
2014).  In any case, robust methods of collecting virus containing particles from exhaled breath 
for reliable analysis remains an unmet challenge (Milton et al., 2013).     
 
The respiratory droplet transmission model has been well characterised (Herlocher et al., 
2001, Maines et al., 2006).  The purpose of this type of model is to allow the separation of 
ferrets; permitting airflow exchange between pairs, while eliminating other sources of direct 
and indirect contact.  This allows for the evaluation of the virus transmissibility, as some 
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viruses which demonstrate transmissibility through direct contact conditions are unable to be 
transmitted by the respiratory or aerosol droplet route.  A limitation of this model is the difficulty 
in discriminating between large respiratory droplets and droplet nuclei. 
 
5.2 Aims 
 
Study 5283 (appendix 1) was designed to establish a model of indirect transmission between 
ferrets infected with the H3N2 strain A/Perth/16/2009 and to explore the influenza transmission 
kinetics between intranasally challenged ferrets and indirect contact ferrets. This allows airflow 
exchange between the two ferrets while eliminating all other sources of direct and indirect 
contact. This study acted as a pilot respiratory transmission cage model which ultimately 
intended to encompass all three recognised modes of transmission: contact, large droplet and 
droplet nuclei, however as animal studies are very expensive and time consuming, as well as 
taking into account ethical considerations around using more ferrets, it was not possible to 
complete within the confines of this project. Details of how the work would have evolved will 
be detailed in the further work section of this chapter (5.6).   
 
The aim of this model was to represent a more natural route of transmission compared with 
forced exposure of single ferrets to aerosol exposure apparatus.  Successful transmission 
between donor and recipient was assessed by the detection of infectious virus in nasal wash 
and/or seroconversion of the recipient.  Previous studies have demonstrated that 
seroconversion in the absence of virus detection is not uncommon.    
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5.3 In vivo Study Outline  
 
5.3.1 Cage Design 
 
 
The modified ferret cages were designed at PHE, Porton Down by the Biosafety Group.   The 
original standard cages were manufactured by Arrowmight (Arrowmight, Hereford, UK) and 
were extensively modified by the Biosafety Department to carry out influenza transmission 
work.  New side panels and doors were manufactured by Prosheet (Prosheet Engineering 
Limited, Crayford, UK) to specification to allow modification of pairs of cages to the 
transmission system.  The ventilation fan units and filter boxes (PFI, Milton Keynes, UK) for 
use on flexible film isolators were suitably modified.  Figure 5.3.1.1 shows how the cages 
were set up.     
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Figure 5.3.1.1 Transmission Cage Design.  Cages were sealed using a combination of rubber seals and sufficient tape.  (a) Ferrets were singly housed in 
separate individual cages and each donor ferret was paired with a singly housed recipient ferret.    
(c) 
(e) 
(d) 
(b) 
(f) 
(a) 
(a) 
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(b)   Air was drawn from the laboratory into the first cage via a high-level vent and then on through into 
the second sealed cage via a connecting tunnel (c).   The aperture of the tunnel was covered with a 
perforated metal mesh on each end.  The mesh was covered in 4.8mm holes giving a 50% open surface 
area and the tunnel was 10cm deep.  Having reached the second cage air was drawn back out into the 
laboratory via a H14 HEPA filter (PFI, Milton Keynes, UK) to prevent any exposure or cross 
contamination.   The system was set up to give 20 air exchanges per hour inside each cage, equating 
to a face velocity of 0.02msec-1 through the connecting tunnel. (d) Cages were clearly marked with the 
direction of airflow to separate procedures carried out on the donor and recipient animals.  This was to 
prevent operator cross-contamination.  (e) To aid the assessment of the viral kinetics and to see if it 
was possible to sample air between cages, a personal air sampling system was used during this 
investigation. (f) Air samplers were set up between cages: 1. 41822-38968, 2. 15557-40513 and 3. 
18704-40487 (ferret ID pairs). 
  
Six transmission cages were set up as shown (Fig. 5.3.1.1). Three of the six paired cages 
were fitted with personal air samplers (Fig 5.3.1.2) to sample the air flowing from the infected 
donor cage to the recipient cage, sampling for 8 hours.   
 
Figure 5.3.1.2 Personal Air Sampler The personal air sampler (Casella UK, Bedford, United Kingdom) 
(a) sampled cage air a total of 4L/min, with sampling taking place each day for approximately 8 hours.  
(b) Each air sampler had a clean gelatine filter fitted every morning on to which the virus was collected.   
a b 
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The individual gelatine filters were then dissolved in 1mL warm (37°C) PBS, aliquoted into two labelled 
cryovials and stored at -80°C.  Air sampling was carried out from +1 to +8 dpi.  At a later date, the air 
sampling aliquots were defrosted, and the RNA was extracted using the QIAgen RNeasy Mini Kit and 
samples analysed by qRT-PCR (Chapter 2 Materials & Methods). 
 
5.3.2 Study Design 
 
 
Figure 5.3.2.1 Study timeline. Baseline bleeds were taken from all ferret at -3dpi.  At 0 dpi donor 
ferrets were sedated and inoculated via the intranasal route with 1x105 PFU/ferret of A/Perth/16/2009 
and placed singly into individual cages.  Recipient ferrets were placed singly into donor-paired cages 
at 1dpi of donor ferrets.  Nasal washes were collected in PBS from 1 dpi to 11 dpi.  Air sampling of 
cages was carried out from 1 dpi to 8 dpi on three of the six paired cages.  Three donors were culled 8 
dpi and the remaining were culled at 13 dpi. All recipients were culled at 14 dpi.  At cull spleen and 
whole blood were taken for the evaluation of the cellular immune response.  Blood for sera, was also 
taken to evaluate the humoral immune response. 
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5.3.3 Ferrets 
 
A mixture of ferrets were obtained from Highgate Farm, UK, and Simonsen Laboratories, GA, 
USA, and were 12-16 weeks of age at the time of the study. A total of 12 ferrets were used, 
with 6 donor animals and 6 matched recipient animals, randomly assigned, as shown in Table 
5.3.3.1. All baseline sera samples had HAI titres of less than 4 to H3N2 A/Perth/16/2009, and 
it was deemed that these ferrets had no previous exposure to H3N2 and so were suitable for 
challenge.  
 
Table 5.3.3.1 Ferret Identification Numbers 
Donor Group Matched Recipient Group 
Number Origin Starting Weight 
(g) 
Number Origin Starting Weight 
(g) 
40434 (m) Simonsen 1110 95099 (f) Simonsen 750 
40400 (m) Simonsen 1262 11981 (m) Highgate 593 
40418 (m) Simonsen 1203 12950 (f) Highgate 1106 
41822 (f) Simonsen 760 38968 (m) Highgate 613 
15557 (f) Highgate 724 40513 (m) Simonsen 543 
18704 (f) Highgate 533 40487 (f) Simonsen 692 
 
 
5.3.4 Virus 
 
Donor ferrets were inoculated intranasally with H3N2 A/Perth/16/2009 P+2A challenge stock 
virus diluted in PBS to provide a challenge dose of 1x105 pfu/ferret. Donors were inoculated 
intranasally on day zero.  The challenge dose of 1x105 pfu/ferret was chosen to ensure the 
donor ferrets were successfully infected and was based on a previous H1N1 study using 
similar transmission cages at PHE Porton (Otte et al., 2016). The dose was confirmed on day 
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of administration by back-titration using plaque assay. The challenge material was given to 
each animal in a volume of 0.2 ml via the intranasal route.  Infected ferrets were then 
transferred into the donor halves of the transmission cages.  Recipients were placed into the 
other half of the transmission cages on T=1.  From this stage until the end of the study the 
recipient ferrets were always handled before the donor ferrets to avoid potential cross 
contamination between uninfected recipients and infected donors.  
 
5.3.5 Sample collection 
 
Nasal washes were obtained, and cell counts were performed prior to the nasal washes being 
frozen down for plaque assay at a later date. Nasal wash samples were taken from all ferrets 
prior to study start on -1 dpi and then at 1 dpi to 11 dpi or until culled.  Three ferrets from the 
donor group were culled at 8 dpi.  The remaining 3 ferrets from the donor group were 
euthanised at 13 dpi.  All ferrets from the recipient group were terminated at 14 dpi. At cull 
terminal blood samples were taken for serum and for PBMC isolation.  Spleens were collected 
into RPMI media for harvesting splenocytes. Nasal washes were also collected at cull.   
Termination timepoints of donor ferrets were determined by availability of staff to carry out 
culls and necropsy.  The recipient ferrets were culled on 14 dpi to allow for seroconversion to 
occur. 
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5.4 Results 
 
5.4.1 Nasal wash cell counts and titres in donor and recipient ferrets  
 
Nasal wash cell counts (Fig. 5.4.1.1) from the first four days of nasal wash collection indicated 
that not all recipients became infected simultaneously.  As the study progressed it became 
apparent that 2 out of 6 of the recipient ferrets had a productive H3N2 infection. Recipient 
ferrets 11981 and 12950 showed a rise in nasal wash cells similar to those seen in the donor 
ferret group.  All nasal washes were analysed by plaque assay on study completion to 
determine if virus had been shed from animals despite a lack of substantially increased nasal 
wash cell count from some of the recipients.  The most effective way to view the data produced 
was to examine the nasal wash virus titres as individual pairs.   
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Figure 5.4.1.1 Nasal wash cell counts Nasal washes were collected at 1 to 8/11 dpi.  All nasal washes 
were counted to ascertain the number of cells being shed from each animal at each timepoint. Donor = 
purple. Recipient = orange.  
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Figure 5.4.1.2 shows the viral titres determined for each donor and recipient pair. The 
previously observed double peak of virus production was seen in all of the donor animals at 6 
dpi.  This second peak has been observed in the previous intranasal infection studies 
(Chapter 3).  The first peak in all donor animals occurred at 2 days post infection with a mean 
viral shedding titre of 2.3x105 pfu/mL.  The area under the curve calculation for the two 
recipients that did shed virus (11981 and 12950) shows that the total amount of virus produced 
was found to be less than the total amount of virus produced by the donor ferrets.  This could 
be due to the possible low titre of virus received by recipients and due to the route of 
transmission, aerosol instead of intranasal.  Interestingly both 11981 and 12950 appear to 
have a triple peak of viral shedding at 4, 6 and 8 dpi.  This has not been seen previously in 
any of the low dose intranasally inoculated animals. 
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Figure 5.4.1.2 Nasal wash titres Nasal washes were plaque assayed to ascertain viral titres shed from 
recipient and donor ferrets at all timepoints.  Four out of six of the recipient ferrets had no viral titre in 
their nasal wash.   Donor = purple. Recipient = orange. 
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5.4.2 Clinical signs of infection in donor and recipient ferrets  
 
Weight was monitored daily throughout the study. The means for the donor and recipient 
groups show each group gained weight over the course of the study. 
 
 
Figure 5.4.2.1 Weight percentage change from baseline.  Percentage weight changes for all ferrets 
from day of infection of donor ferrets. 
 
Weight loss below baseline was observed in three out of six of the donor ferrets; 40434, 40400 
and 40418.  Ferrets 40400 and 40418 experienced a small negative percentage change in 
weight from baseline over 1 and 2 dpi but then proceeded to stay at a weight above baseline 
for the remainder of the study.   The weight of the three remaining donors, 41822, 15557 and 
18704, all stayed above baseline for the duration of the study.   
 
Percentage weight loss below baseline was observed for four out of six ferrets in the recipient 
group at 1 dpi (of the donor group); 95099, 11981, 12950 and 40513.  The recipient ferrets 
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were placed within their new paired cages at 1 dpi and the weight loss could be attributed to 
the change in environment as it would be too soon for the weight loss to be due to infection 
with IAV based on the results from low dose IAV studies.   
 
Figure 5.4.2.2 Weight percentage change from baseline.  Percentage weight changes for recipient 
ferrets that shed detectable live virus titre; 12950 and 11981. 
 
Following 1 dpi all ferrets maintained their weight above baseline apart from ferret 12950 which 
had lost 8.4% of its baseline weight by 3 dpi. Ferret 12950 is one of the two recipient ferrets 
that became infected (Fig 5.4.2.2). The other recipient ferret that became infected, 11981, did 
not lose any weight below baseline during the study.  The recipient ferret group all appeared 
to lose weight at 9 dpi, with weight gain continuing at 10 dpi. Incidentally the two heaviest 
donors were the ferrets that successfully infected their paired recipients.  
 
All ferrets in both the donor and recipient groups had normal activity levels throughout the 
study with no appetite loss or incidence of diarrhoea.   
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Table 5.4.2.1: Cumulative incidence of nasal discharge and sneezing 
Donor Incidence Paired Recipient Incidence 
40434 3 95099 0 
40400 1 11981 1 
40418 7 12950 3 
41822 1 38968 0 
15557 0 40513 0 
18704 1 40487 0 
 
Table 5.4.2.1 shows the cumulative incidence of nasal discharge and sneezing recorded over 
the course of the study for each ferret.  The donor group had several animals with increased 
sneezing and nasal discharge over 2 dpi to 6 dpi, with ferret 40418 having both the highest 
incidence of sneezing and nasal discharge. This ferret was paired with one of the successfully 
infected recipients; 12950. Nasal discharge and sneezing was not recorded in any of the 
recipient ferrets that were not shedding virus. Recipient ferrets 12950 and 11981 were both 
recorded to have nasal discharge and sneezing was recorded for 12950 at one time point. 
This incidence numbers are similar to the rest of the donor group excluding ferret 40418.  
 
5.4.3 Evidence of seroconversion in donor and recipient ferrets 
 
The HAI assay (Fig 5.4.3.1) confirmed that all donor ferrets seroconverted following infection.  
Ferrets 15557 and 18704 had slightly lower HAI titres (128 HA units vs >512 HA units) as they 
were culled and bled at 8 dpi. Had they been allowed to survive to 13 dpi it is probable that 
their titres would have continued to rise above 128 HA units to >512 HA units. (The dilution 
point of 1 in 512 was the end point of this HAI assay). The remaining donor ferrets all had HAI 
titres exceeding 512 HA units.  Of the recipients, only ferrets 11981 and 12950 seroconverted.  
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These results confirm, along with the nasal wash titre results, that these ferrets are the only 
two recipients to become infected successfully with IAV.  The remaining recipient ferrets failed 
to seroconvert and gave titres expected of naive animals.  
 
 
Figure 5.4.3.1 HAI Titres Serum was taken from ferrets at cull.  All sera were treated with receptor 
destroying enzyme (RDE) and HAI assayed against A/Perth/16/2009. Titres of <20 are considered to 
be seronegative.  
 
 
5.4.4 Influenza-specific interferon gamma responses present found in the spleen 
and peripheral circulating blood of donor and recipient ferrets   
 
Splenocytes and PBMCs were isolated as described in the materials and methods, Section 
2.4.  The samples from this study were used to optimise the ELISpot Kit for use with 
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A/California/04/2009 and A/Perth16/2009 infected ferret tissues and whole blood.  Therefore, 
only a limited number of samples were available for the analysis described.  The PBMCs of 
two recipient ferrets, 12950 and 40513, were tested for influenza-specific IFN-γ responses.  
Ferret 12950 had shown a productive infection with confirmed seroconversion, while ferret 
40513 had shown no signs of successful infection and remained seronegative.  In line with 
these results ferret 12950 (882 SFU) showed significant influenza-specific IFN-γ responses in 
PBMCs while 40513 (0 SFU) had no detectable influenza-specific IFN-γ responses. 
 
Splenocytes were analysed for donor ferrets 40434, 40418 and recipient ferrets 95099, 38968 
and 40487 (Fig 5.4.4.1).  The three recipient ferrets analysed had no viral titre detected in 
their nasal wash and remained seronegative when the study concluded.  Donor ferrets 40434 
and 40418 had influenza-specific IFN-γ responses in the splenocytes.  Unexpectedly, the 
three recipient ferrets, 95099, 38968 and 40487 all had influenza-specific IFN-γ responses 
(above 850 SFU) suggesting that although the ferrets didn’t become infected or seroconvert 
that they were exposed to the virus enough to trigger a T cell response.  For reference naive 
ferrets inoculated with PBS have low values for influenza-specific IFN-γ responses in the 
spleen (less than 160 SFU).  
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Figure 5.4.4.1 Cellular immune responses seen in the spleen of selected donor and recipient 
animals Splenocytes were isolated from ferret spleens on the day of cull. Results were normalised by 
subtracting individual sample allantoic fluid control values from virus stimulated samples.  Influenza-
specific IFN-γ responses were seen in all ferrets assayed.   
 
5.4.5 Air Sampling of the Cages 
 
Air sampling was carried out on 3 of the 6 paired cages due to the availability of air samplers.  
Cages were randomly selected.  These cages were designated at random.  The air sampling 
was carried out on paired cages 1. 41822-38968, 2. 15557-40513 and 3. 18704-40487. None 
of these recipient ferrets became infected.  All filters were processed, and RNA extracted 
(Qiagen) for analysis using qRT PCR.  Interestingly, greater than baseline viral RNA copies 
were picked up on the filter samples (Fig. 5.4.5.1) for all paired cages tested.  This suggests 
that influenza virus was aerosolised by the donor ferret and passed through the transmission 
cage.  The amount of RNA detected at each timepoint varied across the cages and there 
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appears to be no discernible pattern between each pair.  However, each pair does appear to 
have a ‘double peak’ in RNA detected.  Despite detectable virus in the samplers none of the 
paired recipient ferrets became infected. This could be because the virus was dispersed into 
such a low concentration that it failed to successfully infect the recipient ferrets.  The detection 
of viral RNA also indicates the presence of viral copies, it cannot determine if the virus is 
infectious.  Successful infection of ferrets would be defined as recipient ferrets shedding 
detectable live virus from their nasal washes.    
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Figure 5.4.5.1 Viral load of air samplers. 1. 41822-38968, 2. 15557-40513 and 3. 18704-40487. 
Filters were melted in 1ml of PBS when removed from the air samplers following the 8-hr sampling 
period.  Copies per milligram were calculated by using a standard curve as detailed in Chapter 2 
Materials and Methods.  
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5.5 Discussion 
 
When this study was designed, it was intended to be a preliminary investigation into the 
aerosol transmissibility of A/Perth/16/2009. At the time it wasn’t deemed critical that the ferrets 
be of a weight, sex or from a particular origin (Table 5.3.3.1).  However, this may have 
influenced the outcome.  For example, larger ferrets, with a greater tidal volume would be able 
to produce a larger volume of aerosol over the infection period.  Both the recipient ferrets that 
became infected were paired with the two largest ferrets 40400 and 40418 respectively.   
 
A relatively high dose of 1x105 pfu of virus per animal was used to inoculate ferrets to ensure 
that donor ferrets would become infected, start shedding virus and therefore be able to 
transmit the virus to recipients.  However, considering the results obtained in Chapter 3, a 
lower dose of 1x102 pfu of virus per animal would have been a robust inoculation dose and 
may have led to more virus shedding in total than the 1x105 pfu dose (Marriott et al., 2014). 
Transmission only partly corresponded with the amount of sneezing and nasal discharge in 
donors, and the successful transmission donors did not have significantly higher peak titres in 
nasal wash.  
 
Comparing the two infected recipients to the four uninfected recipients, nasal wash counts, 
and sneezing and nasal discharge were clear clinical markers for infection, whereas weight 
loss was of no value in determining infection.  The observation of influenza-specific IFN-γ 
responses in HAI negative ferrets raises the possibility that the IFN-γ ELISpot is more sensitive 
to sub-infectious influenza dose than antibody response but is only based on a single 
observation from three ferrets assayed.  
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It was noted that the viral titres of the two infected recipients reached roughly the same peak 
titres (1x105 to 1x106 pfu/ml) seen in ferrets inoculated with a low dose H3N2.  There appeared 
to be a triple peak seen in the two recipients, this contrasts with the distinctive double peak 
seen in the viral kinetics of ferrets infected intranasally with a low dose.    
 
Crude cage sampling was carried out between 3 out of 6 of the paired cages. Viral RNA was 
detected passing between the cages but none of the recipient ferrets became infect.  It would 
have been advantageous if all paired cages were included in the air sampling to allow 
comparison of results between successfully infected recipients and recipients that did not 
become infected.   Subsequent studies have shown that live virus can be plaque assayed from 
air sample filters (Bekking et al., 2019), therefore it would have been advantageous if samples 
had been taken for quantification of live virus.  This would have allowed a picture of how much 
live virus was present in the air samples.  
 
5.6 Further Work 
 
This study was designed with the intention that all recipient ferrets would be infected 
successfully. There could be numerous reasons why only 2 out of 6 ferrets became infected.  
There are no published transmission studies using the A/Perth/16/2009 strain and other 
studies that do use H3N2 strains have very small group sizes (Gustin et al., 2011, Herlocher 
et al., 2001) and use different cage set ups and airflows (MacInnes et al., 2011).   
 
A transmission study using a bioluminescent H1N1 A/California/04/2009 that encoded a 
luciferase provided a snapshot of influenza infection and transmission by in vivo imaging 
(Karlsson et al., 2015). This studydemonstrated that IAV was able to successfully enter the 
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respiratory tract of the ferrets, however a successful infection was not established as identified 
by virus in nasal washes or seroconversion.  This suggests that the infection could be sub 
clinical. The ferret antibody responses were assessed using microneutralisation (MN) assays 
and a humoral immune response was confirmed despite no virus being shed.  The MN assay 
has been shown to give a similar result to HAI assays.  In the study discussed in this chapter 
recipient ferrets that did not shed live virus also did not have an HAI titre, therefore it can be 
assumed that these ferrets did not become infected with virus. 
 
Going forward using a low (1x102 pfu/ferret) donor inoculum would allow for extended 
shedding of virus which would mean a longer period of exposure for recipient ferrets.  This 
longer window of exposure could help boost the chances of recipient ferrets becoming 
infected.   Additionally, using an alternative H3N2 isolate which is found to transmit better than 
A/Perth/16/2009, could be an option if attempting to successfully infect all recipient ferrets.  
Using a larger sample size could also be an improvement, potentially allowing for statistics to 
be performed; however, there are ethical considerations to consider when using a large 
number of ferrets for subsequent studies.   
 
Recently a study evaluation of bioaerosol samplers was published (Bekking et al., 2019) using 
H1N1 and H3N2 strains.  It assessed the differences between a polytetrafluoroethylene filter 
(PTFE filter), a 2‐stage National Institute of Occupational Safety and Health cyclone sampler 
(NIOSH cyclone sampler) and the 6‐stage viable Andersen impactor (Andersen impactor).   
They showed that the PTFE and NIOSH samplers were both useful for influenza virus RNA 
collection for clinical and environmental samples (Bekking et al., 2019).   This is encouraging 
as the PFTE sampler used in this published study is similar to the sampler used in this 
transmission cage study.   If further transmission cage studies were to take place samplers 
would need to be placed in between each paired cage.  This would allow a comparison of the 
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amount of viral RNA passing between the cages of infected and non-infected recipients.  It 
would answer whether the amount of viral RNA collected from the air passing through the 
cages has an effect on the ability of the recipient ferret to become infected, or if there is another 
factor involved in the ability of the virus to infect.   
 
A clear improvement on this transmission work would be to carry out more extensive and 
complete cellular immune response analysis on recipient ferrets.  This would include collecting 
spleen, whole blood and lung samples at study termination for analysis of influenza-specific 
IFN-γ responses using ELISpot.  It would also be useful to take sequential small volume whole 
blood samples to build a time course of influenza-specific IFN-γ responses circulating in the 
periphery using ELISA.  These results would confirm how reproducible the influenza-specific 
IFN-γ response seen in otherwise virus negative animals is. 
 
5.7 Conclusions 
 
It is evident from these results that evaluation of transmission using transmission cages and 
paired recipient and donors is complex.  The aim of this model was to represent a more natural 
route of transmission compared with the nose-only aerosol route evaluated previously.  
Successful transmission between donors and recipients occurred between two out of six 
paired ferrets.  This could be due to a several variables that were present in the study e.g. 
weight.   However, the study did show that A/Perth/16/2009 is able to be transmitted between 
ferrets without contact, although the transmission rate may be less than 100%.   
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6 Comparison of H3N2 and H1N1 Subtypes in the 
Intranasal Ferret Model  
 
The two circulating seasonal subtypes of IAV in humans are currently H3N2 and H1N1.   The 
H1N1 virus originated from the 2009 influenza pandemic caused by a triple reassortment of 
human, swine and bird type A influenza (Neumann et al., 2009), while the current seasonal 
H3N2 strain originated from the 1968 Hong Kong pandemic when genomic exchange of RNA 
occurred between human and avian viruses (Wendel et al., 2015).  While this work was being 
undertaken several studies using a seasonal H1N1 strain, A/California/04/2009, took place.   
Comparing these two clinically relevant strains allows for assessment of the intranasal model 
further.  
 
6.1 Aims 
 
The aims of this chapter are to compare and contrast the H3N2 and the H1N1 intranasal 
infection models: 
 
 to ascertain if there are any similarities or differences between the ability of the two 
seasonal influenza strains to establish an infection. 
 to establish if the viral kinetics of both viruses is similar in the low dose intranasal ferret 
model. 
 to investigate if the cellular immune response elicited in the ferret by each virus is the 
same.  
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6.2 Intranasal Comparison Outline 
 
 
The data from Chapter 3, Section 3.6 is used here for comparison against a low dose H1N1 
intranasal model arm of Study 5549 (appendix 1).   Results for the H1N1 infected ferrets were 
generated and analysed separately from this project but are being used here to examine the 
similarities and differences between the two main seasonal subtypes of currently circulating 
IAVs; H3N2 and H1N1. This data contributes to the publication attached to this thesis (Ryan, 
Slack et al. 2018). 
 
6.2.1 Ferrets 
 
Table 6.2.1 Ferret Identification Numbers 
H3N2 Low Dose (5719) H1N1 Low Dose (5549) Mock (5549) 
86654, 86811, 86809, 86659, 
86812, 86660 
 
46707,50573, 52238, 47025, 
48889, 46915 
55432, 45891, 53132, 49686, 
52094, 45627 
 
Ferrets were intranasally infected with previously characterised low dose of influenza  (1x102 
plaque forming units (PFU) per ferret) of either A/California/04/2009 (H1N1) (Marriott et al., 
2014) or A/Perth/16/2009 (H3N2) (Chapter 3).  
 
Female ferrets were obtained from Highgate Farm, UK and were 4-6 months at the time of the 
study.  A total of 18 ferrets were used.  All ferrets were culled at 14 days post infection.  Ferrets 
were group housed in floor pens designed in accordance with the requirements of the United 
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Kingdom Home Office Code of Practice for the Housing and Care of Animals Used on 
Scientific Procedures (1989). 
 
6.2.2 Prior to Inoculation 
 
At seven and three days prior to inoculation ferrets were fully sedated by an intramuscular 
injection of Ketamine/Xylazine (1ml Ketamine (100mg/ml) plus 0.4ml Xylazine (20mg/ml) 
given at a dose of 0.25ml/Kg bodyweight).  At -7 dpi whole blood samples were collected from 
all ferrets. At -3 dpi whole blood samples were collected from all ferrets. These two whole 
blood samples were used to calculated baseline values for the IFN-γ ELISA. Additional 
baseline blood samples were taken at -3 dpi from the anterior vena-cava vessel of each ferret, 
2ml blood collected into SST tubes for sera isolation and a baseline nasal wash was 
performed. Sera were tested by HAI for the presence of any pre-existing antibodies to 
influenza H3N2 A/Perth/16/2009.  All baseline sera samples had titres of less than 4 HAI units 
to H3N2 A/Perth/16/2009, and it was deemed that these ferrets had no previous exposure to 
H3N2 and so were suitable for challenge. 
 
6.2.3 Virus 
 
Ferrets were fully sedated by an intramuscular injection of Ketamine/Xylazine (1ml Ketamine 
(100mg/ml) plus 0.4ml Xylazine (20mg/ml) given at a dose of 0.25ml/Kg bodyweight).  Ferrets 
were inoculated intranasally with either H3N2 A/Perth/16/2009 P+2A or H1N1 
A/California/04/2009 P+3H challenge stock virus diluted in PBS to provide 1x102 PFU/ferret. 
The dose was confirmed on day of administration by back-titration. Each animal was 
inoculated with a volume of 0.2ml by the intranasal route.  
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6.2.4 Sample Collection 
 
Following inoculation, weight was recorded daily, and clinical signs recorded twice daily.  
Temperatures were not recorded.  Nasal washes were collected from 1 to 8 days post 
infection.  Whole blood samples were collected from all ferrets at 2, 5, 8 11 and 14 days post 
infection. Ferrets were sedated by intramuscular injection of Ketamine/Xylazine (1ml Ketamine 
plus 0.4ml Xylazine) given at a dose of 0.25ml/Kg bodyweight. Following overdose samples 
were collected from each ferret; nasal wash, blood in SST for serum and blood into heparin 
tubes for PBMCs.  Lungs were collected into RPMI 1640 media. 
 
6.3 Results 
 
6.3.1 Nasal wash cell counts and titres 
 
Nasal wash cell counts from all influenza infected ferrets began to increase between 2 and 4 
dpi whilst mock infected ferrets did not increase over the 8 days of monitoring (Fig 6.3.1.1).    
As anticipated, there was a significant difference found between the virus infected groups and 
the mock groups (P 0.022).  No significant difference was found between the total amounts of 
cells shed between the groups infected with H1N1 and H3N2 (P 0.7104)    
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Figure 6.3.1.1 Nasal wash cell counts. Nasal washes were collected at 1 to 8 dpi. All nasal washes 
were counted to ascertain the number of cells being shed from each individual ferret at each time point 
(n=18). The area under the curve was calculated for the H3N2 (n=6), H1N1 (n=6) and mock (n=6) 
groups.  A Mann-Whitney test was performed and a statistical difference (P 0.022) was found between 
ferrets intranasally infected with both A/Perth/16/2009 (H3N2 group), and A/California/04/2009 (H1N1) 
and the PBS (mock group).    There was no significant difference (P 0.7104) found between the ferrets 
intranasally infected with A/Perth/16/2009 (H3N2 group) and A/California/04/2009 (H1N1 group). 
 
Nasal washes were tested for the presence of replicating virus (Fig 6.3.1.2).  As mentioned 
previously, 4 out of 6 ferrets infected with H3N2 began to shed detectable virus at 1 dpi.  The 
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remaining two ferrets, 86654 and 86660, began to shed detectable virus at 2 dpi.  All ferrets 
infected with H1N1 began to shed virus at 1 dpi.  Viral shedding for ferrets infected with H3N2 
peaked at 3 dpi, compared to ferrets infected with H1N1 which peaked at 2 dpi.  The peaks 
were followed by a decrease in virus load and a subsequent smaller, second peak at 5 dpi 
(H1N1 group) and one at 6 dpi (H3N2 group) that has been seen previously.   
 
The peak shedding titre was found to have a strong positive correlation and significance (R 
+0.986, P <0.0001) with the total virus shed from the H3N2 and H1N1 groups. Consequently, 
as seen previously, the more virus shed by an animal the higher the peak titre of virus found 
in nasal wash. 
 
Figure 6.3.1.2 Nasal wash titres. Nasal washes were subsequently plaque assayed to ascertain the 
amount of virus being shed from each individual ferret at all time points collected.   The area under the 
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curve was calculated for the H3N2 (n=6) and H1N1 (n=6) groups to ascertain the amount of virus shed.  
A Mann-Whitney test was performed and a statistical difference (P 0.022) was found between the 
amount of virus shed by ferrets intranasally infected with A/Perth/16/2009 (H3N2 group) and 
A/California/04/2009 (H1N1 group), with the H1N1 group shedding the most. Ferrets were monitiored 
up to day 14. No virus was shed after day 14. 
 
6.3.2 Clinical signs of infection 
 
All ferrets were monitored twice daily for sneezing, nasal discharge, inactivity, diarrhoea and 
loss of appetite.  As per Section 2.3.4, activity level was scored as 0 for normal, 1 for reduced 
activity and 2 for inactive.  Animals infected with H1N1 showed more severe clinical signs 
compared to ferrets infected with H3N2. In particular, the H1N1 infected ferrets presented with 
sneezing, nasal discharge and inactivity.  By contrast, the H3N2 infected ferrets presented 
with sneezing only, suggesting that this H3N2 virus produces a much milder disease in ferrets 
that the H1N1 A/California/04/2009. 
 
Table 6.3.2.1 Cumulative incidence of nasal discharge, sneezing and inactivity. 
Group Total Nasal Discharge Total Sneezing Total Inactivity 
H3N2 
 
0 24 0 
H1N1 
 
10 27 48* 
Mock 
 
0 0 0 
*This score is the sum of 48 recorded incidences of reduced activity. A score of 1= reduced activity, a 
score of 2= inactive. 
 
Weight was monitored daily for each ferret. Overall, weight loss from baseline (Fig 6.3.2.1) 
was seen in both the H3N2 and H1N1 groups.  The mock group of ferrets gained weight over 
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the course of monitoring.   The weight loss recorded in the H1N1 infected animals was more 
severe than that recorded in the H3N2 animals, with a mean peak of -5% weight loss from 
baseline for the H1N1 compared to a peak of -2.5% weight loss from baseline for H3N2 
infected animals.  This combined with the clinical observations suggests that seasonal H1N1 
produces a more severe clinical infection in ferrets when compared to a seasonal H3N2 strain.  
 
Figure 6.3.2.1 Weight percentage change from baseline.  Mean percentage weight change of ferrets 
infected with H3N2 (n=6), H1N1 (n=6) and PBS (n=6). 
 
6.3.3 Evidence of seroconversion in ferrets 
 
HAIs were performed on sera of all ferrets.  As previously reported in Section 3.6, all ferrets 
inoculated with H3N2 gave HAI titres of ≥512 to A/Perth/16/2009.  Ferrets in the mock group 
inoculated with PBS had HAI titres of <4 to the corresponding viruses confirming they were 
not infected.   All ferrets inoculated with H1N1 also gave HAI titres of ≥512 to 
A/California/04/2009.  These results confirm that both groups of ferrets inoculated with H3N2 
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and H1N1 were successfully infected with virus and gave a robust humoral immune response 
to the corresponding strain of inoculation.  
 
6.3.4 Longitudinal time course of influenza-specific IFN-γ responses in the periphery 
 
Small volumes of heparinised whole blood were collected from all ferrets at -7, -1, 2, 5, 8, 11, 
and 14 dpi to assess the influenza-specific IFN-γ responses in peripheral blood. Samples from 
each ferret were assessed by ELISA and a longitudinal time course of influenza-specific IFN-
γ responses was produced (Fig. 6.3.4.1).  Two samples were collected prior to infection to 
demonstrate that there were limited influenza-specific IFN-γ responses in the ferrets prior to 
infection.  All ferrets were found to have responses below 270 pg/ml of IFN-γ in pre-infection 
samples. These responses were averaged for each animal and represented by the 0 dpi time 
point (Fig. 6.3.4.1).  Following infection with either H1N1 or H3N2, low level influenza-specific 
IFN-γ responses were detectable in ferrets at 5 dpi and increased at 8 and 11 dpi with 
responses peaking at 11 to 14 dpi.  At 14 dpi, responses in the majority of ferrets appear to 
decrease while some others continue to increase.  This variation could be due to the outbred 
nature of the ferrets. There was no significant difference (P 0.3939) found between the total 
influenza-specific IFN-γ produced by whole blood from ferrets infected with the H1N1 and 
H3N2 subtypes. Ferrets in the mock group inoculated with PBS had responses below 270 
pg/ml over the 14 days. 
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Figure 6.3.4.1 Quantification of influenza-specific IFN-γ production by ELISA. Diluted whole blood 
samples were collected from all ferrets at -7, -1, 2, 5, 8, 11, and 14 days post infection, stimulated with 
appropriate antigens and the supernatants harvested. Supernatants were used in the Ferret IFN-γ 
ELISA Development Kit (ALP).  Influenza-specific IFN-γ responses became detectable at 5 days post 
infection with a peak at 11-14 days post infection for all virus infected animals.  No responses were 
detected in the mock group.  A Mann-Whitney test was performed and no statistical difference (P 
0.3939) was found in the total influenza-specific IFN-γ detected between ferrets intranasally infected 
with A/Perth/16/2009 (H3N2 group) and A/California/04/2009 (H1N1 group). 
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6.3.5 Cellular immune responses measured by ferret specific IFN-γ enzyme linked 
immunospot assay (ELISpot) 
 
Animals were culled at 14 dpi.  Lymphocytes were isolated from whole lung (lung MNCs) (Fig 
6.3.5.1b) and whole blood (PBMCs) (Fig 6.3.5.1a) and the number of IFN-γ secreting cells 
was quantified by ferret-specific INF-γ ELISpot.  A significant difference was found in the 
number of cells producing influenza-specific IFN-γ responses in H1N1 infected animals 
compared to H3N2 infected animals (P 0.0043) (Fig 6.3.5.1b).  Additionally, it found a 
significant difference in the responses between the mock group and H1N1 group (P 0.0022). 
Comparison of lung MNCs in influenza and mock infected group showed no significant 
difference in the influenza-specific IFN-γ responses for mock group and H3N2 group.  As 
mentioned previously in Section 3.6, only one of the H3N2 infected ferrets was found to have 
influenza-specific IFN-γ responses in lung MNCs, no responses were detected in remaining 
ferrets. A moderate positive correlation for all virus groups were found between the peak virus 
titre shed and the number of lung MNCs secreting influenza-specific IFN-γ (R -0.6767, P 
0.0043).  A positive correlation was found between the total amount of virus shed by ferrets 
and the number of lung MNCs secreting influenza-specific IFN-γ (R +0.7396, P 0.0088).  
 
Both virus infected groups showed a significant increase in the number of influenza-specific 
INF-γ secreting PBMCs when compared to the mock group 14 dpi (H1N1 P 0.0022, H3N2 P 
0.0022).  No significant difference (P 0.1797) was observed between the number of PBMCs 
producing influenza-specific IFN-γ responses in the H1N1 and H3N2 groups (Fig. 6.3.5.1a).   
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Figure 6.2.5.1. Cellular immune responses in ferrets infected with A/Perth/16/2009 and 
A/California/04/2009 PBMCs (a) and Lung MNCs (b) were collected form all animals (n=18) at 14 dpi.  
Results were normalised by subtracting the individual sample allantoic fluid control values from virus 
stimulated sample values.   (a) Influenza-specific IFN-γ responses in PBMCs were seen in all ferrets 
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inoculated with virus.    (b) Influenza-specific IFN-γ responses in lung MNCs. The values measured for 
each ferret are plotted as spot forming units (SFU) per million cells. Bars show mean and standard 
deviation for each group. 
 
 
6.3.6 Discussion 
 
It has previously been demonstrated, using the H1N1 A/California/04/2009 virus, that there is 
an approximately 100-fold increase in the inflammatory immune cell count in the nasal wash 
when infecting animals at a dose of 1x102 PFU, with a delay in peak cell count compared to 
infection with a high dose (1x106 PFU).  This suggests a delay in the activation of inflammatory 
immune cell response found in the nasal wash which comprises of mostly neutrophils and 
monocytes/macrophages (Chen et al., 1995). During this thesis this increase did not occur in 
ferrets infected with a 1x102 PFU of the H3N2 A/Perth/16/2009 virus compared to 1x106 PFU, 
where nasal cell wash counts were approximately the same for both amounts of virus.  
 
However, it has also been shown during this thesis that a lower challenge dose of H3N2 does 
not lead to reduced virus shedding, but instead leads to increased shedding both in terms of 
total virus shed over the course of the infection, and peak titre of shed virus.  This has also 
been reported for H1N1 A/California/04/2009 (Marriott et al., 2014).   This comparison has 
demonstrated that ferrets infected with a low dose of H1N1 virus shed significantly more virus 
over an 8 day period compared to ferrets infected with an equivalent dose of H3N2 virus.  This 
also correlates strongly with the peak shedding titre seen in the ferrets, with H1N1 infected 
ferrets having a higher peak shedding titre than animals infected with H3N2 virus.  This 
comparison has also highlighted that a low dose of H1N1 produces a more severe clinical 
disease in ferrets when contrasted with the milder H3N2 low dose infection.  It has been shown 
that the H1N1 subtype that emerged during the 2009 pandemic has distinct clinical features.  
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For example, in several animal models it has been show to cause severe inflammation in the 
lungs leading to respiratory failure and in some cases, death (Itoh et al., 2009, Fraser et al., 
2009).  This contrasts with the milder seasonal H1N1 that was circulating endemically in the 
human population pre-2009. 
 
Comparison of the H1N1 and H3N2 influenza-specific IFN-γ time course in peripheral blood 
shows a similar pattern of responses in ferrets infected with either subtype. These results, 
combined with the PBMC ELISpot results, obtained at 14 dpi, suggest that the influenza-
specific IFN-γ response seen in ferrets infected with H1N1 and H3N2 is not differentiated by 
subtype and is instead comparable across both strains in the periphery.  It has been 
established previously that the increase in the number of IFN-γ producing lymphocytes 
following challenge suggests an expansion of the numbers of influenza-specific T cells as a 
consequence of progressive viral infection (Martel et al., 2011). Similar kinetics of influenza-
specific IFN-γ responses in PBMCs have been reported in pigs infected with a swine influenza 
(H1N2) virus (Talker et al., 2016). This suggests that the influenza-specific IFN-γ responses 
seen in the periphery do not vary significantly between seasonal strains or perhaps even host; 
however, it is possible that the responses seen in a more clinically severe strain, such as 
H5N1 or H7N9, may be different. Although the responses observed in the periphery are not 
direct representations of the responses at the site of infection it is valuable to monitor the 
cellular immune response across a time course, especially in a model where only small 
volumes of blood can be collected.   
 
The key significant difference seen between the groups of infected ferrets was the number of 
influenza-specific IFN-γ producing cells seen in lung MNCs of ferrets infected with H1N1 
compared to H3N2 infected ferrets and the mock group.  It has previously been shown that 
A/California/04/2009 can be detected in the lung following low dose intranasal infection 
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(Marriott et al., 2014).  These results are in line with the viral burden and pathology seen in 
the lungs of ferrets infected with H3N2 A/Perth/16/2009 in this thesis (Section 3.4), and with 
ferrets infected with H1N1 A/California/07/2009 in published (Marriott et al., 2014), and 
unpublished data generated by the Influenza Group at Porton Down.  qRT-PCR data in 
Section 3.4 showed that vRNA copies were not readily detected in the lungs of ferrets infected 
with H3N2 A/Perth/16/2009.  Only one ferret out of eight tested has vRNA present in the lungs 
at 4 dpi. However, all ferrets were successfully infected, producing live virus in their nasal 
washes.  This is in comparison to ferrets infected with H1N1 A/California/04/2009 in published 
data (Marriott et al., 2014) that shows vRNA present in the lungs of ferrets at 1, 2, 4 and 5 dpi, 
and unpublished data that shows vRNA in the lungs of ferrets at  2, 3, 4 and 8 dpi. 
 
Data in Section 3.4 shows that there is minimal pathology found in the lungs of ferrets infected 
with a low dose of H3N2 A/Perth/16/2009.  In comparison published data (Marriott et al., 2014) 
shows that at 4 and 5 dpi the lung pathology of low dose H1N1 A/California/04/2009 ferrets 
ranges from minimal to marked, exhibiting a much higher frequency and severity of 
pathological observations compared to the H3N2 virus.  These results correlate with evidence 
showing that the H1N1 subtype that emerged in 2009 has a lung tropism, predominately 
replicating in alveolar pneumocytes of the lung and possibly infecting lung dendritic cells 
(Bhatnagar et al., 2013).   Evidence also shows that H1N1 replicates efficiently in the lungs of 
mice (Belser et al., 2010) and ferrets (Maines et al., 2009).   In contrast, it has been reported 
that seasonal H3N2 infrequently go to the lungs of ferrets (Music et al., 2014, Carolan et al., 
2014, Gustin et al., 2011, Roberts et al., 2012, van den Brand et al., 2012, Roberts et al., 
2011).   This suggests that the influenza-specific IFN-γ responses seen in lung MNCs of ferrets 
infected with H1N1 was due to virus causing infection in the lungs.  In comparison the lungs 
of ferrets infected with H3N2 have either no or very low influenza-specific IFN-γ responses.   
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This comparison also demonstrates that it is possible to successfully evaluate cellular immune 
responses to seasonal influenza infection over a time-course in the ferret and reveals that 
there are differences in the immune signatures induced by different influenza strains.  Using 
these complementary techniques, it has been illustrated that the responses to H1N1 and H3N2 
infections in the lung were markedly different and correlated well with known tropisms of the 
virus strains used.  
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7 General Discussion 
7.1 Chapter Summary 
 
Viral respiratory tract infections are a leading cause of morbidity and mortality worldwide.  
Influenza A virus is a major contributor to to this, however there are several other key 
contibuters; measles virus (MV), respiratory syncytial virus (RSV), rhinovirus, adenovirus and 
coronavirus.  All of these viruses can be transmited via the routes discussed previously; 
contact (direct or indirect), droplet and aerosol.  Transmission in humans via each of these 
routes is complex and depends upon many variables including; environmental factors (e.g. 
humidity, temperature) and social factors (e.g. occupation, over-crowding) as well as host 
factors (e.g. receptor distribution). Each of these variables can affect the different transmission 
routes of these respiratory viruses in a dissimilar way resulting in difficulties investigating them 
experimentally both in humans and in animal models (Kutter et al., 2018).  
 
This piece of work has contributed to the further understanding of the influenza ferret model 
and to the ferret model as a whole.   For example, based on findings here, when the ferret 
model is being used for the investigation of a new emerging respiratory pathogens the 
intranasal route of infection should be selected over the nose only aerosol and transmission 
cage models.   This, and other published work demonstrates that the intranasal route is easlily 
reproducible and would allow for less variability infection rates if the new pathogen could 
successfully replicate the ferrets.  Ideally when infecting the ferret for the first time intransally 
a dose ranging study would be conducted to ensure that the correct concentration of pathogen 
was delivered.  However, despite a dose of 102 pfu working well for an influenza infection in 
the ferret, this does not mean that it would work well for other respiratory viruses.  Potentially 
higher doses would need to be considered.  Volume of inoculum would also need to be taken 
into account when developing a new model of infection in the ferret.  For instance, if a disease 
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of the lower respiratory tract was required then a volume of 1ml would be used preferentially 
over the volume of 0.2ml used in this work based upon published data (Belser et al., 2016).   
 
Influenza virus infections cause seasonal, yearly epidemics which are the source of a 
significant public health burden worldwide.  The ferret model for human IAV is widely used 
and has several advantages over other animal models such as comparable symptomology, 
similar receptor distribution in the respiratory tract to humans and the ability to be infected with 
human isolates without the need for adaptation.  Ferrets are a reliable model for influenza 
infection as shown by the reproducibility of the low dose intranasal infection. However, a major 
disadvantage of the model has been a lack of reagents for the evaluation of the cellular 
immune response.  Investigation of T cell mediated immunity in ferrets is crucial to vaccine 
development and efficacy studies.  
 
Studies investigating the H3N2 circulating seasonal strain of influenza have not been as 
numerous as those looking at the H1N1 strain. This is especially the case following the 2009 
H1N1 pandemic.  The seasonal H3N2 strain is equally as significant to public health as the 
H1N1 strain, and often predominates Flu seasons as was the case for 2018/2019.  This set of 
studies sought to address the gap in the knowledge surrounding the H3N2 subtype of 
influenza A virus and how it behaved in the ferret model.  This is important for ongoing vaccine 
and therapeutic studies using the ferret model. 
 
Characterisation of influenza in the ferret occurs in one outbred species, Mustela putorius.  
There is a large amount of variability that is introduced into the experimental design of animal 
studies prior to the inoculation of animals. Thus far there is no universal standard established 
for ferret studies to evaluate the relative risk of influenza virus.  Ferret gender, age and source 
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can vary between studies and laboratories.  Young adult ferrets (4-12 months) are frequently 
used, but this can differ depending on the question being posed, for example looking at young 
or aged ferrets (Huang et al., 2012, Paquette et al., 2014).   During the studies carried out as 
part of this thesis a variety of ferret ages were used.  This was due to the availability of ferrets 
to work with for this project.  When designing future projects using all female ferrets aged 4-6 
months would be advantageous as much of the cellular immunology that was carried out in 
the project was performed on female ferrets of that age range.  This would allow for 
consistency between and provide additional uniformity in studies.  
 
Genetically modified ferrets are not yet readily available for research in the same way the 
mouse is.  However, ferrets have been previously been cloned to produced animals without a 
CFTR gene, the gene that provides instruction for producing a protein called the cystic fibrosis 
transmembrane conductance regulator, in an attempt to create a ferret model of cystic fibrosis 
(Sun et al., 2008).  CFTR-knockout ferrets have been shown to develop a multi organ disease 
of the lung, pancreas, gall bladder and liver, unlike the CFTR-knockout mouse wich failed to 
present with any related symptoms of CF disease.  Pancreatic disease in CF patients often 
leads to diabetes.  This means that this genetically modified ferret provides a model in which 
to research disease of the lungs and pancreas where the mouse model is unable to.     
 
Additonally, genetic information provided by the completion of the ferret genome enabled a 
transgenic ferret model where targeted knock-in ferrets using CRISPR technology were 
engineered (Yu et al., 2019).  Although no work has been published with transgenic ferrets 
and influenza, these developments in the ferret model will no doubt aid future influenza 
research.   For example, a transgenic ferret in the future could allow investigation of influenza 
infection and it’s impact in combination with cystic fibrosis.   
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7.2 The study hypothesis  
 
The following hypotheses were investigated:  
 
1. That the pathogenesis of disease following different infection delivery models is 
similar despite the route of delivery and that pathogenesis is a property of the virus 
receptor rather than delivery route. 
 
2. That influenza infection results from a combination of both droplet (fomite) and 
aerosol particles and that both particle types contribute to transfer. 
 
This collection of studies sought to address whether disease following different infection 
delivery models is similar despite the route of delivery.   This was achieved by setting up three 
different experimental models of infection; low dose intranasal, nose-only aerosol and 
transmission cage (non-contact droplet) models.  Within each of these models a variety of 
techniques were used to interrogate the viral kinetics and the immune response in the ferrets 
to establish the pathogenesis of the seasonal influenza H3N2 (A/Perth/16/2009).   
 
From the results collected it’s been shown that the pathogenesis of disease following different 
infection delivery models is similar despite the route of delivery differing.  Regardless of the 
delivery route, animals infected with a low dose of H3N2 were shown to have mild clinical 
symptoms throughout these studies.  Weight loss was not a marker of disease, and some 
ferrets infected with H3N2 appeared to gain weight despite infection.   In studies where lung 
tissues were assessed the evidence for the presence of virus was very low despite varying 
inoculation routes.  
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Many studies using the intranasal infection route to inoculate the ferret use a high titre of virus 
(approximately 1x106 PFU) (Maines et al., 2009, Govorkova et al., 2011, Kim et al., 2013), this 
causes an early peak in viral shedding titre, coupled with an overall lower amount of virus shed 
compared to ferrets inoculated with a lower dose.  While inoculation with a high titre of virus 
can guarantee infection, it has been shown that the titre of virus used to inoculate ferrets does 
not correlate with disease severity (Marriott et al., 2014, Oh et al., 2015).   Lower dose models 
offer more clinically relevant viral shedding kinetics that gradually rise, peak and then resolve.  
Often a double peak can be identified in the pattern of shedding.  From the studies completed 
as part of this thesis and other published studies, ferrets infected with H3N2 appear to shed 
virus in a biphasic manner (Roberts et al., 2012, Roberts et al., 2011) with a peak occurring 
1-3 days following inoculation, a decline in virus load detected, before a second peak around 
days 5-7 followed by virus clearance.    This pattern of shedding has also been observed in 
H1N1 infected ferrets (Dimmock et al., 2012).   It appears to be essential that sampling take 
place at least daily otherwise the peak can be missed, as was most likely the case for the low 
dose infected group in Section 3.3. 
 
It has been demonstrated previously that ferrets are reliably infected with a low dose (1x102 
PFU) influenza virus (H1N1 A/California/04/2009) (Marriott et al., 2014, Dimmock et al., 2012). 
This collection of studies demonstrates that ferrets can be reliably infected with the same low 
dose (1x102 PFU) of H3N2 A/Perth/16/2009 via the intranasal route, showing sero-conversion, 
virus shedding and clinical signs of disease.  Comparison of the low dose intranasal models 
for H3N2 and H1N1 demonstrated that despite the viruses being inoculated using the same 
method and the same titre, the pathogenesis of each virus was different.  The clinical 
observations of ferrets infected with H1N1 were more severe than those seen in ferrets 
infected with H3N2.   Comparatively, H1N1 infected ferrets shed more virus than H3N2 
infected ferrets and they also had higher peak titres of virus than ferrets infected with H3N2. 
Additionally, the presence of a cellular immune response in the lungs of ferrets infected with 
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H1N1 suggested that this virus travelled more readily to the ferret lung than H3N2, despite 
being administered to ferrets via the exact same method.   This correlates with published 
tropisms of each subtype. Ultimately, from these results, it can be concluded that the 
pathogenesis of the virus is a property of the virus rather than the delivery route.  
 
Additionally, this piece of work was carried out to address if influenza infection with H3N2 
A/Perth/16/2009 can result from a range of infection routes with direct intranasal, contact, non-
contact droplet and aerosol routes all successfully infecting ferrets. The robustness and 
reproducibility of these routes of infection have been shown to vary, with the intranasal low 
dose inoculation of ferrets being the most reliable and reproducible of the models.   This route 
was the most straightforward to characterise and interpret and allowed for comparison of 
seasonal viruses.  
 
The infection of ferrets using the transmission cage model replicates one of the most natural 
routes of infection presented in this piece of work.  While this is a more clinically relevant route 
of infection, there are additional requirements for more animals and complex caging systems 
to be used to form a robust study.  It would be useful for viruses used in this non-contact 
transmission cage model to be efficiently transmitted via aerosol, so they could provide full, or 
close to 100% donor to recipient infection.  An alternative H3N2 strain could be sourced.  It 
has been demonstrated that with this cage set up that two different strains of the same H1N1 
subtype can have different infection rates in recipients (Otte et al., 2016).  This study examined 
two H1N1 strains; one from the early 2009 pandemic phase and one from the late 2009 
pandemic phase.  Donor and recipient ferrets were housed in pairs. The late phase pandemic 
H1N1 strain was shown to readily  infect ferrets via the non-contact aerosol transmission route 
with 5 out of 6 recipients becoming infected via this route, with the 6th recipient becoming 
infected via contact with its cage mate.  The early phase pandemic H1N1 strain only caused 
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infection of half of the recipient ferrets, with the remaining half of the recipeints becoming 
infected by their cage mates.  This study determined that H1N1 strains isolated later in the 
pandemic had mutations in their viral genome that conferred viral fitness and aided pandemic 
spread.   Alternatively, using a larger number of animals would help increase the number of 
successfully infected ferrets by viruses that are less efficient at being transmitted naturally via 
the non-contact route.  However, this would be considerably more expensive due to cage 
adjustments and ethical considerations would need to be considered due to numbers of ferrets 
being used.  
 
The nose only aerosol model allows aerosol infection to occur directly without the need for a 
donor ferret.  In this study we have shown that a low dose of aerosolised H3N2 has exhibited 
similar viral shedding kinetics to a low dose intranasal infection.  The nose-only aerosol model 
also allows ferrets to be infected with poorly transmissible strains that wouldn’t readily infect 
recipient ferrets when placed into the non-contact transmission cage model.    In theory, the 
nose-only aerosol model should allow for a more standardised delivery of a known titre of virus 
via a more natural transmission route. However, as has been shown, only one ferret became 
infected via the aerosol route, therefore the method of delivery demonstrated in this piece of 
work is not yet reproducible and reliable.   Other published work using nose ony aerosol has 
shown varying success in infecting all ferrets with IAV.  In comparison, measles,  a highly 
contagious negative sense RNA virus transmitted via the respiratory route, has been shown 
to successfully infect all NHPs challenged (the model for the measles virus) via the aerosol 
route (Ludlow et al., 2013, de Vries et al., 2012).  Demonstrating that successful aerosol 
challenge may well be down to the fitness of the virus to be transmitted via the aerosol route 
as opposed to a technical component introduced by the use of different equipment.  It also 
demonstrates that the transmission of influenza between hosts is very much via a mixture of 
routes; fomite, large aerosol droplets and aerosol nuclei.   
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In the studies reported above, the initial transmission cage and nose-only aerosol models 
resulted in a similar percentage of animals being successful infected.  Upon reflection, there 
was an unrealistic assumption that both these models would have a more successful infection 
rate, much like that of the low dose intranasal infection route.   Based on these finidings, the 
persuit of aiborne transmission, via natural transmission and nose-only aerosol, may not be 
worthwhile, and would depend on the question that was being asked of the animal model. The 
practical difficulties and variability associated with both the transmission and nose only aerosol 
models means that the low dose intranasal model is a far more technically sound method of 
infection.  The low dose intranasal model would provide a much more robust and reliable 
means of evaluating vaccine and therapeutics even though it doesn’t mimic ‘real life’ infection 
as closely as natural transmission and nose-only aerosol might do.  Ultimately their use would 
depend purpose of the research taking place, and if a new respiratory pathogen was being 
investigated in the ferret model the intranasal method of infection would be the most 
dependable route to attempt.    
 
7.3 Future Work 
 
Future work to develop each model has already been discussed in depth at the end of each 
results chapter.  In addition to what has been discussed, the contributory role of fomites to 
H3N2 infection would be interesting to investigate.  There is limited data on the pathogenesis 
of disease in the ferret model following infection via fomites.  Ideally ferrets would be 
intranasally inoculated with a low dose of H3N2 and place into individual cage for 48 - 36 
hours.  Ferrets would then be removed from the cage and a naïve ferret would be placed 
individually into each cage.  It would be important not to change bedding, water bottle, food 
bowls or enrichment during this period of change.  This would allow infection of ferrets via 
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contaminated fomites to take place.   Nasal wash samples and whole blood would then be 
collected from these ferrets during the study as per previous chapters for viral kinetic and 
cellular immune response analysis.  Whole blood and lungs would be taken on study 
termination for assessment of the humoral and cellular immune response.   Alternatively, to 
reduce the number of ferrets used, cages could be “spiked” with known quantities of influenza 
diluted in PBS, ferrets placed in cages and monitored as described.   
 
However, this work is outside the scope and funding of this project.  In addition, ethical 
considerations would need to be considered when using further animals to investigate this 
route of infection and evaluating the benefit of this model. 
 
7.4 Conclusions  
 
To date mice, rats, ferrets, hamsters, guinea pigs and NHPs have been extensively used for 
modelling human respiratory virus infection.   The availability of immune reagents and ease of 
genetic manipulation means that the mouse is the most commonly used model. Despite this, 
the ferret remains the preferred animal model for assessing influenza infection.  However, 
there are many challenges when setting up model of infection.  The simplest is the low dose 
intranasal infection model, providing reproducibility and reliability. This is in line with the vast 
majority of of models for respiratory viruses which use intranasal inoculation to deliver virus. 
For this ferret model, both the nose-only aerosol and transmission cage models require a great 
deal more work to get them to the same reproducibility of the low dose intranasal model. 
Unfortunately, the time constraints and scope of this PhD meant that these models were 
unable to be progressed further beyond the work presented in this thesis.   
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Part of the work in this thesis has been successfully published and highlights the differences 
in the cellular immune response between seasonal H3N2 and H1N1 (Ryan et al., 2018). The 
evaluation of cellular immune responses in the ferret model is important for use of the model 
in future influenzas vaccine development.  Current inactivated vaccines are poor inducers of 
T-cell responses.   It’s known that cross-reactive T-cell responses are important in the 
protective response to novel vaccines, especially those based on internal virus antigens 
(Berthoud et al., 2011).  Therefore, the ability to measure these responses in the ferret model 
of influenza is becoming increasingly valuable. In the future both humoral and cellular 
responses will need to be measured in animal models as new vaccines are likely to require 
induction of both.  
 
Ultimately this work enhances and improves the versatility of the ferret model for studying the 
pathogenesis of influenza and, in the long run can provide information, support and guidance 
for the public health response to influenza in humans. 
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8 Appendix 1 
 
Study Index  
 
Study 
Numbers 
4965 5087 5256 5283 5530 5549 5719 
Study 
description 
Intranasal 
Dose Pilot 
Study 
Serial Cull 
Study 
Study to 
Demonstrate 
the 
Reproducibility 
& Reliability of 
the Low Dose 
Intranasal 
Inoculation 
Transmission 
Cage Model  
Nose-only 
Aerosol 
Infection 
Model 
Low Dose 
Model to 
Investigate 
Cellular 
Immune 
Responses/ 
H1N1 
Comparison 
Low Dose 
Model to 
Investigate 
Cellular 
Immune 
Responses/ 
H1N1 
Comparison 
Number of 
ferrets 
4 
 
8 6 12 12 12 6 
Age 4-6 months 9.5-14.5 
weeks 
10+ weeks 12-16 weeks 4-6 months 4-6 months 4-6 months 
ID 
Numbers 
27043 (m) 
47575 (m) 
30654 (f) 
27027 (m) 
26166 (f) 
27207 (f) 
18992 (m) 
26624 (f) 
76400 (f) 
31048 (m) 
33920 (f) 
86670 (f) 
57277(m) 
80693(f) 
87677(f) 
93202(m) 
55702(m) 
88448(m) 
40434 (m)  
40400 (m) 
40418 (m) 
41822 (f) 
15557 (f) 
18704 (f) 
95099 (f) 
11981(m) 
12950 (f) 
38968 (m) 
40513 (m) 
40487 (f) 
40761 (f) 
47791 (f) 
49800 (f) 
53177 (f) 
51352 (f) 
46171 (f) 
50706 (f) 
46313 (f) 
46392 (f) 
46476 (f) 
48186 (f) 
41787 (f) 
55432 (f) 
45891 (f) 
53132 (f) 
49686 (f) 
52094 (f) 
45627 (f) 
46707 (f) 
50573 (f) 
52238 (f) 
47025 (f) 
48889 (f) 
46915 (f) 
86654 (f) 
86811 (f) 
86809 (f) 
86659 (f) 
86812 (f) 
86660 (f) 
Timepoint 
culled 
14 dpi 2, 3, 4 & 8 
dpi 
8 dpi 8, 13 and 14 
dpi 
14 dpi 14 dpi 14 dpi 
Samples 
collected 
Clinical 
Obs, 
weight, NW, 
sera 
Clinical 
Obs, 
weight, 
NW, sera 
Clinical Obs, 
weight, NW, 
sera 
Clinical Obs, 
weight, NW, 
sera, whole 
blood, spleen 
Clinical 
Obs, 
weight, 
NW, sera, 
whole 
blood, 
spleen, 
BAL, lung 
Clinical 
Obs, 
weight, NW, 
sera, whole 
blood, lung 
Clinical 
Obs, 
weight, NW, 
sera, whole 
blood, lung 
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